Datasets:

RJuro

/

neuro_patents

like 2

1999-01-27

Y

1. A cancellation system for removing selected signals from a traffic signal prior to decoding in a receiver that receives communication signals from a transmitter (19) over a CDMA air interface, the system comprising: a system input (147) for receiving the communication signals; said system input (147) inputted as input (103) to a traffic signal cancellation system (101) having an output (O) equal to the desired traffic signal minus the unwanted traffic signals; said signal input (147) also inputted as input (63) to a pilot signal cancellation system (61), the system (61) processing the input (63) to remove a global pilot signal and having an output (Oadd) equal to the desired traffic signal minus the global pilot signal; and whereby the output (Oadd) of the pilot signal cancellation system (61) is subtracted from the output (O) of the traffic signal cancellation system (101) to provide the cancellation system output (151). 2. The cancellation system according to claim 1 wherein the traffic cancellation system (101) comprises a desired traffic signal despreader (91) coupled to a sum and dump processor (97) to produce an output (Osd3) and an unwanted traffic signal canceler (1151-n), the despreader (1151-n) comprising: an unwanted traffic signal despreader (1391-n) having a signal input (103) coupled to said system input (63) and a summed output; the unwanted traffic signal despreader (1391-n) comprising an unwanted traffic signal code generator (1191-n) and a mixer (1171-n) for mixing an output of the generator (1191-n) with the input (103) to produce a unwanted traffic signal canceler output; said unwanted traffic signal despreader summed output coupled to a hard decision processor (1251-n) having a phase output (phi) and a data output (d); said hard decision processor phase output (phi) coupled to a low pass filter (1271-n), said low pass filter having an output (Olpfn); said low pass filter (1271-n) output (Olpfn) coupled to an input of a processor (1291-n) that filters the product of the unwanted traffic signal to desired traffic signal cross-correlation outputting the unwanted traffic signal strength; said processor (1291-n) output multiplied with said hard decision data output (d) with a first multiplier (1311-n) having an output delivered to an adjustable amplifier (1371-n); an unwanted traffic code generator (119) output coupled to an input of a complex conjugate processor (1351-n) having an output; said complex conjugate output mixed with a complex conjugate of the desired traffic signal code by a first mixer (1331-n) having an output; said first mixer (1331-n) output coupled to an input of a first sum and dump processor (1231-n) having an output; said first sum and dump processor (1231-n) coupled to an input of an amplifier (1371-n) having an adjustable gain controlled by said multiplier (1311-n) output; and said output of said amplifier (1371-n) is coupled to an adder (143) which subtracts the output (1411-n) of each variable amplifier (1371-n) from the output (Osd3) of the desired traffic signal despreader (91) to get the output (O) of the traffic signal cancellation system (101). 3. The cancellation system according to claim 1 wherein the pilot signal cancellation system (61) comprises: a global pilot despreader (65) coupled to said input (63) having a summed output (Osd1); a desired traffic signal and global pilot cross-correlation means having an output (Osd2); said global pilot despreader (65) output (Osd1) coupled to a pilot strength determining means, said determining means having an output (Opm); said pilot strength determining means output (Opm) multiplied with said cross-correlation means output (Osd2); and said multiplied product is said output (Oadd). 4. The cancellation system according to claim 3 wherein said cross-correlation means comprises: a global pilot spreading code complex conjugate code generator (69); a desired traffic signal complex conjugate code generator (79); a second mixer (81) for cross-correlating said global pilot signal code and said desired traffic signal complex conjugate code; and a second sum and dump processor (85) for summing over time said cross-correlation product. 5. The cancellation system according to claim 4 wherein said means to derive said global pilot signal strength further comprises: a low-pass filter (75) having an output (Olpf); and a processor (77) coupled to said low-pass filter (75) deriving and outputting the global pilot signal strength. 6. A global pilot signal cancellation system (61) for use in a receiver that receives communication signals from a transmitter over a CDMA air interface that removes the global pilot signal from a desired traffic signal prior to decoding, the system comprising: an input (63) for receiving the communication signals and a system output (Oadd); said input coupled to a global pilot despreader (65) and a desired traffic signal despreader (91) each having a summed output a desired traffic signal and global pilot cross-correlation means; said global pilot despreader (65) output (Osd1) coupled to a pilot strength determining means, said determining means having an output (Opm); said pilot strength determining means output (Opm) multiplied with said cross-correlation means output (Osd2); and said multiplied product subtracted from a summed output (Osd3) of said desired traffic signal despreader (91) output outputting (Oadd) the desired traffic signal free from the global pilot signal. 7. The global pilot signal cancellation system (61) according to claim 6 wherein said means to derive said global pilot signal strength further comprises: a low-pass filter (75) having an output (Olpf); and a processor (77) coupled to said low-pass filter (75) deriving and outputting the global pilot signal strength (Opm). 8. A traffic signal cancellation system (101) for use in a receiver that receives communication signals from transmitter (19) over a CDMA air interface that removes at least one unwanted traffic signal from a desired traffic signal prior to decoding, the system comprising: an input (103) for receiving the communication signals and a system output (O); said input (103) coupled to a desired traffic signal despreader (91) having a first summed output (Osd3); an at least one unwanted traffic signal canceler (1151-n) comprising: an unwanted traffic signal despreader (1391-n) having an input coupled to said first summed output and a second summed output; the unwanted traffic signal despreader (1391-n) comprising an unwanted traffic signal code generator (1191-n) and a mixer (1171-n) for mixing an output of the generator (1191-n) with the input (103) to produce a unwanted traffic signal despreader output; said unwanted traffic signal despreader (1391-n) summed output coupled to a hard decision processor (1251-n) having a phase output (phi) and a data output (d); said hard decision processor (1251-n) phase output (phi) coupled to a low pass filter (1271-n), said low pass filter (1271-n) having an output (Olpfn); said low pass filter (1271-n) output (Olpfn) coupled to an input of a processor (1291-n) that filters the product of the unwanted traffic signal to desired traffic signal cross-correlation outputting the unwanted traffic signal strength; said processor (1291-n) output multiplied with said hard decision data output (d) with a multiplier having an output delivered to an adjustable amplifier (1371-n); an unwanted traffic code generator (1191-n) output coupled to an input of a complex conjugate processor (1351-n) having an output; said complex conjugate output mixed with a complex conjugate of the desired traffic signal code by a mixer (1331-n) having an output; said mixer (1331-n) output coupled to an input of a second sum and dump processor (1231-n) having an output; said second sum and dump processor (1231-n) coupled to an input of an amplifier (1371-n) having an adjustable gain controlled by said multiplier (1311-n) output; and said output of said amplifier (1371-n) is coupled to an adder (143) which subtracts the output (1411-n) of each variable amplifier (1371-n) from the output (Osd3) of the desired traffic signal despreader (91) to get the output (O) of the traffic cancellation system (101). 9. The cancellation system according to claim 6 wherein said cross-correlation means comprises: a global pilot signal code generator (65); a desired traffic signal complex conjugate code generator (79); a second mixer (81) for cross-correlating said global pilot signal code and said desired traffic signal complex conjugate code; and a second sum and dump processor (85) for summing over time said cross-correlation product. 10. The cancellation system according to claim 9 wherein said means to derive said global pilot signal strength further comprises: a low-pass filter (75) having an output; and a processor (77) coupled to said low-pass filter (75) deriving and outputting the global pilot signal strength. 11. A method for cancelling a global pilot signal from a desired traffic signal, comprising: providing an input for receiving communication signals from a transmitter over a CDMA air interface; said input coupled to a global pilot despreader (65) and a desired traffic signal despreader (91) each having a summed output; identifying a desired traffic signal and provides a global pilot cross correlation means; said global pilot despreader (65) output coupled to a pilot strength determining means having an output, said pilot strength determining means output multiplied with said cross-correlation means output where said cross-correlation means comprising; and said multiplied product subtracted from said desired traffic signal despreader output and outputting the desired traffic signal free from the global pilot signal. 12. The method according to claim 11 wherein said means to derive said global pilot signal strength further comprises: a low-pass filter having an output, and a processor coupled to said low-pass filter (75) derivi

en

CANCELLATION OF PILOT AND UNWANTED TRAFFIC SIGNALS IN A CDMA SYSTEM

64768944_US

65355626_US

H04B 1/7097,H04B 1/7103,H04B 1/7107,H04B 1/71075,H04B2201/70701

1998-12-08

Y

1. A compound of the formula wherein Ar' is a mono or bicyclic aryl or heteroaryl radical substituted with one to three substituents selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<1> is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio; R<2> is phenyl, naphthyl or (C3-C12)cycloalkyl substituted with one or two substituents selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<3> is selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; X is -(C=O)-, -CHOH- or -CH2-; or a pharmaceutically acceptable salt, racemate, optical isomer or solvate thereof. 2. A compound of Claim 1 wherein Ar' is phenyl or pyridine. 3. A compound of Claim 2 wherein Ar' is phenyl substituted with (C1-C6)alkoxy. 4. A compound of Claim 3 wherein R<2> is phenyl or (C3-C12)cycloalkyl. 5. A compound of Claim 4 wherein R<1> is hydrogen. 6. A compound of Claim 5 wherein X is -C=O. 7. A method of antagonizing the serotonin 1A receptor which comprises administering to a patient in need of such treatment an effective amount of a compound of Claim 1 or a pharmaceutically acceptable salt, racemate, optical isomer or solvate thereof. 8. A method of alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine which comprises the administration to a patient in need of such treatment of an effective amount of a compound of the formula wherein Ar' is a mono or bicyclic aryl or heteroaryl radical substituted with one to three substituents selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<1> is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio; R<2> is phenyl, naphthyl or (C3-C12)cycloalkyl substituted with one or two substituents selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<3> is selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; X is -(C=O)-, -CHOH or -CH2-; or a pharmaceutically acceptable salt, racemate, optical isomer or solvate thereof. 9. A method of Claim 8 wherein the compound is 1-(2-methoxyphenyl)-4-[3-(benzoyl)-3-(phenyl)propyl]piperazine; 1-(2-pyridyl)-4-[3-(cyclohexanecarbonyl)-3-(phenyl)propyl]piperazine; 1-(2-ethoxyphenyl)-4-[3-(cyclohexanecarbonyl)-3-(phenyl)propyl]piperazine hydrochloride; 1-(2-methoxyphenyl)-4-[3-(benzoyl)-3-(phenyl)butyl]piperazine oxalate; 1-(2-methoxyphenyl)-4-[3-(cycloheptanecarbonyl)-3-(phenyl)propyl]piperazine hydrochloride; 1-(2-methoxyphenyl)-4-[3-(cyclopentanecarbonyl)-3-(phenyl)propyl]piperazine hydrochloride; and 1-(2-methoxyphenyl)-4-[4-(cyclohexyl)-4-(hydroxy)-3-(phenyl)butyl]piperazine oxalate. 10. A method of treating anxiety comprising administering to a patient in need of such treatment an effective amount of a compound of the formula wherein Ar' is a mono or bicyclic aryl or heteroaryl radical substituted with one to three substituents selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<1> is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio; R<2> is phenyl, naphthyl or (C3-C12)cycloalkyl substituted with one or two substituents selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<3> is selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; X is -(C=O)-, -CHOH- or -CH2-; or a pharmaceutically acceptable salt, racemate, optical isomer or solvate thereof. 11. A method of treating depression, hypertension, cognitive disorders, psychosis, sleep disorders, gastric motility disorders, sexual dysfunction, brain trauma, memory loss, eating disorders, obesity, substance abuse, obsessive-compulsive disease, panic disorder or migraine, comprising administering to a patient in need of such treatment an effective amount of a compound of the formula wherein Ar' is a mono or bicyclic aryl or heteroaryl radical substituted with one to three substituents selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<1> is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio; R<2> is phenyl, naphthyl or (C3-C12)cycloalkyl substituted with one or two substituents selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<3> is selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; X is -(C=O)-, -CHOH- or -CH2-; or a pharmaceutically acceptable salt, racemate, optical isomer or solvate thereof. 12. A method for potentiating the action of a serotonin reuptake inhibitor in increasing the availability of serotonin, norepinephrin and dopamine in the brain, comprising administering to a patient in need of such treatment a serotonin reuptake inhibitor in combination with an effective amount of a compound of the formula wherein Ar' is a mono or bicyclic aryl or heteroaryl radical substituted with one to three substituents selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<1> is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio; R<2> is phenyl, naphthyl or (C3-C12)cycloalkyl substituted with one or two substituents selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<3> is selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; X is -(C=O)-, -CHOH- or -CH2-; or a pharmaceutically acceptable salt, racemate, optical isomer or solvate thereof. 13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 1. 14. A method of Claim 8 wherein an effective amount of a serotonin reuptake inhibitor is administered. 15. A method of Claim 14 wherein the serotonin reuptake inhibitor is fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine or paroxetine. 16. A method of assisting a patient in ceasing or reducing their use of tobacco or nicotine comprising administering to a patient an effective amount of a compound of the formula wherein Ar' is a mono or bicyclic aryl or heteroaryl radical substituted with one to three substituents selected from the group consisting of hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<1> is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio; R<2> is phenyl, naphthyl or (C3-C12)cycloalkyl substituted with one or two substituents selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; R<3> is selected from the group consisting of hydrogen (C1-C6)alkyl, (C1-C6)alkoxy, (C1-C6)alkylthio, (C2-C6)alkenyl, (C2-C6)alkynyl, (C1-C6)alkylhalo, (C3-C8)cycloalkyl, (C3-C8)cycloalkenyl or halo; X is -(C=O)-, -CHOH- or -CH2-; or a pharmaceutically acceptable salt, racemate, optical isomer or solvate thereof. 17. A compound of the formula: or the pharmaceutically acceptable salts thereof. 18. A compound which is (+)-1-(2-methoxyphenyl)-4-[3-cyclohexanecarbonyl)-3-(phenyl)butyl]piperazine and the pharmaceutically acceptable salts thereof. 19. A compound according to claim 18 wherein the pharmaceutically acceptable salt is a dihydrochloride salt. 20. A compound according to claim 18 wherein the pharmaceutically acceptable salt is an oxalate salt. 21. A compound according to claim 18 wherein the pharmaceutically acceptable salt is a maleate salt. 22. A compound according to claim 18 wherein the pharmaceutically acceptable salt is a phosphate salt. 23. A compound which is (+) -1-(2-methoxyphenyl)-4-[3-(cyclohexanecarbonyl)-3-(phenyl)butyl]piperazine monohydrochloride. 24. A method of alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine which comprises the administration to a patient in need of such treatment of an effective amount of a compound of the formula: or the pharmaceutically acceptable salts thereof. 25. A method of alleviating the symptoms caused by withdrawal or partial withdrawal from the use of tobacco or of nicotine which comprises the administration to a patient in need of such treatment of an effective amount of (+)-1-(2-methoxyphenyl)-4-[3-cyclohexanecarbonyl)-3-(phenyl)butyl]piperazine or the pharmaceutically accepta

en

ARYLPIPERAZINES HAVING ACTIVITY AT THE SEROTONIN 1A RECEPTOR

64504836_US

68156489_US,68325384_US,68340107_US,69223679_US,69734728_US

A61K 31/495,A61K 31/496,A61P 1/00,A61P 3/04,A61P 9/00,A61P 9/12,A61P 15/10,A61P 25/00,A61P 25/06,A61P 25/18,A61P 25/20,A61P 25/22,A61P 25/24,A61P 25/28,A61P 25/30,A61P 25/34,A61P 43/00,C07C 45/004,C07C 45/29,C07C 45/40,C07C 45/515,C07C 45/59,C07C 45/68,C07C 49/563,C07C 49/577,C07C 49/583,C07C 49/86,C07D 213/74,C07D 295/088,C07D 295/092,C07D 295/104,C07D 295/108

2000-02-02

Y

1. A compound of the formula wherein A and B rings are phenyl rings; n and m are, selected, independently, from one, two and three; R<1> and R<2> are selected, independently, from hydrogen, (C1-C4) alkyl, (C2-C4) alkenyl, and (C2-C4) alkynyl, or R<1> and R<2> together with the nitrogen to which they are attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R<1> and R<2> are attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, with the proviso that said ring can not contain two adjacent oxygen atoms or two adjacent sulfur atoms, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C1-C6) alkyl; R<3> and R<4> are selected, independently, from hydrogen and (C1-C4) alkyl optionally substituted with from one to three fluorine atoms, or R<3> and R<4> together with the carbon to which they are attached, form a four to eight membered saturated carbocyclic ring, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C1-C6) alkyl; or R<2> and R<3>, together with the nitrogen to which R<2> is attached and the carbon to which R<3> is attached, form a four to eight membered saturated ring containing one or two heteroatoms, including the nitrogen to which R<2> is attached, wherein the second heteroatom, when present, is selected from oxygen, nitrogen and sulfur, with the proviso that said ring can not contain two adjacent oxygen atoms or two adjacent sulfur atoms, and wherein said ring may optionally be substituted at available binding sites with from one to three substituents selected, independently, from hydroxy and (C1-C6) alkyl; each X is selected, independently, from hydrogen, halo (i. e., chloro, fluoro, bromo or iodo), (C1-C4) alkyl optionally substituted with from one to three fluorine atoms, (C1-C4) alkoxy optionally substituted with from one to three fluorine atoms, cyano, nitro, amino, (C1-C4) alkylamino, di-[(C1-C4)alkyl]amino, NR<5>(C=O)(C1-C4) alkyl, SO2NR<5>R<6> and SO2(C1-C6) alkyl, wherein R<5> and R<6> are selected, independently, from hydrogen and (C1-C6) alkyl, and p is zero, one or two; and each Y is selected, independently, from hydrogen, (C1-C6) alkyl and halo; with the proviso that: (a) no more than one of NR<1>R<2>, CR<3>R<4> and R<2>NCR<3> can form a ring; and (b) at least one X must be other than hydrogen when (i) R<3> and R<4> are both hydrogen, (ii) R<1> and R<2> are selected, independently, from hydrogen and (C1-C4) alkyl, and (iii) ring B is mono- or disubstituted with, respectively, one or two halo groups; or a pharmaceutically acceptable salt thereof. 2. A compound or salt according to claim 1, wherein n is one, X is fluoro, R<3> and R<4> are hydrogen, R<1> is hydrogen, R<2> is methyl, m is two and Y is Ym is 3,4-dichloro. 3. A compound or salt according to claim 1, wherein m is zero, n is one, R<3> and R<4> are hydrogen, X is chloro, bromo, iodo or methyl, R<1>is hydrogen and R<2> is methyl. 4. A compound or salt according to claim 1, wherein said compound or salt is selected from the following compounds and their pharmaceutically acceptable salts: [2-(3,4-Dichlorophenoxy)-5-fluorobenzyl]-dimethylamine; [2-(3,4-Dichlorophenoxy)-5-fluorobenzyl]-methylamine; [2-(3,4-Dichlorophenoxy)-5-trifluoromethylbenzyl]-dimethylamine; N-[4-(3,4-Dichlorophenoxy)-3-dimethylaminomethylphenyl]-acetamide; {1-[2-(3,4-Dichlorophenoxy) phenyl]-ethyl}-dimethylamine; [2-(3,4-Dichlorophenoxy)-4-trifluoromethylbenzyl]-dimethylamine; [2-(3,4-Dichlorophenoxy)-4-trifluoromethylbenzyl]-methylamine; [4-Chloro-2-(3,4-dichlorophenoxy)-benzyl]-methylamine; {1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine; {1-[2-(3,4-Dichlorophenoxy)phenyl}-ethyl}-methylamine; {1-[2-(4-Chlorophenoxy)phenyl]ethyl}-methylamine; [2-(3, 4-Dichlorophenoxy)-5-methoxybenzyl]-methylamine; [2-(4-Chlorophenoxy)-5-fluorobenzyl]-methylamine; {1-[2-(4-Chlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine; [2-(3,4-Dichlorophenoxy)-5-methylbenzyl]-dimethylamine; [4-Bromo-2-(3,4-dichlorophenoxy)-benzyl]-methylamine; [5-Bromo-2-(3,4-dichlorophenoxy)-benzyl]-methylamine; [2-(3,4-Dichlorophenoxy)-4,5-dimethoxybenzyl]-methylamine; [2-(3,4-Dichlorophenoxy)-4-methoxybenzyl]-dimethylamine; 4-(3,4-Dichlorophenoxy)-3-methylaminomethyl-benzonitrile; [2-(3,4-Dichlorophenoxy)-4,5-dimethylbenzyl]-methylamine; 3-(3,4-Dichlorphenoxy)-4-methylaminomethyl-benzonitrile; (+)-{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine; (-)-{1-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-ethyl}-methylamine; [2-(3,4-Dichlorophenoxy)-5-trifluoromethyl-benzyl]-methylamine; [2-(3,4-Dichlorophenoxy)-4-methoxybenzyl]-methylamine; [2-(4-Chloro-3-fluorophenoxy)-5-fluorobenzyl]-methylamine; [2-(3-Chloro-4-fluorophenoxy)-5-fluorobenzyl]-methylamine; (+/-)-2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-pyrrolidine; (-)-2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-pyrrolidine; (+)-2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-pyrrolidine; and 2-[2-(3,4-Dichlorophenoxy)-5-fluorophenyl]-N-methylpyrrolidine. 5. A pharmaceutical composition for treating a disorder or condition selected from hypertension, depression, (depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression), generalized anxiety disorder, in a mammal, preferably a human, comprising an amount of a compound according to claim 1 that is effective in treating such disorder or condition and a pharmaceutically acceptable carrier. 10. A pharmaceutical composition for treating a disorder or condition that can be treated by inhibiting the reuptake of serotonin, dopamine or norepinephrine in a mammal, preferably a human, comprising an amount of a compound of the formula 1, or a pharmaceutically acceptable salt thereof, that is effective in treating such disorder or condition and a pharmaceutically acceptable carrier. 11. A method for treating a disorder or condition selected from hypertension, depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression), generalized anxiety disorder in a mammal, preferably a human, comprising an amount of a compound according to claim 1 that is effective in treating such disorder or condition and a pharmaceutically acceptable carrier. 12. A method for treating a disorder or condition that can be treated by inhibiting the reuptake of serotonin, dopamine or norepinephrine in a mammal, comprising administering to a mammal in need of such treatment an amount of a compound according to claim 1, that is effective in treating such disorder or condition. 13. A pharmaceutical composition for treating a condition or disorder that can be treated by inhibiting the reuptake of serotonin, dopamine or norepinephrine in a mammal, comprising: a) a pharmaceutically acceptable carrier; b) a compound according to claim 1; and c) an NK-1 receptor antagonist or a 5HT1D receptor antagonist, or a pharmaceutically acceptable salt thereof; wherein the amount of the active compounds (i. e., the compound of formula I and the NK-1 receptor antagonist or <5>HT1D receptor antagonist) are such that the combination is effective in treating such disorder or condition. 14. A method for treating a disorder or condition that can be treated by inhibiting the reuptake of serotonin, dopamine or norepinephrine in a mammal, comprising administering to a mammal requiring such treatment: a) a compound of the formula 1, defined above, or a pharmaceutically acceptable salt thereof; and b) an NK-1 receptor antagonist or 5HT1D receptor antagonist, or a pharmaceutically acceptable salt thereof; wherein the amounts of the active compounds (i. e., the compound of formula I and the NK-1 receptor antagonist or 5HT1D receptor antagonist) are such that the combination is effective in treating such disorder or condition.

en

MONOAMINE REUPTAKE INHIBITORS FOR TREATMENT OF CNS DISORDERS

64994367_US

67776770_US,64742870_US,68570245_US,69732263_US

A61P 1/04,A61P 3/04,A61P 5/00,A61P 9/12,A61P 13/10,A61P 15/10,A61P 17/14,A61P 25/00,A61P 25/06,A61P 25/08,A61P 25/16,A61P 25/18,A61P 25/22,A61P 25/24,A61P 25/28,A61P 25/30,A61P 25/32,A61P 25/34,A61P 25/36,C07C 217/58,C07C 217/90,C07C 233/18,C07C 235/34,C07C 255/37,C07C 255/59,C07C 311/29,C07C 317/32,C07C 323/20,C07D 207/08,C07D 211/22,C07D 265/30,C07D 279/12,C07D 295/096

1999-03-24

Y

1. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, and in need of an effective treatment thereof, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof. 2. A method of claim 1, wherein said dose of cabergoline is about 0.1 to 6 mg per patient per administration, on an as needed basis. 3. A method of claim 2 wherein said dose of cabergoline is administered once a day. 4. A method of claim 2 wherein said dose of cabergoline is administered 4 or 5 times a week in amounts from about 0.25 to 6 mg per administration. 5. A method of claim 2 wherein said dose of cabergoline is administered 2 or 3 times a week in amounts from about 0.25 to 6 mg per administration. 6. A method of claim 5 wherein said dose of cabergoline is administered once a week in amounts from about 0.25 to 6 mg per administration. 7. A method of claim 1, wherein said dose of Cabergoline is about 0.25 to 4 mg/day. 8. A method of claim 1, wherein said dose of Cabergoline is about 0.25 to 2 mg/day. 9. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, who has previously been treated, or is concurrently being treated with one or more of; a dopamine agonist, a benzodiazepine, or a psychotropoic agent, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof. 10. A method of claim 9, wherein the previous or concurrent treatment is or was with a dopamine agonist and the dose of Cabergoline is about 0.1 to 6 mg/day. 11. A method of claim 9, wherein said dopamine agonist is or was levodopa. 12. A method of claim 11, wherein said dose of Cabergoline is about 0.25 to 4 mg/day. 13 A method of claim 9, wherein said previous or concurrent treatment is or was with a benzodiazepines and said dose of Cabergoline is about 0.25 to 4 mg/day. 14. A method of claim 13, wherein said benzodiazepine is clonazepam (Klonopin). 15. A method of claim 9, wherein said previous or concurrent treatment is or was with said psychotropoic agent, wherein said psychotropoic agent is an opioid and said dose of Cabergoline is about 0.1 to 4 mg/day. 16. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, where the patient has suffered from or is considered susceptible to suffer from agumentation or rebound effects from a previous treatment for RLS wherein the previous treatment consists of being treated with one or more of ; a dopaminergic agent, a dopamine agonist, a benzodiazepine, or a psychotropoic agent, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof. 17. A method for treating patients who are not sleeping well, comprising the adminstration of an effective amount of cabergoline or its pharmaceutically acceptable salts. 18. A method of claim 17 where said patients have an abnormal sleep pattern as measured by standard sleep tests. 19. A method of claim 16 where said effective amount of cabergoline is between about 0.25 to 5 mg per patient per day. 20. A method of claim 16 where said previous treatment consisted of being treated with a dopamine agonist, wherein said dopamine agonist is levodopa and said effective amount of cabergoline or salt thereof is from 0.25- 4 mg per patient per day. 21. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, where the patient has suffered from tolerance from a previous treatment for RLS wherein the previous treatment consisted of being treated with one or more of; a dopaminergic agent, a dopamine agonist, a benzodiazepine, or a psychotropoic agent, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof. 22. A method of claim 21 where said previous treatment consisted of being treated with a dopamine agonist, wherein said dopamine agonist is levodopa and said effective amount of cabergoline or salt thereof is from 0.1- 4 mg per patient per day. 23. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, and in need of an effective treatment thereof, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof in combination with an effective amount of levodopa or its pharmacologically acceptable salts. 24. A once a day method for treating restless legs syndrome (RLS) in patient suffering from RLS, and in need of an effective treatment thereof, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof to the patient, once a day. 25. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, and in need of an effective treatment thereof, comprising: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof, but without the administration of another dopaminergic agent. 26. A method for treating restless legs syndrome (RLS) in patient suffering from RLS, and in need of an effective treatment thereof, consisting essentially of: the administration of an effective amount of cabergoline or a pharmacologically acceptable salt thereof. 27. Any treatments of claims 1-26 where the cabergoline is administered to the patient once a day. 28. Any treatments of claims 1-26 where the cabergoline is administered to the patient every other day. 29. Any treatments of claims 1-26 where the cabergoline is administered to the patient about 2-3 times per week. 30. The use of cabergoline or its pharmaceutically acceptable salts in the manufacture of a medicament to treat RLS, and for any of the RLS symptoms described herein.

en

USE OF CABERGOLINE IN THE TREATMENT OF RESTLESS LEGS SYNDROME

15604703_US,68170275_US

64257288_DE

A61K 31/48,A61K 31/485,A61K 31/55,A61K 45/06,A61P 25/00,A61P 25/02,A61P 25/14,A61P 25/20,A61P 43/00,Y10S 514/923

2018-03-29

N

Receive, from the base station. based on the unnsmitted ACID NACK feedback, a retransmission of one of the set of CBEs or the fir. subset of CBe r s Receive, from a base station, a set of CBGs including a first subset of (Bilis and a second subset of CB(is, the first subset of CB( is laving been transmitted on at least partially punctured resources I Reeeicen mdlcator indicant, the at least p Ily 1004 ,Lune resouce, Decode the set of [Reis Transmd, to the base station, an ACK/NACK feedback based on the decoding 1006 1008 1002 1010 Receive from the base station, in a retrammission 1012 L grant. CBG fist dad a retransmission type indicator s W O 20 18/187 163 Al ......i... m r .. T 02 41 ... 014 first subset Adl set of of type indicator indicntes ...\'-- ..... CBCts retransmission of the ed of CBGs or ...-- •••• w . the first subset of CBSis.--\'..\' 11022 rDetemnne. based on the mtransmramcal iDetermtne, based on the =MS1311.100 tyPI I type indiCE.,118t II, CBG RC I indicator, that the CBG list indicates CBGs I I Indicates CBGs for which previously I l_blinlrarMs.ttted . theeLlanZnissiee_ I I gored I I It v sluesaonld I, nulled I f — / 1(7[3 — i 1024 I Determine dam ilt' CBGs indiCaleerm — the - I E Decode the retransmitted f • subset 1 I CBG list correspond to CB(rs which failed I I of CBGs •,,illeut perfornung soft . I the deccdinL I I umnbining based on the prusiousJy + 020 I stored LLB values a - the first subset ) of CBGs I r Decode., in response to detcrnining that the L 3 _,1026 I CMGs in fi ll ' ne°P°33 ' dno I r Decode the retransmitted second I :he CBG. Ini • r the I ....tr...., arse wths „ t wt ., w ith out I I subaet of CBCrsuab soil g 1 iperfirming soft combining based on preriouly I I based on previously stored LLR stored 1.1-R verses for . .he first subset of CFSt • I slues for the second subset of CBGs FIG. 10 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT omit VIII °nolo III OH mom VIII 10110111110 mil (10) International Publication Number WO 2018/187163 Al (51) International Patent Classification: HO4L 1/18 (2006.01) (21) International Application Number: PCT/US2018/025229 (22) International Filing Date: 29 March 2018 (29.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/481,089 03 April 2017 (03.04.2017) US 15/939,165 28 March 2018 (28.03.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; ATTEN: International IP Administration, 5775 Morehouse Drive, San Diego, California, US 92121-1714 (US). (72) Inventors: SUN, Jing; c/o QUALCOMM INCORPO- RATED, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). JIANG, Jing; c/o QUALCOMM IN- CORPORATED, 5775 Morehouse Drive, San Diego, Cali- fornia 92121-1714 (US). (74) Agent: HODGES, Jonas J. et al.; c/o Arent Fox LLP, 1717 K Street NW, Washington, District of Columbia 20006-5344 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: FEEDBACK FOR CODEBLOCK GROUP BASED TRANSMISSIONS (57) : Various features related to a single bit ACK/NACK feedback for CBG based transmissions in a communication system are described. In an aspect, a base station may transmit, to a UE, a set of CBGs of a TB including a first subset of CBGs and a second subset of CBGs, the first subset of CBGs being transmitted on at least partially punctured resources. The base station may receive an ACK/NACK from the UE based on the transmitted set of CBGs, and retransmit to the UE one of the full set of CBGs or the first subset of CBGs based the received ACK/NACK. In an aspect, a UE may decode the set of CBGs received from the base station, transmit ACK/NACK feedback based on a result of the decoding, and receive, based on the transmitted ACK/NACK feedback, a retransmission of either the full set of CBGs, or the first subset of CBGs. [Continued on next page] WO 2018/187163 Al Dill Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

en

FEEDBACK FOR CODEBLOCK GROUP BASED TRANSMISSIONS

52280328_US

56459191_US,69733127_US

H03M 13/1111,H04L 1/0013,H04L 1/1819,H04L 1/1861,H04L 1/1864,H04L 5/0048,H04L 5/0055

2018-02-23

N

Transmit the SR with the ACK / NACK FIG. 20 Receive one or more downlink transmissions from a base station Determine to transmit an uplink transmission to the base station Jr_ I Determine whether to transmit the scheduling 2006 I request with the ACK / NACK or to transmit the r I scheduling request using dedicated resource r Perform QPSK mapping of a fast bit value I assodated with the scheduling request and a second r\'\' I bit value associated with the ACK / NACK r Perform at least one of channel coding or data I scrambling of the scheduling request and the ACK / 1 1 3 - 10 NACK after the QPSK mapping 1 Perform BPSK mapping of the second hit value 12012 associated with the ACK/NACK I II Determine if the scheduling request is transmitted 13 014 with the ACK / NACK 1 i 2002 2004 e' r I Shift the BPSK mapping of the second bit value 2016 I associated with the ACK / NACK by 90 .1 or another I predetermined angle L J lr 2000 W O 20 18/ 175 0 42 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIPO I PCT (51) International Patent Classification: H04L 5/00 (2006.01) HO4W 72/12 (2009.01) H04W 52/50 (2009.01) H04W 74/00 (2009.01) (21) International Application Number: PCT/US2018/019535 (22) International Filing Date: 23 February 2018 (23.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 201741010253 23 March 2017 (23.03.2017) IN 201741016601 11 May 2017 (11.05.2017) IN 15/718,418 28 September 2017 (28.09.2017) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; Atten: International IP Administration, 5775 Morehouse Drive, San Diego, California, US 92121-1714 (US). (72) Inventors: WANG, Xiao feng; c/o Qualcomm Incor- porated, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). RICO ALVARINO, Alberto; c/o Qual- comm Incorporated, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). BHATTAD, Kapil; c/o Qual- comm Incorporated, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). XU, Hao; c/o Qualcomm In- corporated, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (74) Agent: HODGES, Jonas J. et al.; c/o Arent Fox LLP, 1717 K Street NW, Washington, District of Columbia 20006-5344 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: SCHEDULING REQUEST FOR ONE OR MORE UPLINK TRANSMISSIONS USING NARROWBAND COMMUNI- = CATIONS 011101 V III o Ho ilom No VII IE (10) International Publication Number WO 2018/175042 Al (57) : The present disclosure may support dedicated scheduling re- quest resources in a NPUSCH format resource structure, a NPRACH, and/ or an ACK / NACK transmission associated with a downlink transmission received at the UE. In addition, the present disclosure may provide various techniques to mitigate collisions between scheduling requests transmitted by a UE, uplink transmissions sent by different UEs, and/or downlink transmis- sions sent by a base station. In an aspect of the disclosure, a method, a com- puter-readable medium, and an apparatus are provided. The apparatus may receive one or more downlink transmissions from a base station. The appa- ratus may determine to transmit an uplink transmission to the base station. The apparatus transmit, to the base station, a scheduling request for the uplink transmission with an ACK / NACK associated with the one or more downlink transmissions using a narrowband NPUSCH format resource structure. [Continued on next page] WO 2018/175042 Al MIDEDIMOMMIDIREIDIOMMEEINNIEHIMEMOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

en

SCHEDULING REQUEST FOR ONE OR MORE UPLINK TRANSMISSIONS USING NARROWBAND COMMUNICATIONS

52280328_US

71790391_US,68937361_US,56570006_US,67553613_US

H04L 1/1671,H04L 1/18,H04L 1/1854,H04L 1/1861,H04L 1/1896,H04L 5/0007,H04L 5/0053,H04L 5/0055,H04L 27/18,H04W 28/06,H04W 72/12,H04W 72/1284,H04W 76/27,H04W 88/02

2017-10-26

N

12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111 RH 0 HI 010 IIM IV I I 0 101110 Ell 1101E1011H MI 1111 1111 Organization International Bureau (10) International Publication Number International Publication Date ......0\'\'1 WO 2018/078053 Al 03 May 2018 (03.05.2018) WIP0 I PCT (51) (21) (22) (25) Filing Language: (26) (30) (71) International Patent Classification: PEUTICS INC. [CA/CA]; 2714 West 31st Avenue, Van- A61K 39/12 (2006.01) A61K 47/18 (2017.01) couver, British Columbia V6L 2A1 (CA). A61K 39/39 (2006.01) A61K 9/127 (2006.01) (72) Inventors: BAUMHOF, Patrick; Erlenstr. 28, 72144 Dus- A61P 31/16 (2006.01) CO7C 219/06 (2006.01) A61P 31/14 (2006.01) CO7C 229/16 (2006.01) slingen (DE). FOTIN-MLECZEK, Mariola; Chemnitzer A61K 9/51 (2006.01) CO7C 233/18 (2006.01) Weg 10, 71065 Sindelfmgen (DE). HEIDENREICH, A61K 31/225 (2006.01) CO7C 255/24 (2006.01) Regina; BirkenstraBe 15, 72072 Tubingen (DE). HOPE, A61K 9/16 (2006.01) Michael J.; 3550 West 11th Avenue, Vancouver, British Columbia V6R 2K2 (CA). JASNY, Edith; Mohringer Str. International Application Number: 159, 70199 Stuttgart (DE). LAZZARO, Sandra; Michael- PCT/EP2017/077517 str. 9, 72070 Tiibingen (DE). LIN, Paulo Jia Ching; 2837 E. 54th Ave., Vancouver, British Columbia V5S 1Y4 (CA). International Filing Date: LUTZ, Johannes; HauBer Str. 142, 72076 Tiibingen (DE). 26 October 2017 (26.10.2017) MUI, Barbara; 1158 East 11th Avenue, Vancouver, British English Columbia V5T 2G3 (CA). PETSCH, Benjamin; Hagel- Publication Language: English locher Weg 44, 72070 Tubingen (DE). RAUCH, Susanne; Im Winkelrain 18, 72076 Tiibingen (DE). SCHMIDT, Kim Priority Data: Ellen; Talstr. 27, 72135 Dettenhausen (DE). TAM, Ying; PCT/EP2016/075843 3575 West 19th Avenue, Vancouver, British Columbia V6S 26 October 2016 (26.10.2016) EP 1C3 (CA). PCT/EP2016/075929 (74) Agent: PHARMA CONCEPTS GMBH; Unterer Rhein- 27 October 2016 (27.10.2016) EP weg 50, 4057 Basel (CH). PCT/EP2017/064066 09 June 2017 (09.06.2017) EP (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, Applicants: CUREVAC AG [DE/DE]; Paul-Ehrlich- AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, StraBe 15, 72076 Tubingen (DE). ACUITAS THERA- CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, EEEEE 7 S Y, ii 2 , g O -. . s a a an of (54) Title: LIPID 1.1o.- lx1C - c ix106- 1?) E 1,105- 1x10\' - 1x10 .3 NANOPARTICLE MRNA VACCINES PpLuc expression i.m. - 24h , A _ ixioB 'Ix A.R 4 1. A. • .. - § 1 • • .—. 1 , ,p • 118- s 1,10 7 • • - , 3 - 3 Is * ¨ 4 ci, ' c • , g g ix106 • '2 0, s 1,105 o_ o_ 1x10\' 1x10 3 PpLuc expression i.m. - 48h 4.-4,A 41-* • 4 4 * ;1. .• . .. 1 • -W- — ¨ .4. * :70. • • ¨ - 0 4 0 , , 0 ti0 A 4f ,, , > 0 ) .s> 4 ,zs f> , ,> ff 4S s p s Of A A A A A 4 A 4 A A ti ~4 's , • 's , p. 's , , c,,'\' 's ,C) . '' , s p4 , , ,s2 0 , 4 \ p4 . , ,,A , ,s2 , , p,s2 , , y 4 c) , , p4 A • • ;SY . c > t ' ) \'›.. ''). ob . , SO - ' 4: NS ) p' \'; .es.%'' , f,' ' GA 0 R V ' c k e ,o , , ,,, of' , , z sY A N- 0 e \,‘ 0 N . ,' N3- \ O ,o6 ° CP S c FIG. 1A FIG. 113 : The invention relates to mRNA comprising lipid nanoparticles and their medical uses. The lipid nanoparticles of the invention comprise a cationic lipid according to formula (I), (II) or (III) and/or a PEG lipid according to formula (IV), as well mRNA compound comprising an mRNA sequence encoding an antigenic peptide or protein. The invention further relates to the said lipid nanoparticles as vaccines or medicaments, in particular with respect to influenza or rabies vaccination. ,—, M un C> VD IN c: : :: , (57) -- -- GC present ,1 as 0 use ei C [Continued on next page] WO 2018/078053 Al MIDEDIMOMOIDEIREIDIONOMMOIREIMOVOIS DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) — with sequence listing part of description (Rule 5.2(a))

en

LIPID NANOPARTICLE MRNA VACCINES

71485142_CA,56227581_DE

56309438_DE,71104339_DE,57510297_DE,71935644_DE,71060926_CA,71710262_DE,71708492_DE,71639113_CA,56506012_DE,71164987_CA,56480518_DE,64601951_DE,71831033_CA

A61K 9/1272,A61K 9/19,A61K 9/5123,A61K 31/16,A61K 31/23,A61K 31/40,A61K 31/7105,A61K 39/12,A61K 39/145,A61K 39/385,A61K 39/39,A61K 47/14,A61K 47/6929,A61K2039/53,A61K2039/54,A61K2039/55555,A61K2039/6018,A61K2039/70,A61P 31/14,A61P 31/16,A61P 37/02,B82Y 5/00,C07C 211/21,C07C 219/06,C07C 219/08,C07C 229/16,C07C 233/18,C07C 233/36,C07C 255/24,C07C2601/14,C12N2760/16134,C12N2760/16234,C12N2760/20134

2018-04-11

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIP0 I PCT omit VIII °nolo VIII miono Hs (10) International Publication Number WO 2018/194523 Al (51) International Patent Classification: G16H 50/30 (2018.01) (21) International Application Number: PCT/TH2018/000019 (22) International Filing Date: 11 April 2018 (11.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1701002141 19 April 2017 (19.04.2017) TH (71) Applicants: NATIONAL SCIENCE AND TECHNOL- OGY DEVELOPMENT AGENCY [TH/TH]; 111 Thai- land Science Park, Phahonyothin Road, Khlong 1, Khlong Luang, Pathum Thani, 12120 (TH). SOFTWARE ISARA ORDINARY PARTNERSHIP [TH/TH]; 64/43 Soi Lad- phrao 83, Ladprao Road, Wangthonglang, Bangkok, 10310 (TH). (72) Inventors: THIEMJARUS, Surapa; 111 Thailand Science Park, Phahonyothin Road, Khlong 1, Khlong Lu- ang, Pathum Thani, 12120 (TH). ANANTAVRASILP, Isara; 64/43 Soi Ladphrao 83, Ladprao Road, Wangth- onglang, Bangkok, 10310 (TH). (74) Agent: RUANGSIN, Ratchada et al.; 111 Thailand Science Park, Phahonyothin Road, Khlong 1, Khlong Lu- ang, Pathum Thani, 12120 (TH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (54) Title: SYSTEM FOR RECORDING, ANALYZING RISK(S) OF ACCIDENT(S) OR NEED OF ASSISTANCE AND PROVIDING REAL-TIME WARNING(S) BASED ON CONTINUOUS SENSOR SIGNALS (57) : This invention relates to a system for recording, analyzing risk(s) of accident(s) or need of assistance and providing real-time warning(s) based on continuous sensor signals, wherein the system according to this invention comprising at least one mea- suring device(s) and at least one administrative device(s), wherein the said measuring device(s) receives various data related to the user for processing and displaying on the administrative device(s). More complex system may comprise of at least one signal fusion device(s) for transferring data related to the examinee(s), for a wider area of coverage, and/or at least one server(s) that records various data related to the examinee and administrator(s), in order to playback, process and/or transfer data to other administrative device(s) or transfer warning data to relative(s) of the examinee. The data analytical-processing step may be performed on the measuring device(s) itself or distributed to various parts of the system. Wherein said data processing step comprises a data processing and displaying step, which further comprising a data input step, a context recognition step, an inference for estimating risk and a warning step, a database record step, a display step, and a warning configuration step. The system for recording, analyzing risk(s) of accident(s) or need of assistance and providing real-time warning(s) based on continuous sensor signals according to this invention can continuously notify various data measurement and analysis related to the examinee and warn the administrator(s) when the examinee is at risk as identified in the system for a particular examinee. This allows the administrator(s) to help or adjust the state of the examinee appropriately, in order to reduce a chance of unwanted incidents that may happen to the examinee. Moreover, the measured data can also be used by physician(s) or the administrator(s) to analyze for diagnosis, treatment and caring methods for the examinee.

en

SYSTEM FOR RECORDING, ANALYZING RISK(S) OF ACCIDENT(S) OR NEED OF ASSISTANCE AND PROVIDING REAL-TIME WARNING(S) BASED ON CONTINUOUS SENSOR SIGNALS

74318072_TH,74315788_TH

74122855_TH,73895769_TH

A61B 5/1117,A61B 5/112,A61B 5/742,A61B 5/7455,A61B 5/746,G08B 21/0446,G08B 21/0453,G16H 50/30

2017-10-27

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111101111011101 HIM 0110100111111111 H1111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\' WO 2018/085149 Al 11 May 2018 (11.05.2018) WIPO I PCT (51) International Patent Classification: California 92121-1714 (US). KADOUS, Tamer; c/o H04W 72/04 (2009.01) QUALCOMM INCORPORATED, 5775 Morehouse Dri- (21) ve, San Diego, California 92121-1714 (US). LIU, Chih- International Application Number: Hao; c/o QUALCOMM INCORPORATED, 5775 More- PCT/US2017/058824 house Drive, San Diego, California 92121-1714 (US). PA- (22) International Filing Date: TEL, Chirag; c/o QUALCOMM INCORPORATED, 5775 27 October 2017 (27.10.2017) Morehouse Drive, San Diego, California 92121-1714 (US). RICO ALVARINO, Alberto; c/o QUALCOMM INCOR- (25) Filing Language: English PORATED, 5775 Morehouse Drive, San Diego, California (26) Publication Language: English 92121-1714 (US). (30) Priority Data: (74) Agent: HODGES, Jonas J. et al.; c/o ARENT FOX LLP, 62/416,651 02 November 2016 (02.11.2016) US 1717 K Street NW, Washington, District of Columbia 15/635,018 27 June 2017 (27.06.2017) US 20006-5344 (US). (71) Applicant: QUALCOMM INCORPORATED [US/US]; (81) Designated States (unless otherwise indicated, for every ATTEN: International IP Administration, 5775 Morehouse kind of national protection available): AE, AG, AL, AM, Drive, San Diego, California, US 92121-1714 (US). AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (72) Inventors: YERRAMALLI, Srinivas; c/o QUALCOMM DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, HN, INCORPORATED, 5775 Morehouse Drive, San Diego, (54) Title: WIRELESS COMMUNICATION BETWEEN WIDEBAND ENB AND NARROWBAND UE = = 1000 = = U L transmission unit _ ... ... — _ ....-• ....... .... ... ... ... ... .... .... .. ... 1002 1004 ---. ...-- ...... , , ..... r _. = I UE1 :5 ms ON period UE1 :5 ms OFF period = 1006 \ 1008 ri UE1 on, UE 2 off UE1 off,UE2 on = = = = = FIG. 10 ,-1 (57) : A method and apparatus for wireless communication in the unlicensed spectrum between an eNB and UEs having CN different bandwidths, e.g., between a narrowband UE and a wideband eNB. A user equipment apparatus segments an uplink duration in 71' , 1 each frame into multiple transmission units for each frequency, wherein a frame comprises an integer number of the transmission units. In The apparatus transmits uplink communication based on the multiple transmission units, wherein each transmission unit comprises at °O least one on period and at least one off period corresponding to each of a plurality of frequencies, wherein during an on period the 0 —. UE transmits uplink communication on the corresponding frequency and during an off period the UE refrains from transmitting uplink *1: communication on the corresponding frequency. Each transmission unit may comprise multiple on periods and multiple off periods. 1-1 c;;;;) The on/off periods may be configured by a base station or specified for each frame type. ei O [Continued on next page] WO 2018/085149 Al MIDEDIMOMOIDEIREIDIONIMHEMOEHHOMOVOIMIE HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

en

WIRELESS COMMUNICATION BETWEEN WIDEBAND ENB AND NARROWBAND UE

52280328_US

68937361_US,71809032_US,71919680_US,56324952_US,71212601_US

H04B 1/713,H04L 1/12,H04L 1/189,H04L 5/001,H04L 5/0012,H04L 5/0023,H04L 5/0048,H04L 5/14,H04L 67/12,H04W 4/70,H04W 16/14,H04W 28/26,H04W 72/0413,H04W 72/042,H04W 72/0446,H04W 72/0453,H04W 72/048,H04W 72/1289,H04W 74/004,H04W 74/0808,H04W 88/02,H04W 88/08

2013-05-17

N

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 November 2013 (21.11.2013) WIPOIPCT (10) International Publication Number WO 2013/173761 A2 (51) International Patent Classification: C07K16/24 (2006.01) C12N15/11 (2006.01) (21) International Application Number: PCT/US2013/041656 (22) International Filing Date: 17 May 2013 (17.05.2013) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 61/649,147 18 May 2012 (18.05.2012) US 61/792,619 15 March 2013 (15.03.2013) US (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, California 91320-1799 (US). (72) Inventors: SMITH, Dirk E.; 11633 Meadowmeer Circle NE, Bainbridge Island, Washington 98110 (US). FOLTZ, Ian; 2108 Knightswood Place, Burnaby, BC V5A 4B9 (CA). KING, Chadwick T.; 1325 Moody Avenue, North Vancouver, BC V7L 3T5 (CA). LIM, Ai Ching; 7105 82nd Avenue SE, Mercer Island, Washington 98040 (US). CLARK, Rutilio; 5335 Old Mill Road NE, Bainbridge Is­ land, Washington 98110 (US). COMEAU, Michael R.; 1044 High School Road NE, Bainbridge Island, Washing­ ton 98110 (US). KETCHEM, Randal R.; 6332 152nd Street SE, Snohomish, Washington 98296 (US). SHI, Donghui; 3198 Rickey Court, Thousand Oaks, California 91362 (US). MIN, Xiaoshan; 2108 Clarice Lane, Burl- ingame, California 94010 (US). WANG, Zhulun; 660 Glenbrook Drive, Palo Alto, California 94306 (US). (74) Agent: WRONA, Thomas J.; Amgen Inc., 1201 Amgen Court W¿ Seattle, Washington 98119-3105 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available)'. AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available)'. ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, ¿ [Continued on next page] (54) Title: ST2 ANTIGEN BINDING PROTEINS < 1 \' P FIG. 8 i-H o CJ (57) Abstract: Described herein are compositions and methods related to antigen binding proteins that bind to human ST2, includ - © ing antibodies. In particular embodiments, the disclosure provides fully human anti-ST2 antibodies and derivatives and variants thereof. Further provided are nucleic acids encoding such antibodies and antibody fragments, variants, and derivatives. Also, provided are methods of making and using such antibodies including methods of treating and preventing autoimmune and inflam­ matory disorders. WO 2013/173761 A2 I lllll llllllll II llllll III lllll lllll III III III lllll llll llll lllll lllll lllll lllll lllllll llll llll TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: ¿ as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) ¿ as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: ¿ without international search report and to be republished upon receipt of that report (Rule 48.2(g)) ¿ with sequence listing part of description (Rule 5.2(a))Se describen en la presente composiciones y métodos relacionados con proteínas de unión a antígeno que se unen al receptor ST2 humano, incluyendo anticuerpos. En modalidades particulares, la divulgación provee anticuerpos completos dirigidos contra ST2 humano, y derivados y variantes de los mismos. Además se proveen ácidos nucleicos que codifican dichos anticuerpos y fragmentos de anticuerpo, variantes, y derivados. También se proveen métodos para elaborar y usar dichos anticuerpos, incluidos métodos para tratar y prevenir trastornos autoinmunitarios e inflamatorios.

en

ST2 ANTIGEN BINDING PROTEINS

6179688_US

12598550_US,50238826_CN,16665820_US,12598668_US,12708752_US,46535138_US,73554509_US,12583091_CA,16796181_CA,46862565_US

A61K 39/44,A61K2039/505,A61P 1/04,A61P 7/00,A61P 9/00,A61P 11/00,A61P 11/02,A61P 11/06,A61P 17/00,A61P 17/02,A61P 19/02,A61P 19/08,A61P 25/00,A61P 27/16,A61P 29/00,A61P 31/04,A61P 31/18,A61P 35/00,A61P 37/00,A61P 37/02,A61P 37/06,A61P 37/08,A61P 43/00,C07K 16/24,C07K 16/244,C07K 16/28,C07K 16/2866,C07K2317/21,C07K2317/33,C07K2317/34,C07K2317/51,C07K2317/515,C07K2317/56,C07K2317/565,C07K2317/76,C07K2317/92,C12N 15/11,C12N 15/63,Y10S 530/809

2018-01-11

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 July 2018 (19.07.2018) WI PO I PCT Hu omit VIII OH olo offinionimoilowo Hs (10) International Publication Number WO 2018/132590 Al 101 102 103 (51) International Patent Classification: GOOK 9 / 2 0 (2006.01) GOOK 9 / 8 0 (2006.01) GOOK 9 / 4 6 (2006.01) GOOF 17/18 (2006.01) (21) International Application Number: PCT/US2018/013344 (22) International Filing Date: 11 January 2018 (11.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 201710018395.1 11 January 2017 (11.01.2017) CN 15/864,572 08 January 2018 (08.01.2018) US (71) Applicant: ALIBABA GROUP HOLDING LIMITED [ /US]; Fourth Floor, One Capital Place, P.O. Box 847, George Town (KY). (72) Inventors: WANG, Linqing; c/o Ants Patent Team, 17F Building B, Huanglong Times Plaza, No.18 Wantang Road, Hangzhou, 310099 (CN). ZENG, Xiaodong; c/o Ants Patent Team, 17F Building B, Huanglong Times Plaza, No.18 Wantang Road, Hangzhou, 310099 (CN). ZHANG, Hong; c/o Ants Patent Team, 17F Building B, Huanglong Times Plaza, No.18 Wantang Road, Hangzhou, 310099 (CN). LIN, Feng; c/o Ants Patent Team, 17F Building B, Huanglong Times Plaza, No.18 Wantang Road, Hangzhou, 310099 (CN). (74) Agent: STALFORD, Terry, J.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, MN 55440-1022 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (54) Title: IMAGE RECOGNITION METHOD AND APPARATUS BASED ON AUGMENTED REALITY Gather user information uploaded by an augmented reality client terminal v Screen out picture feature samples associated with the user information from a preset picture feature sample library • Generate, on the basis of the screened-out picture feature samples, a picture feature sample sub-library corresponding to the user information, and push the picture feature sample sub-library to the augmented reality client terminal, so that during image scanning in an offline environment of a user, the AR client terminal performs image recognition on the scanned image information on the basis of the picture feature sample sub-library FIG. 1 O (57) : The present application provides an image recognition method based on augmented reality, which includes: gathering user information uploaded by an augmented reality client terminal; screening out picture feature samples associated with the user information from a preset picture feature sample library; and generating, on the basis of the screened-out picture feature samples, a picture feature sample sub-library corresponding to the user information, and pushing the picture feature sample sub- library to the augmented reality client terminal, so that during image scanning in an offline environment of the user, the augmented reality client 00 terminal performs image recognition on the scanned image information on the basis of the picture feature sample sub-library. The O present application can improve the image recognition efficiency of an AR client terminal. C [Continued on next page] WO 2018/132590 Al MIDEDIMOMOIDEIREEMOMOMMOHINEOMMEHOIS KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

IMAGE RECOGNITION METHOD AND APPARATUS BASED ON AUGMENTED REALITY

11236634_

56332459_CN,72014544_CN,74287629_CN,67857500_CN

G06F 16/5838,G06T 11/60,G06T 19/006,G06V 10/44,G06V 10/751,G06V 20/20,G06V 20/30,H04L 67/131,H04L 67/53,H04L 67/535,H04L 67/55

2018-02-09

N

W O 20 18/ 175 0 12 Al FIG. 24 2410 ( -2412 Generate, based on the compadson, missing target samples using at least one of a reform= frame based on the reference channel or a target frame based on the modified newt channel. where the fins, signal corresponds to a portion lithe reference frame, and where the second signal ourresponds to a portion of the target frame. ( 2408 Determine a temporal correlertion value indicative of a tempond ourrelertion between a fina signal associated with the referemx channel and a wound signal associated with the modified target channel ( .2404 Identify a target channel and a .eference channel, the target channel and the reference channel identified film the two or more channels based on a mismatch value ( 2406 Caleraa a modified Ursa channel by tempondly adjusting the target channel bawd on the mismatch value. the mismatch value indicative of an amount of tumoral mismatch between the target channel and the reference channel Compare the tniaporill corre (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIP0 I PCT ill mu °mons I SID o olommoollm VIII VII VII IE (10) International Publication Number WO 2018/175012 Al (51) International Patent Classification: G10L 19/008 (2013.01) (21) International Application Number: PCT/US2018/017654 (22) International Filing Date: 09 February 2018 (09.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/474,010 20 March 2017 (20.03.2017) US 15/892,130 08 February 2018 (08.02.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; ATTN: International IP Administration, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (72) Inventors: ATTI, Venkatraman; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). CHEBIYYAM, Venkata Subrahmanyam Chandra Sekhar; 5775 More- house Drive, San Diego, California 92121-1714 (US). (74) Agent: TOLER LAW GROUP, PC et al.; 8500 Bluffstone Cove, Suite A201, Austin, Texas 78759 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: TARGET SAMPLE GENERATION (57) : A method of encoding audio channels includes receiving two or more channels at an encoder and identifying a target channel and a reference channel. The target channel and the reference channel are identified from the two or more channels based on a mismatch value. The method also includes generating a modified target channel by temporally adjusting the target channel based on the mismatch value. The mismatch value is indicative of an amount of temporal mismatch between the target channel and the reference channel. The method also includes determining a temporal correlation value indicative of a temporal correlation between a first signal associated with the reference channel and a second signal associated with the modified target channel. The method also includes comparing the temporal correlation value to a threshold. The method further includes generating missing target samples based on the comparison, a coder type, or both.

en

TARGET SAMPLE GENERATION

52280328_US

71175944_US,71203048_US

G10L 19/005,G10L 19/008,G10L 19/12,H04S 3/008,H04S2400/03,H04S2400/15

2018-01-12

N

Singleprocessor Vision Sensor System 1350 Queries Peripheral Circuitry —0 1370 Dedicated Processor 1312 1314 r- 1 1340 Visual Sensor Array Unit Face Detection Event A 1330 4 0 1372 1374 110 Device Controller Memory CV Hardware Controller Core Application Processor Core Visual Input FIG. 13B 1-1 00 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 July 2018 (26.07.2018) WIP0 I PCT omit VIII °nolo 10110111 OH oimIE (10) International Publication Number WO 2018/136325 Al (51) International Patent Classification: GOOK 9/00 (2006.01) GOOK 9 / 5 6 (2006.01) GOOK 9 / 4 6 (2006.01) (21) International Application Number: PCT/US2018/013501 (22) International Filing Date: 12 January 2018 (12.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 15/413,390 23 January 2017 (23.01.2017) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; ATTN: International IP Administration, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (72) Inventors: GOUSEV, Evgeni; 5775 Morehouse Dri- ve, San Diego, California 92121-1714 (US). GOVIL, Alok; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). MAITAN, Jacek; 5775 Morehouse Dri- ve, San Diego, California 92121-1714 (US). RASQUIN- HA, Nelson; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). RANGAN, Venkat; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). PARK, Ed- win Chongwoo; 5775 Morehouse Drive, San Diego, Cali- fornia 92121-1714 (US). (74) Agent: CHANG, Ko-Fang et al.; Kilpatrick Townsend & Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, N.E., Suite 2800, Atlanta, Georgia 30309 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (54) Title: SINGLE-PROCESSOR COMPUTER VISION HARDWARE CONTROL AND APPLICATION EXECUTION (57) : Apparatuses, methods, and systems are presented for reacting to scene-based occurrences. Such an apparatus may comprise dedicated computer vision (CV) computation hardware configured to receive sensor data from a sensor array comprising a plurality of sensor pixels and capable of computing one or more CV features using readings from neighboring sensor pixels of the sensor array. The apparatus may further comprise a first processing unit configured to control operation of the dedicated CV computation hardware. The first processing unit may be further configured to execute one or more application programs and, in conjunction with execution of the one or more application programs, communicate with at least one input/output (I/O) device controller, to effectuate an I/O operation in reaction to an event generated based on operations performed on the one or more computed CV features. [Continued on next page] WO 2018/136325 Al MIDEDIMOMOIDEIREEMOMMIMIMMOHOMEHOIS DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))

en

SINGLE-PROCESSOR COMPUTER VISION HARDWARE CONTROL AND APPLICATION EXECUTION

52280328_US

74321839_US,74403541_US,74057320_US,73481778_US,74055909_US,73901086_US

G06V 10/36,G06V 10/50,G06V 10/955,G06V 20/44,G06V 40/107,G06V 40/16

2018-04-19

N

FirstLoudspeaker Second Output Channel 128 Second Loudspeaker 144 First Audio Channel 130 (\'Reference Channel\') Second Audio Channel 132 (Target Channel\') Second Microphone 148 First Microphone 146 Modified Non Harmonic HB Flag (y) 920 Down-Mix Bitstream 216 ICBWE Bitstream 242 High-Band Mid Channel Bitstream 244 Low-Band Bitstream 246 Modified Non Harmonic FIB Flag (y) 920 Down-Mix Bitstream 216 ICBWE Bitstream 242 High-Band Mid Channel Bitstream 244 Low-Band Bitstream 246 100 First Output Channel 126 First Device 104 Memory 153 Instructions 191 Transmitter 110 Input I nterface(s) 112 Encoder 200 Inter-Channel BWE Encoder 204 Non Harmonic HB Flag (x) 910 Modified Non Harmonic HB Flag (y) 920 ( 106 Second Device Decoder 300 I ICBWE Decoder 306 I Modified Non Harmonic HB Flag (y) 920 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIP0 I PCT ill IIIIIl °million °nolo mu imm Eno iflo oimIE (10) International Publication Number WO 2018/195299 Al (51) International Patent Classification: G1OL 19/008 (2013.01) G1OL 21/038 (2013.01) G1OL 19/02 (2013.01) (21) International Application Number: PCT/US2018/028338 (22) International Filing Date: 19 April 2018 (19.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/488,654 21 April 2017 (21.04.2017) US 15/956,645 18 April 2018 (18.04.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; ATTN: International IP Administration, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (72) Inventors: CHEBIYYAM, Venkata Subrahmanyam Chandra Sekhar; 590 Mill Creek Lane, #205, Santa Clara, California 95054 (US). ATTI, Venkatraman; 5775 More- house Drive, San Diego, California 92121-1714 (US). (74) Agent: TOLER LAW GROUP, PC et al.; 8500 Bluffstone Cove, Suite A201, Austin, Texas 78759 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (54) Title: NON-HARMONIC SPEECH DETECTION AND BANDWIDTH EXTENSION IN A MULTI-SOURCE ENVIRON- = MENT FIG. 1 M Sound Source152 (57) : A device includes a multi-channel encoder configured to receive a first audio signal and a second audio signal, to perform a downmix operation on the first audio signal and the second audio signal to generate a mid signal, to generate a low-band mid signal and a high-band mid signal based on the mid signal, and to determine, based at least partially on a low band voicing value corresponding to the low band signal and a gain value corresponding to the high-band mid signal, a value of a multi-source flag that 00 flag associated with the high-band mid signal. The multi-channel encoder is configured to generate a high-band mid excitation signal O based on the multi-source flag and to generate a bitstream based on the high-band mid excitation signal. The device also includes a transmitter configured to transmit the bitstream and the multi-source flag to a second device. C [Continued on next page] WO 2018/195299 Al OII (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

NON-HARMONIC SPEECH DETECTION AND BANDWIDTH EXTENSION IN A MULTI-SOURCE ENVIRONMENT

52280328_US

71203048_US,71175944_US

G10L 19/008,G10L 19/0204,G10L 21/038,G10L 21/0388

2017-11-03

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 11111111111111111111111111111111111111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\' WO 2018/128691 Al 12 July 2018 (12.07.2018) WIP0 1 PCT (51) International Patent Classification: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, A01K 67/027 (2006.01) C12N 15/85 (2006.01) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, C12N 15/90 (2006.01) CO7K 16/00 (2006.01) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: (84) Designated States (unless otherwise indicated, for every PCT/US2017/060006 kind of regional protection available): ARIPO (BW, GH, (22) International Filing Date: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 03 November 2017 (03.11.2017) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (25) Filing Language: English EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (26) Publication Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (30) Priority Data: KM, ML, MR, NE, SN, TD, TG). 62/417,845 04 November 2016 (04.11.2016) US 62/567,932 04 October 2017 (04.10.2017) US Declarations under Rule 4.17: — (71) Applicant: REGENERON PHARMACEUTICALS, of inventorship (Rule 4.17(iv)) INC. [US/US]; 777 Old Saw Mill Rover Road, Tarrytown, Published: NY 10591-6706 (US). — with international search report (Art. 21(3)) — before the expiration of the time limit for amending the (72) Inventors: GUO, Chunguang; c/o Regeneron Pharmaceu- claims and to be republished in the event of receipt of ticals, Inc., 777 Old Saw Mill Rover Road, Tarrytown, NY amendments (Rule 48.2(h)) 10591 (US). HARRIS, Faith; c/o Regeneron Pharmaceuti- cals, Inc., 777 Old Saw Mill Rover Road, Tarrytown, NY = 10591 (US). VORONINA, Vera; c/o Regeneron Pharma- _ ceuticals, Inc., 777 Old Saw Mill Rover Road, Tarrytown, NY 10591 (US). MCWHIRTER, John; c/o Regeneron =_ — Pharmaceuticals, Inc., 777 Old Saw Mill Rover Road, Tar- rytown, NY 10591 (US). LEVENKONA, Natasha; c/o Re- generon Pharmaceuticals, Inc., 777 Old Saw Mill Rover = Road, Tarrytown, NY 10591 (US). MACDONALD, Lynn; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill Rover Road, Tarrytown, NY 10591 (US). TU, Naxin; c/o = _ Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill Rover = Road, Tarrytown, NY 10591 (US). MURPHY, Andrew, _ J.; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill = = Rover Road, Tarrytown, NY 10591 (US). Agent: SCHONEWALD, Stephanie, L.; Choate, Hall & (74) Stewart LLP, Two International Place, Boston, MA 02110 = (US). = (81) Designated States (unless otherwise indicated, for every — kind of national protection available): AE, AG, AL, AM, = AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, = — 1-1 MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, Il ON (54) Title: NON-HUMAN ANIMALS HAVING AN ENGINEERED IMMUNOGLOBULIN LAMBDA LIGHT CHAIN LOCUS GO (57) : Non-human animals (and/or non-human cells) and methods of using and making the same are provided, which non- e\'' human animals (and/or non-human cells) have a genome comprising human antibody-encoding sequences (i.e., immunoglobulin genes). 1-1 —. Non-human animals described herein express antibodies that contain human Igk light chains, in whole or in part. In particular, non- GO human animals provided herein are, in some embodiments, characterized by expression of antibodies that contain human Ig?. light 1-1 © chains, in whole or in part, that are encoded by human Igk light chain-encoding sequences inserted into an endogenous Igk light chain f'1 locus of said non-human animals. Methods for producing antibodies from non-human animals are also provided. 0

en

NON-HUMAN ANIMALS HAVING AN ENGINEERED IMMUNOGLOBULIN LAMBDA LIGHT CHAIN LOCUS

55538596_US

71251733_US,71179821_US,55118631_US,71328346_US,56532202_US,55461541_US,57330592_US,71897378_US

A01K 67/0278,A01K2207/15,A01K2217/05,A01K2217/072,A01K2217/075,A01K2227/105,A01K2267/01,C07K 16/00,C07K2317/14,C07K2317/24,C12N 15/907,C12N2015/8518,C12N2800/30

2018-03-23

N

subfame n F 1 SF PSCCH PSCCH PSCCH PSSCH PSSCH PSSCH PSCCH PSCCH PSCCH PSSCH PSSCH PSSCH PSCCH PSCCH PSCCH PSSCH PSSCH PSSCH PSCCH PSCCH PSCCH PSSCH PSSCH PSSCH PSCCH PSCCH PSCCH PSSCH PSSCH PSSCH 922 924 926 928 930 932 934 936 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIP0 I PCT ill mu °mons I SID o VIII SID Hiolom No VII IE (10) International Publication Number WO 2018/175822 Al (51) International Patent Classification: HO4W 72/02 (2009.01) H04 TY 72/10 (2009.01) H04 TY 72/06 (2009.01) H04 TY 84/18 (2009.01) (21) International Application Number: PCT/US2018/023911 (22) International Filing Date: 23 March 2018 (23.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/476,330 24 March 2017 (24.03.2017) US 15/928,652 22 March 2018 (22.03.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; Attn: International IP Administration, 5775 Morehouse Dri- ve, San Diego, CA 92121-1714 (US). (72) Inventors: GULATI, Kapil; 5775 Morehouse Drive, San Diego, CA 92121 (US). NGUYEN, Tien Viet; 5775 More- house Drive, San Diego, CA 92121 (US). BAGHEL, Sud- hir Kumar; 5775 Morehouse Drive, San Diego, CA 92121 (US). WU, Zhibin; 5775 Morehouse Drive, San Diego, CA 92121 (US). PATIL, Shailesh; 5775 Morehouse Drive, San Diego, CA 92121 (US). (74) Agent: TEMPEL, Michael, J. et al.; Smith Tempel Blaha LLC, 50 Glenlake Parkway, Suite 340, Atlanta, GA 30328 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (54) Title: LOW LATENCY ENHANCEMENTS TO CV2X AUTONOMOUS RESOURCE SELECTION AND RE-SELECTION PROCEDURE FOR VEHICLE-TO-VEHICLE COMMUNICATIONS Freq 1 SF 1 SF 900 940 942 944 946 PSCCH PSCCH PSCCH PSSCH PSSCH PSSCH PSCCH PSCCH PSCCH PSSCH PSSCH PSSCH PSCCH PSCCH PSCCH PSSCH PSSCH PSSCH PSCCH PSCCH PSCCH PSSCH PSSCH — PSSCH PSCCH PSCCH PSCCH PSSCH PSSCH PSSCH 00 N 00 O O 938- ) T2 ( -901 =Candidate resources for 910 resource (re)selection (set S B ) Candidate resources without exclusions FIG. 9 (57) : Low latency enhancements for communication systems, including autonomous driving and/or selection scenarios, are provided. A method for communication includes monitoring communication resources in a communication system, determining a set of candidate resources to use for subsequent transmission of information within a time window such that the time window is minimized based on a desired communication latency parameter that considers at least one or more of communication channel congestion and a priority of transmission, determining a set of lowest energy resources from the set of candidate resources, selecting a low energy resource from the set of lowest energy resources, and transmitting data on the selected low energy resource. Other aspects, embodiments, and features are also claimed and described. [Continued on next page] Time WO 2018/175822 Al MIDEDIMOMMIDIREEM3111111111111111111111111111111111111111111111111 CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

LOW LATENCY ENHANCEMENTS TO CV2X AUTONOMOUS RESOURCE SELECTION AND RE-SELECTION PROCEDURE FOR VEHICLE-TO-VEHICLE COMMUNICATIONS

52280328_US

74264305_US,73968545_US,71931965_US,73488171_US,74004761_US

H04B 17/382,H04L 5/006,H04L 5/0064,H04L 5/0071,H04W 4/40,H04W 4/44,H04W 4/46,H04W 24/02,H04W 24/08,H04W 28/021,H04W 72/02,H04W 72/044,H04W 72/06,H04W 72/10,H04W 76/14,H04W 84/005,H04W 84/18,H04W 88/06,H04W 92/10

2018-03-22

N

PSSPit-t-tt PBCH Bandwidth/ Third Bandwidth Time Self- Decodable F rst Portion of Bandwidth PBCH 425; Second Bandwidth Frequency Sync Signal Frequency 430 SSS 410 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIP0 I PCT ill mu °million °nolo Oil mo Ho oimIE (10) International Publication Number WO 2018/194790 Al (51) International Patent Classification: HO4L 1/00 (2006.01) H04L 5/00 (2006.01) (21) International Application Number: PCT/US2018/023835 (22) International Filing Date: 22 March 2018 (22.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/488,637 21 April 2017 (21.04.2017) US 62/564,030 27 September 2017 (27.09.2017) US 15/877,976 23 January 2018 (23.01.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; ATTN: International IP Administration, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (72) Inventors: LY, Hung; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). JIANG, Jing; 5775 More- house Drive, San Diego, California 92121-1714 (US). RI- CO ALVARINO, Alberto; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). WANG, Xiao Feng; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). LUO, Tao; 5775 Morehouse Drive, San Diego, Cal- ifornia 92121-1714 (US). SORIAGA, Joseph, Binamira; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). SARKIS, Gabi; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (74) Agent: ANDERSON, Thomas D.; Holland & Hart LLP, P.O. Box 11583, Salt Lake City, Utah 84147 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: TECHNIQUES TO ENCODE OR DECODE A SELF-DECODABLE PORTION OF A PHYSICAL BROADCAST CHAN- NEL IN A SYNCHRONIZATION SIGNAL BLOCK (57) : Techniques for wireless communication are de- scribed. A method of wireless communication at a user equip- ment (UE) includes receiving a synchronization signal within a synchronization signal (SS) block; receiving at least a portion of a physical broadcast channel (PBCH) of the SS block, the PBCH comprising a self-decodable portion and an outside portion; and decoding the PBCH based at least in part on receiving the self- decodable portion of the PBCH. The synchronization signal has a first bandwidth. The self-decodable portion of the PBCH has a second bandwidth substantially within the first bandwidth. The outside portion having a bandwidth that is outside of the second bandwidth and within a PBCH bandwidth, the PBCH bandwidth being greater than the first bandwidth. W O 20 18/ 19 47 90 Al 415 ---r..7771 PBCH 420 DMR S FIG. 4 400 [Continued on next page] WO 2018/194790 Al MIDEDIMOMMIONE101301ROMOIROMMEM# TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))

en

TECHNIQUES TO ENCODE OR DECODE A SELF-DECODABLE PORTION OF A PHYSICAL BROADCAST CHANNEL IN A SYNCHRONIZATION SIGNAL BLOCK

52280328_US

69248658_US,65672214_US,56543372_US,73946143_US,68937361_US,56459191_US,67553613_US

H04L 1/0009,H04L 1/0045,H04L 1/0057,H04L 1/0071,H04L 1/04,H04L 1/08,H04L 5/005,H04L 5/0053,H04W 56/001,H04W 88/02,H04W 88/08

2018-05-03

N

Determinea channel format for transmitting uplink communications in a slot, where the channel format is based on at least a payload size r Determine whether intra-slot frequency hopping is configured „... 402 404 W O 20 18/ 20 4666 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) WIP0 I PCT 0111111010 0111 °nolo HoloimilmoilioluovoimIE (10) International Publication Number WO 2018/204666 Al (51) International Patent Classification: H04L 5/00 (2006.01) (21) International Application Number: PCT/US2018/030916 (22) International Filing Date: 03 May 2018 (03.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/502,421 05 May 2017 (05.05.2017) US 15/969,477 02 May 2018 (02.05.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; ATTN: International IP Administration, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (72) Inventors: WANG, Renqiu; c/o QUALCOMM INCOR- PORATED, 5775 Morehouse Drive, San Diego, Califor- nia 92121-1714 (US). HUANG, Yi; c/o QUALCOMM IN- CORPORATED, 5775 Morehouse Drive, San Diego, Cali- fornia 92121-1714 (US). XU, Hao; c/o QUALCOMM IN- CORPORATED, 5775 Morehouse Drive, San Diego, Cali- fornia 92121-1714 (US). GAAL, Peter; c/o QUALCOMM INCORPORATED, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (74) Agent: BINDSEIL, James J. et al.; c/o ARENT FOX LLP, 1717 K Street NW, Washington, District of Columbia 20006-5344 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: CHANNEL FORMATS WITH FLEXIBLE DURATION IN WIRELESS COMMUNICATIONS (57) : Aspects herein describe determining a channel format for transmitting uplink communications in a slot, wherein the channel format is selected from multiple channel formats based at least in part on a payload size of the uplink communications, determining a starting symbol and an ending symbol of an uplink channel duration of the slot for transmitting the uplink communications, determining, based at least in part on the starting symbol and the ending symbol, a portion of the channel format to utilize in transmitting the uplink communications in the slot, and transmitting the uplink com- munications in the slot, wherein transmitting the uplink communications is based on the portion of the channel format. Determine a starting symbol and an ending symbol of an uplink channel duration of the slot Determine, based at lent in part on the starting symbol and the ending symbol, a portion of the channel format to utilize k nansmitting the uplink communications rldetermine a user multiplewng scheme. I 410 I spreading factor, or orthogonal cover I set based on the channel format Transmit the uplink communications in the slot based on the portion aloe channel format , ,412 FIG. 4 [Continued on next page] / 408 WO 2018/204666 Al MIDEDIMOMMIDIRE101001010IMEHROMEMOIS TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

CHANNEL FORMATS WITH FLEXIBLE DURATION IN WIRELESS COMMUNICATIONS

52280328_US

56570006_US,69235791_US,56286106_US,71547434_US

H04B 1/713,H04J 13/16,H04J2013/165,H04L 5/0007,H04L 5/001,H04L 5/0012,H04L 5/0016,H04L 5/0023,H04L 5/0042,H04L 5/0044,H04L 5/0048,H04L 5/0092,H04L 5/1469,H04W 72/044,H04W 72/1268

2017-10-26

N

artCy {in CDR) y-region mAb constant region peptide---N () INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 03 May 2018 (03.05.2018) WIP0 I PCT omit °nolo omm im °mono lio iflo oimIE (10) International Publication Number WO 2018/081370 Al (51) International Patent Classification: C07K 14/47 (2006.01) A61K 38/04 (2006.01) (21) International Application Number: PCT/US2017/058455 (22) International Filing Date: 26 October 2017 (26.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/413,586 27 October 2016 (27.10.2016) US 62/413,613 27 October 2016 (27.10.2016) US (71) Applicant: JANSSEN PHARMACEUTICA NV [BE/BE]; Turnhoutseweg 30, B-2340 Beerse (BE). (72) Inventor; and (71) Applicant (for US only): MACIELAG, Mark [US/US]; 1400 McKean Road, Spring House, PA 19477 (US). (72) Inventors: MACIELAG, Mark; 1400 McKean Road, Spring House, PA 19477 (US). PATCH, Raymond, J.; 1400 McKean Road, Spring House, PA 19477 (US). ZHANG, Rui; 1400 McKean Road, Spring House, PA 19477 (US). CASE, Martin, A.; 3210 Merryfield Row, San Diego, CA 92121 (US). RANGWALA, Shamina, M.; 1400 McKean Road, Spring House, PA 19477 (US). LEONARD, James, N.; 1400 McKean Road, Spring House, PA 19477 (US). CAMACHO, Raul, C.; 1400 McKean Road, Spring House, PA 19477 (US). HUNTER, Michael, J.; 3210 Merryfield Row, San Diego, CA 92121 (US). D'AQUINO, Katharine, E.; 1400 McKean Road, Spring House, PA 19477 (US). EDWARDS, Wilson; 3210 Merryfield Row, San Diego, CA 92121 (US). SWANSON, Ronald, V.; 3210 Merryfield Row, San Diego, CA 92121 (US). MAN, Wenying; 1400 McKean Road, Spring House, PA 19477 (US). ZHANG, Yue-Mei; 1400 McKean Road, Spring House, PA 19477 (US). WALL, Mark; 1400 McK- ean Road, Spring House, PA 19477 (US). CHI, Ellen; 3210 Merryfield Row, San Diego, CA 92121 (US). (74) Agent: BARANIAK, Andrew, P. et al.; Panitch Schwarze Belisario & Nadel LLP, Two Commerce Square, 2001 Mar- ket Street, Suite 2800, Philadelphia, PA 19103 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) = (54) Title: ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEU- = ROPEPTIDE Y RECEPTORS Fig. I O (57) : The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. \' The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, C treating or ameliorating diseases and disorders disclosed herein. [Continued on next page] 1-1 O N 1-1 00 WO 2018/081370 Al MIDEDIMOHNOIREIEREIMMENHOMMEHOIS Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))

en

ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS

55088190_BE

71951748_US,71305223_US,71810478_US,71885247_US,71647517_US,71892891_US,71203025_US,71543903_US,65137180_US,71955525_US,69230829_US,71691104_US,71691104_US,71302727_US,71328251_US,72024167_US

A61K 9/0019,A61K 38/00,A61K 38/17,A61K 38/1709,A61K 38/22,A61K 38/26,A61K 45/06,A61K 47/542,A61K 47/60,A61K 47/64,A61K 47/68,A61K 47/6811,A61K 47/6845,A61K 47/6883,A61K 47/6889,A61K 49/0032,A61K 49/0052,A61K 49/0056,A61K2039/505,A61P 3/00,A61P 3/04,A61P 3/06,A61P 3/08,A61P 3/10,C07K 1/061,C07K 1/1072,C07K 1/12,C07K 1/18,C07K 5/0205,C07K 14/575,C07K 14/57545,C07K 16/00,C07K 16/24,C07K2317/14,C07K2317/21,C07K2317/24,C07K2317/33,C07K2317/52,C07K2317/55,C07K2317/56,C07K2317/565,C07K2317/567,C07K2317/71,C07K2317/92,C07K2317/94,C07K2319/30

2018-04-25

Y

This system is used to rejuvenate youth by targeting the pituitary gland to produce HGH and testosterone. Also, with this system, a personal avatar is created, so that a person with the help of virtual reality, optional, simulate traveling to a specific brain site and giving a stimulation to that site. Also, the personal avatar will travel inside a designated vehicle type for that purpose. Also, The Smart Brain System is a type of a platform that can work with all brain stimulation products. It should become the model that people will use for brain control via the internet. Using this system, the brain is re-wired or re-programmed as to where a stimulation is received within the brain. A person will view a simulation of an electrical stimulation current that transmits to an area of the brain they desire to stimulate. Watching the smart brain simulations enables the mind to have a visual perception of the area of the brain to stimulate. So that by using the mind, vision and sense of hearing and touch, we can show the brain where a stimulation should be received within the brain. Also, using this system will allow the individual to have a more personal role in their brain stimulation therapy. This system can be used in clinical and office settings, although it is primarily for use via the internet. The smart brain system can be produced for use in all languages and marketed to all countries via the internet. The person will log into the smart brain web site. They will be asked to purchase the E-transporter system. It consists of a USB cable that has rectangular panels along its length. These panels are lights, which are programmed to indicate the direction of a current or movement of an object or stimulus within the cable. It will attach at the hand and continue up the arm and onto the back of the neck. Electrode wires with pads branch out at the neck to be placed on the head. This E-transporter and controller have a vibrational capacity, an electrical stimulation capacity, a speech and speech recognition capacity, and a sound effect capacity. It plugs into the computer at the USB port. The user will upload a photo of them self, preferably while wearing the E-transporter, to the web sites database. (This step is optional since a generic photo and E-transporter system can be used). A pre-programmed format will graft a computerized version of the brain into their photo. The therapist or individual will impute the type of brain stimulation they want to generate. When prompted, the program will display a cut-out view of their head displaying the computerized brain inside. When prompted, a pre-programmed video displays a simulated current that transmits to the target region of the brain to be stimulated. When the simulated current enters the target region of the brain, signs and signals will be displayed indicating that the area is being stimulated or that a downloading is in progress. The E-transporter lighting effects, vibrations and tactile properties will work simultaneously with the copy of the E-transporter and simulations that are displayed on the screen. The E-transporter wearable unit and the personal photo enhances the biofeedback that the simulated stimulations are occurring in the individual's own brain. Different concepts of brain design and brain activities can be used. One example would be: simulating the brain as an electronic component and displaying its electronic properties as brain activities. Another example is: simulating the brain as having caves and having a tunnel system that the stimulus travels through etc. The smart brain web site and E-transporter system will be produced by neuroscientists, medical illustrators, computer programmers, video production programmers, graphic designers, business developers, patent attorneys, and many others. Clinical trials are still needed to prove that this type of visual and neuronal feedback is an effective tool for brain stimulation therapy and that it adds a real benefit to brain stimulation therapy that is already being done.

en

Device and method for localization of brain function related applications

58021426_US

58021426_US

A61B 5/375,A61B 5/378,A61B 5/38,A61B 5/4064,A61M 21/00,A61M2021/0072,G06F 3/015,G06T 13/00,G16B 5/00,G16H 50/50

2018-04-27

N

APCOR TUMOR CELL APC OR TUMOR CELL REINVIGORATED T CELL CYTOKINES EFFECTOR MECHANISMS INHIBITORY aTIM- ACTIVATION SIGNAL SIGNAL PD-1 LAG-3 TCR )ritAG-3 aPD-1 EXHAUSTED T CELL ACTIVATION SIGNAL TCR Ag MHC TIM-3 Ag MHC (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT omit VIII °nolo Holollm olo lionoiliflo oimIE (10) International Publication Number WO 2018/201096 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2018/030027 (22) International Filing Date: 27 April 2018 (27.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/491,221 27 April 2017 (27.04.2017) US 62/578,215 27 October 2017 (27.10.2017) US 62/614,998 08 January 2018 (08.01.2018) US 62/625,276 01 February 2018 (01.02.2018) US 62/657,384 13 April 2018 (13.04.2018) US (71) Applicants: TESARO, INC. [US/US]; 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). ANAP- TYSBIO, INC. [US/US]; 10421 Pacific Center Court, Suite 200, San Diego, CA 92121 (US). (72) Inventors: JUN, Helen, Toni; c/o Anaptysbio, Inc., 10421 Pacific Center Court, Suite 200, San Diego, CA 92121 (US). KEHRY, Marilyn; c/o Anaptysbio, Inc., 10421 Pacific Center Court, Suite 200, San Diego, CA 92121 (US). BOWERS, Peter; c/o Anaptysbio, Inc., 10421 Pa- cific Center Court, Suite 200, San Diego, CA 92121 (US). KING, David, J.; c/o Anaptysbio, Inc., 10421 Pacific Center Court, Suite 200, San Diego, CA 92121 (US). BOBILEV, Dmitri; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). GHOSH, Srimoyee; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). HUANG, Baochuan; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). JENKINS, David; c/o Tesaro, Inc., 1000 Winter Street North, Suite 3300, Waltham, MA 02451 (US). (74) Agent: ESPINO, Christine, G. et al.; Proskauer Rose LLP, One International Place, Boston, MA 02110 (US). (54) Title: ANTIBODY AGENTS DIRECTED AGAINST LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) AND USES THERE- OF FIGURE 1 1-1 01 O O 1-1 (57) : The disclosure provides antibody agents that bind to a Lymphocyte Activation Gene-3 (LAG-3) protein. Particular immunoglobulin heavy chain polypeptide and immunoglobulin light chain polypeptide sequences are explicitly provided. Also provided 0 are related nucleic acids, vectors, compositions, and methods of using anti-LAG-3 antibody agents to treat a disorder or disease that is \' responsive to LAG-3 inhibition, such as, for example, cancer or an infectious disease. C [Continued on next page] WO 2018/201096 Al MIDEDIMOMOIDEIRDERI00101011M0101101EIMOVOIMIE (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))

en

ANTIBODY AGENTS DIRECTED AGAINST LYMPHOCYTE ACTIVATION GENE-3 (LAG-3) AND USES THEREOF

71731222_US,56534361_US

73787348_US,56490901_US,73470684_US,71726370_US,71259870_US,56431054_US,71003247_US,74264596_US

A61K 39/3955,A61K 45/06,A61K2039/505,A61K2039/507,A61K2039/54,A61K2039/545,A61P 35/00,C07K 16/2803,C07K 16/2818,C07K2317/41,C07K2317/70,C07K2317/76,C07K2317/92,Y02A 50/30

2018-03-13

N

WO 18/ 169989 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIP0 I PCT ill~~~~~~~~ 011101VIIIVIIIVIII olo VIII VIII omom oimIE (10) International Publication Number WO 2018/169989 Al (51) International Patent Classification: H04N 19/00 (2014.01) (21) International Application Number: PCT/US2018/022226 (22) International Filing Date: 13 March 2018 (13.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/470,809 13 March 2017 (13.03.2017) US 15/919,060 12 March 2018 (12.03.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; ATTN: International IP Administration, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (72) Inventors: CHUANG, Hsiao-Chiang; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). CHEN, Jianle; 10756 Corte De Tiburon, San Diego, California 92130 (US). CHEN, Yi-Wen; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). LI, Xiang; 10574 Gaylemont Lane, San Diego, California 92130 (US). KAR- CZEWICZ, Marta; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). CHIEN, Wei-Jung; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (74) Agent: JOSEPH, Jeffrey R.; Shumaker & Sieffert, PA., 1625 Radio Drive, Suite 100, Woodbury, Minnesota 55125 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: INTER PREDICTION REFINEMENT BASED ON BI-DIRECTIONAL OPTICAL FLOW (BIO) (57) : A video decoder can be configured to determine that a 220 block of video data is encoded using a bi-directional inter prediction A ,-- --- mode; determine that the block of video data is encoded using a bi-direc- tional optical flow (BIO) process; inter predict the block of video data according to the bi-directional inter prediction mode; perform the BIO • 2 22 process for the block, wherein performing the BIO process for the block comprises determining a single motion vector refinement for a group of pixels in the block, wherein the group of pixels comprises at least two pixels; refine the group of pixels based on the single motion vector refine- ment; and output a BIO refmed predictive block of video data comprising 224 the refmed group of pixels. PERFORM THE BIO PROCESS FOR THE BLOCK, BY DETERMINING A SINGLE MOTION VECTOR REFINEMENT FOR A GROUP OF PIXELS IN THE BLOCK AND REFINING THE GROUP OF PIXELS BASED ON THE SINGLE MOTION VECTOR REFINEMENT OUTPUT A BIO REFINED PREDICTIVE BLOCK OF VIDEO DATA COMPRISING THE REFINED GROUP OF PIXELS FIG. 21 [Continued on next page] DETERMINE THAT A BLOCK OF VIDEO DATA IS ENCODED USING A BI-DIRECTIONAL INTER PREDICTION MODE DETERMINE THAT THE BLOCK OF VIDEO DATA IS ENCODED USING A BIO PROCESS INTER PREDICT THE BLOCK OF VIDEO DATA USING THE BI-DIRECTIONAL INTER PREDICTION MODE 226 228 WO 2018/169989 Al MIDEDIMOMMIDEFIDIDEMIERCIMEHMOVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

INTER PREDICTION REFINEMENT BASED ON BI-DIRECTIONAL OPTICAL FLOW (BIO)

52280328_US

56282794_US,56524711_US,56424575_US,65641941_US,71792006_US,68099413_US

H04N 5/145,H04N 19/00,H04N 19/107,H04N 19/20,H04N 19/30,H04N 19/517,H04N 19/543,H04N 19/577,H04N 19/61,H04N 19/70

2001-09-25

N

A protein having activities of a human platelet activating factor acetylhydrolase, and represented by an amino acid sequence represented by the following formula (I) or an amino acid sequence having homology therewith; and a DNA encoding the protein: <table-cwu id='TABLE-US-00001'> <number>1</number> <table frame='none' colsep='0' rowsep='0' tabstyle='monospace'> <tgroup align='left' colsep='0' rowsep='0' cols='1'> <colspec colname='1' colwidth='217PT' align='left'/> <tbody valign='top'> <row> <entry></entry> </row> <row> <entry>Met Gly Val Asn Gln Ser Val Gly Phe Pro Pro Val</entry> </row> <row> <entry> </entry> </row> <row> <entry>Thr Gly Pro His Leu Val Gly Cys Gly Asp Val Met</entry> </row> <row> <entry> </entry> </row> <row> <entry>Glu Gly Gln Asn Leu Gln Gly Ser Phe Phe Arg Leu</entry> </row> <row> <entry> </entry> </row> <row> <entry>Phe Tyr Pro Cys Gln Lys Ala Glu Glu Thr Met Glu</entry> </row> <row> <entry> </entry> </row> <row> <entry>Gln Pro Leu Trp Ile Pro Arg Tyr Glu Tyr Cys Thr</entry> </row> <row> <entry> </entry> </row> <row> <entry>Gly Leu Ala Glu Tyr Leu Gln Phe Asn Lys Arg Cys</entry> </row> <row> <entry> </entry> </row> <row> <entry>Gly Gly Leu Leu Phe Asn Leu Ala Val Gly Ser Cys</entry> </row> <row> <entry> </entry> </row> <row> <entry>Arg Leu Pro Val Ser Trp Asn Gly Pro Phe Lys Thr</entry> </row> <row> <entry> </entry> </row> <row> <entry>Lys Asp Ser Gly Tyr Pro Leu Ile Ile Phe Ser His</entry> </row> <row> <entry> </entry> </row> <row> <entry>Gly Leu Gly Ala Phe Arg Thr Leu Tyr Ser Ala Phe</entry> </row> <row> <entry> </entry> </row> <row> <entry>Cys Met Glu Leu Ala Ser Arg Gly Phe Val Val Ala</entry> </row> <row> <entry> </entry> </row> <row> <entry>Val Pro Glu His Arg Asp Arg Ser Ala Ala Thr Thr</entry> </row> <row> <entry> </entry> </row> <row> <entry>Tyr Phe Cys Lys Gln Ala Pro Glu Glu Asn Gln Pro</entry> </row> <row> <entry> </entry> </row> <row> <entry>Thr Asn Glu Ser Leu Gln Glu Glu Trp Ile Pro Phe</entry> </row> <row> <entry> </entry> </row> <row> <entry>Arg Arg Val Glu Glu Gly Glu Lys Glu Phe His Val</entry> </row> <row> <entry> </entry> </row> <row> <entry>Arg Asn Pro Gln Val His Gln Arg Val Ser Glu Cys</entry> </row> <row> <entry> </entry> </row> <row> <entry>Leu Arg Val Leu Lys Ile Leu Gln Glu Val Thr Ala</entry> </row> <row> <entry> </entry> </row> <row> <entry>Gly Gln Thr Val Phe Asn Ile Leu Pro Gly Gly Leu</entry> </row> <row> <entry> </entry> </row> <row> <entry>Asp Leu Met Thr Leu Lys Gly Asn Ile Asp Met Ser</entry> </row> <row> <entry> </entry> </row> <row> <entry>Arg Val Ala Val Met Gly His Ser Phe Gly Gly Ala</entry> </row> <row> <entry> </entry> </row> <row> <entry>Thr Ala Ile Leu Ala Leu Ala Lys Glu Thr Gln Phe</entry> </row> <row> <entry> </entry> </row> <row> <entry>Arg Cys Ala Val Ala Leu Asp Ala Trp Met Phe Pro</entry> </row> <row> <entry> </entry> </row> <row> <entry>Leu Glu Arg Asp Phe Tyr Pro Lys Ala Arg Gly Pro</entry> </row> <row> <entry> </entry> </row> <row> <entry>Val Phe Phe Ile Asn Thr Glu Lys Phe Gln Thr Met</entry> </row> <row> <entry> </entry> </row> <row> <entry>Glu Ser Val Asn Leu Met Lys Lys Ile Cys Ala Gln</entry> </row> <row> <entry> </entry> </row> <row> <entry>His Glu Gln Ser Arg Ile Ile Thr Val Leu Gly Ser</entry> </row> <row> <entry> </entry> </row> <row> <entry>Val His Arg Ser Gln Thr Asp Phe Ala Phe Val Thr</entry> </row> <row> <entry> </entry> </row> <row> <entry>Gly Asn Leu Ile Gly Lys Phe Phe Ser Thr Glu Thr</entry> </row> <row> <entry> </entry> </row> <row> <entry>Arg Gly Ser Leu Asp Pro Tyr Glu Gly Gln Glu Val</entry> </row> <row> <entry> </entry> </row> <row> <entry>Met Val Arg Ala Met Leu Ala Phe Leu Gln Lys His</entry> </row> <row> <entry> </entry> </row> <row> <entry>Leu Asp Leu Lys Glu Asp Tyr Asn Gln Trp Asn Asn</entry> </row> <row> <entry> </entry> </row> <row> <entry>Leu Ile Glu Gly Ile Gly Pro Ser Leu Thr Pro Gly</entry> </row> <row> <entry> </entry> </row> <row> <entry>Ala Pro His His Leu Ser Ser Leu</entry> </row> </tbody> </tgroup> </table> </table-cwu>

en

Platelet activating factor acetylhydrolase, and gene thereof

5618737_JP

31762239_JP,19435894_JP,18489818_JP,19350016_JP

C12N 9/18

2018-02-22

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 August 2018 (30.08.2018) W I P0 I P C T IiiimmomiolollmonolomonllnalionovoimIE (10) International Publication Number WO 2018/153343 Al (51) International Patent Classification: H03M 13/00 (2006.01) (21) International Application Number: PCT/CN2018/076970 (22) International Filing Date: 22 February 2018 (22.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/CN2017/074381 22 February 2017 (22.02.2017) CN (71) Applicant: QUALCOMM INCORPORATED [US/US]; International IP Administration, 5775 Morehouse Drive, San Diego, CA California 92121-1714 (US). (72) Inventors; and (71) Applicants (for US only): YANG, Yang [CN/US]; 5775 Morehouse Drive, San Diego, CA California 92121-1714 (US). JIANG, Jing [CN/US]; 5775 Morehouse Drive, San Diego, CA California 92121-1714 (US). SARKIS, Gabi [CA/US]; 5775 Morehouse Drive, San Diego, CA California 92121-1714 (US). WEI, Chao [CN/CN]; 5775 Morehouse Drive, San Diego, CA California 92121-1714 (US). LI, Jian [CN/CN]; 5775 Morehouse Drive, San Diego, CA California 92121-1714 (US). SANKAR, Hari [US/US]; 5775 Morehouse Drive, San Diego, CA California 92121-1714 (US). XU, Changlong [CN/CN]; 5775 More- house Drive, San Diego, CA California 92121-1714 (US). SORIAGA, Joseph Binamira [US/US]; 5775 Morehouse Drive, San Diego, CA California 92121-1714 (US). (74) Agent: NTD PATENT & TRADEMARK AGENCY LIMITED; 10th Floor, Block A, Investment Plaza, 27 Jin- rongdajie, Xicheng District, Beijing 100033 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (54) Title: MUTUAL-INFORMATION BASED RECURSIVE POLAR CODE CONSTRUCTION 205 210 215 \'Transmitter/ Receiver Memory 220 Encoder/Decoder 225 FIG. 2 200 (57) : Methods, systems, and devices for wireless communication are described. To encode a vector of bits using a polar code, an encoder may allocate information bits of the vector to polarized bit-channels associated with a channel (e.g., a set of unpolar- ized bit-channels) used for a transmission. In some cases, the polarized bit-channels may be partitioned into groups associated with different values of some associated reliability metric (s). The information bits may be allocated to the polarized bit-channels based on the reliability metrics of the different polarized bit-channels and the overall capacity of a transmission. That is, the bit locations of a transmission may depend on the reliability metrics of different polarized bit-channels and the overall capacity of the transmission. To facilitate puncturing, the overall capacity of the transmission may be adjusted and the unpolarized bit-channels may be partitioned into polarized bit-channels based on the adjusted capacity. [Continued on next page] WO 2018/153343 Al MIDEDIMOMOIDEIREEM311011100MOMEHMIE (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

MUTUAL-INFORMATION BASED RECURSIVE POLAR CODE CONSTRUCTION

52280328_US

73946143_US,68578736_CN,71201088_CN,56459191_US,74258152_US,57247260_US,69040232_CN,68749293_US

H03M 13/13,H03M 13/6362,H04L 1/0014,H04L 1/0047,H04L 1/0057,H04L 1/0068,H04L 5/0053

2018-07-13

N

40 -20 -10 6 35% 34 23 (12) INTERNATIONAL APPLICATION PUBLISHED (19) World Intellectual Property Organization International Bureau UNDER THE PATENT COOPERATION TREATY (PCT) IiiiionolivivivillEviiliololoillEvivivEmionvitiovois (10) International Publication Number WO 2019/014586 Al PCT (43) International Publication Date 17 January 2019 (17.01.2019) W I PO I Point Boulevard, Suite 400, South San Francisco, California 94080 (US). (74) Agent: SHORE, David E. et al.; Choate, Hall & Ste- wart LLP, Two International Place, Boston, Massachusetts 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (51) International Patent Classification: CO7K 16/28 (2006.01) (21) International Application Number: PCT/US2018/042074 (22) International Filing Date: 13 July 2018 (13.07.2018) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/532,889 14 July 2017 (14.07.2017) US (71) Applicant: CYTOMX THERAPEUTICS, INC. [US/US]; 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). (72) Inventors: DESNOYERS, Luc Roland; c/o CytomX Therapeutics, Inc., 151 Oyster Point Boulevard, Suite 400, South San Francisco, California 94080 (US). DUPAGE, Amy Grace; c/o CytomX Therapeutics, Inc., 151 Oyster (54) Title: ANTI-CD166 ANTIBODIES AND USES THEREOF Figure 13 Prevalence of CD166 Expression Across Metastatic Indications Number of cases scored -80+ cases Secondary Site 4 7 100-- — 178 % Strong /Mo dera te Exp ression 62 75 50 21 50 25 45 I I 51 71 25 0 e' S b 4 S cc` cc' 4' 9 + ..te s e\ t * 'b- A e t> e • 0 z 42<\' ci e ci° b 3 o <(% ,s 4 b *b c> „, t y , o t z e e e gf;. \ CP se e ( a. ckss s c> ez, kg ke as (20. €.> \ \ .tc` i e b 4, 0 'b. *A e e e e te b t e 43 43 ‘ 9 „ . 4 4 \ f t , c). cc• c° N t b- 2 b , e - - xe 16 t . 4 ‘ 3 Na .0 1-1 GC 71. 1-1 O 1-1 O (57) : The present invention provides, among other things, an antibody or antigen-binding polypeptide that binds or is capa- ble of binding CD 166, compositions including the same, and uses thereof. In certain embodiments, an anti-CD 166 antibody or anti- gen-binding polypeptide of the present invention binds or is capable of binding all or a portion of an intracellular domain (\'ICD\') of CD 166. The present invention also includes, among other things, a nucleic acid molecule encoding an antibody or antigen-binding polypeptide that binds or is capable of binding CD 166. In various embodiments, an anti-CD 166 antibody or antigen-binding polypep- tide is useful in a method of detecting or treating a condition or disease. [Continued on next page] WO 2019/014586 Al IIIIIIIIIIIIHNEHICIII111111111111111111111111111111111111111111111111111111 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

en

ANTI-CD166 ANTIBODIES AND USES THEREOF

56586992_US

77207219_US,76581761_US

A61K 47/6801,A61K2039/505,A61P 35/00,C07K 16/2803,C07K2317/24,C07K2317/515,C07K2317/565,C07K2317/622,C07K2317/76,C07K2317/92,G01N 33/56966,G01N 33/56972,G01N2333/70596

2017-10-18

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) - (19) World Intellectual Property Organization - - 1111111111111111111111111111111111111111111111111111111111111111111111111110111111 ' International Bureau (10) International Publication Number (43) International Publication Date ......0\'\' WO 2018/072705 Al 26 April 2018 (26.04.2018) WIP0 I PCT (51) International Patent Classification: Yuen Road, Shatin, New Territories, Hong Kong 999077 C12Q 1/68 (2006.01) (CN). (21) International Application Number: (74) Agent: INSIGHT INTELLECTUAL PROPERTY PCT/CN2017/106663 LIMITED; 19 A, Tower A, InDo Building, No. 48A (22) International Filing Date: Zhichun Road, Haidian District, Beijing 100098 (CN). 18 October 2017 (18.10.2017) (81) Designated States (unless otherwise indicated, for every (25) Filing Language: English kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (26) Publication Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (30) Priority Data: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 62/410,108 19 October 2016 (19.10.2016) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (71) Applicant: THE CHINESE UNIVERSITY OF HONG MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, KONG [CN/CN]; c/o Office of Research and Knowledge OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, Transfer Services, Room 301, Pi Ch'iu Building, Shatin, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, New Territories, Hong Kong 999077 (CN). TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: LO, Yuk-Ming Dennis; 4th Floor, 7 King Tak (84) Designated States (unless otherwise indicated, for every Street, Homantin, Kowloon, Hong Kong 999077 (CN). kind of regional protection available): ARIPO (BW, GH, _ CHIU, Rossa Wai Kwun; House 31, Double Haven, 52 GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, Ma Lok Path, Shatin, New Territories, Hong Kong 999077 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (CN). CHAN, Kwan Chee; Flat C, 15th Floor, Block 5, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Peak One, Mei Tin Road, Shatin, New Territories, Hong EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, = Kong 999077 (CN). JIANG, Peiyong; Flat 7 on 1st Floor of MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = _ Block B of Kwong Lam Court, Nos. 62-66 (No.62) Siu Lek = (54) Title: GESTATIONAL AGE ASSESSMENT BY METHYLATION AND SIZE PROFILING OF MATERNAL PLASMA DNA = (57) : Temporal variations in one or more characteristics measured from 800 a cell-free DNA sample are used to estimate a gestational age of a fetus. Exam- — 810 ple characteristics include the methylation level measured from the cell-free DNA sample, size of DNA fragments measured from the cell-free DNA sample (e.g., = Arialysits ere-free DNA isoleasks Pisa a Siuttple to determine whether the cell-free DNA molecule is proportion of fetal-derived DNA fragments longer than a specified size), and end- = = — Methylated At one mmotn Sites. ing patterns of the DNA fragments align to a reference genome. =8ID Determine arespectivertumber of cell-free DNA —_ oloteculea thar aremedaylated at each of the one ormore sites = = = — Calculate ameasund methylation level of cell-free DNA = Moleattlea in the sample = Obtain ate or more tatibtathin data pokis Shag speedy a gestational age corresponding to a calibration methylation level 11 850 in Compare the measured metbylation Level to a calibratima medtgladon level of at kart one calibration data points IN 11 © g6 1 N Estimate a gestational age of the fetus based owthe Ir----- comparison © 1-1 Fig. 8 0 N O [Continued on next page] WO 2018/072705 Al MIDEDIMOMMIDIREIHNIFIHMEIIMERVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

GESTATIONAL AGE ASSESSMENT BY METHYLATION AND SIZE PROFILING OF MATERNAL PLASMA DNA

56200690_CN

56378466_CN,56146821_CN,56274289_CN,56377450_CN

C12N 15/1003,C12Q 1/6858,C12Q 1/6883,C12Q 1/6888,C12Q2600/154,G01N 33/53

2018-03-30

N

ModemCommunications Component 190 Assignment Receiving Component 192 UCI Transmitting Component 194 100 • aTN --------- • ---- --• --------- 115 120 135 1 1 505 125 -V. 130 130 FIG. 1 Modem 140 Communications Component 150 Determining Component 152 Cyclic Shifts Determining Component 154 Assigning Component 156 Receiving Component 158 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 25 October 2018 (25.10.2018) WIPO I PCT o °nolo VIII HE °um oimIE (10) International Publication Number WO 2018/194821 Al (51) International Patent Classification: HO4L 1/00 (2006.01) H04L 5/00 (2006.01) HO4L 1/18 (2006.01) (21) International Application Number: PCT/US2018/025524 (22) International Filing Date: 30 March 2018 (30.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/486,414 17 April 2017 (17.04.2017) US 15/940,710 29 March 2018 (29.03.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; ATTN: International IP Administration, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (72) Inventors: WANG, Renqiu; c/o QUALCOMM INCOR- PORATED, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). PARK, Seyong; c/o QUALCOMM IN- CORPORATED, 5775 Morehouse Drive, San Diego, Cali- fornia 92121-1714 (US). XU, Hao; c/o QUALCOMM IN- CORPORATED, 5775 Morehouse Drive, San Diego, Cali- fornia 92121-1714 (US). HUANG, Yi; c/o QUALCOMM INCORPORATED, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (74) Agent: BINDSEIL, James J. et al.; c/o ARENT FOX LLP, 1717 K Street NW, Washington, District of Columbia 20006-5344 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (54) Title: MULTIPLEXING FOR SEQUENCE BASED ACKNOWLEDGEMENT DESIGN FOR NEW RADIO 71' 00 11 00 11 O C (57) : A method and apparatus for improved transmission of ACK and NACK bits to a base station The example method may determine a distance between a first UE and a second UE based on one or more of a sequence length, a number of hypothesis, or a number of UEs sharing an OFDM symbol. The example method may determine a plurality of cyclic shifts for each of the first UE and the second UE. The example method may assign one or more sequences to each UE. The example method may receive, at the base station, a multiplexed signal, wherein the multiplexed signal includes at least one bit of uplink control information (UCI) from the first UE and the second UE multiplexed on an uplink short burst transmitted via the OFDM symbol. The method may enable the receipt of UCI from multiple UEs in a multiplexed signal. [Continued on next page] WO 2018/194821 Al IIMEDIMOMOIDEIREEMOMOICEDIVEINIMEn KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

en

MULTIPLEXING FOR SEQUENCE BASED ACKNOWLEDGEMENT DESIGN FOR NEW RADIO

52280328_US

74268558_US,71547434_US,69235791_US,56570006_US

H04J 1/02,H04L 1/0073,H04L 1/1861,H04L 5/0007,H04L 5/0048,H04L 5/0055,H04W 72/0413,H04W 72/12,H04W 88/02,H04W 88/08

2017-08-22

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property :::` , 1111111011110111011111111111011111010111111111101110111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date .....•\'\' WO 2018/080624 Al 03 May 2018 (03.05.2018) W I PO I PCT (51) International Patent Classification: NARAYANASWAMI, Ravi; 1600 Amphitheatre Park- G06N 3/10 (2006.01) way, Mountain View, California 94043 (US). (21) International Application Number: (74) Agent: HENRY, Joel et al.; Fish & Richardson P.C., P.O. PCT/US2017/047992 Box 1022, Minneapolis, Minnesota 55440-1022 (US). (22) International Filing Date: (81) Designated States (unless otherwise indicated, for every 22 August 2017 (22.08.2017) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (25) Filing Language: English CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, (26) Publication Language: English DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (30) Priority Data: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 15/336,066 27 October 2016 (27.10.2016) US KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 15/465,774 22 March 2017 (22.03.2017) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (71) Applicant: GOOGLE LLC [US/US]; 1600 Amphitheatre SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, Parkway, Mountain View, California 94043 (US). TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: WOO, Dong Hyuk; 1600 Amphitheatre (84) Designated States (unless otherwise indicated, for every Parkway, Mountain View, California 94043 (US). kind of regional protection available): ARIPO (BW, GH, (54) Title: EXPLOITING INPUT DATA SPARSITY IN NEURAL NETWORK COMPUTE UNITS 300-- INSTRUCTIONS, INPUT ACTIVATIONS, AND WEIGHTS/PARAMETERS 303--- t Bitmap 1 1 ° 1 1 1 6 1 1 1 ° 1 1 1 ° ( 1 ) ( ) 3 + ( ) 5 ( ) 7 Weights and Partial Sums (Second Memory 110) Controller 302 310 First Activiations 102 Memory 108 Input 310 310 Activation Bus Parameters MAC 304 T r104a f Parameters MAC 304 r104b IL f Parameters MAC 304 r104c 306 —2 Output Activation Bus I 1 , 308 305 -- UU1 t. EI1 i ,-1 .4 I I - (57) : A computer el a controller of the computing device, whether each of the input activations has either a zero value or a non-zero value. The method 0 further includes storing, GC © activation includes generating - non-zero values. The GC ,_ 1 onto a data bus that is © memory address location N ( 1 ) ( ) 3 ( 5 ) ( ) 7 FIG. 3 -implemented method includes receiving, by a computing device, input activations and determining, by in a memory bank of the computing device, at least one of the input activations. Storing the at least one input an index comprising one or more memory address locations that have input activation values that are method still further includes providing, by the controller and from the memory bank, at least accessible by one or more units of a computational array. The activations are provided, at least associated with the index. one input activation in part, from a C [Continued on next page] WO 2018/080624 Al MIDEDIMOMMIDIREEMOOMMMONEDIDEHMEMOIMIE GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(U)) — as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))

en

EXPLOITING INPUT DATA SPARSITY IN NEURAL NETWORK COMPUTE UNITS

57394858_US

56430398_US,56432157_US

G06F 9/3001,G06F 9/38,G06F 9/3824,G06F 13/1668,G06F 15/76,G06F 17/16,G06N 3/0454,G06N 3/063,G06N 3/08,G06N 3/10,G06N 5/04,G06N 20/00,G06N 20/10,Y02D 10/00

2019-06-14

Y

(19) til-S-01AM,1 -J r 9i0d (19) 1111DIIIIIIIII~Ilili 111111111 I N11111111111 INi (10) (4 3) [AM EPI 2020O11q 19 E (19.11.2020) WO 2020/230340 A1 WIPOlPCT (51) )- : (72)RHj :#(1 T[](ITOKazuhiko); T0640804-l G06T 7/00 (2017.01) V L6 L IN 1 $ E M H 5 7 T H 6 (21) ISl P : PCT/JP2019/023674 $I 74 1'Y IF] Hokkaido (JP). I& Sil, (SATOMakoto); ~0640804 (22) pfl 5 r, :f AE 20199 *6)A14 H (14.06.2019) -l FP 5 FX -A Vq *N 7 T H 6 T1 4- A $:z:' (25) 5 0) : ,* - v'Y NHokkaido (JP). (26) 8 gga (74) ftdT)A : -2 0E r. NijE A (KOIWA Nobuhide et _.0 al.); T2850859 ~:F M * Ifft ? -A.-- J' HR 3 - 1 7Chiba (JP). *R#J 2019-090719 2019*5)J13H(13.05.2019) JP (8 1) ILE_ ZP (Ai PR Gglj) , c WA( 0) P9|AJ 1 (71)-1- - $ 47 M '(MICRONET 9% -Ji): AE, AG, AL, AM, AO, AT, AU, AZ, CO. LTD.) [JP/JP]; T0640804 -lbfU L M$ $ BA, BB, BG, BH, BN, BR, BW. BY, BZ, CA, CH, -5E K(AN 7 T 6 AHokkaido (JP). CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (54) Title: FACIAL RECOGNITION SYSTEM, FACIAL RECOGNITION METHOD, AND FACIAL RECOGNITION 3 Computer at facial authentication processing site 0- t -1 Camera 21 Reception operationexecutigunit 22 Human detection processing unit -23 Ruin-mask-comparisonaunit 24 Poin mask registering uit ____________________25 Outgongfacialimage transmittingunit 26 Com ing facial authentication restreceiving nit SNW1 Internet A Open ngt on ec i itydour CC De tectio n ofsuspiciousperson S(57) Abstract: Provided is afacialrecognition technique with which itis possible to determine false detection of afacial regionathighspeedandtoperformhighlyaccuratefacialrecognition.Thisfacialrecognition system comprises first facialdetectionmeans2havingarelativelylowaccuracyfor performing humanfacial detectionfroma cameraimage 201,andasecondfacialdetectionmeans3forperforminghuman2facial detction withhigheraccuracywith rspecttothe camera image 201. Facial detection isperfored withiuspect teach camera image obtained beach of thefirst facial W O 2020/23 0340 A41111 1 ||||||||||||||||||||||||||||||||||||i|III||||||||||||||||||||||||||||||||||||| |ill| HN, HR, HU, ID, IL, IN, IR, IS, JO, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. 9iht WNE): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), - -5 7 (AM, AZ, BY, KG, KZ, RU, TJ, TM), 9 - F-1 /' (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, Fl, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). - Wip!tW} (M* 21(3)) detection means 2 and the second facial detection means 3. If the second facial detection means 3 is unable to perform facial detection with respect to a facial region detected by the first facial detection means 2, it is determined that the first facial detection means 2 has made a false detection, and the center of gravity coordinates of the facial region are learned as a point mask position. Thereafter, when the first facial detection means 2 has performed facial detection from the camera image 201, the center of gravity coordinates of the facial region is determined. If matching coordinates are found in a group of stored point mask coordinates, the region is determined to be a false detection region, and the highly accurate facial detection by the second facial detection means 3 is not performed with respect to the captured image. 2t0t )5tt 6jAAS&JJ/51 - tttd ZttLVzn 1-eHk0) M PA )10&ff --f 't#L, i2 0 1t t tctt AT QL{ 9EtZkt )1,0& ~ - )0 &fl- ' )A #fiTfI, )O#fI,3L0 tL tEJ1 - lM 7 l-:{itz , , CO2f ,M1 6D A$t4k tf E ISTzRL b t4>fiLkfvi 1:14JLZ- 2 0) PA#43(J -f&3tAO',-'-X SO A&',---F - , A H-' Lkt0

en

Face recognition system, face recognition method and face recognition program

52026390_JP

13227950_,15998049_

G06F 3/14,G06K 9/6262,G06V 10/22,G06V 10/98,G06V 20/52,G06V 40/161,G06V 40/166,G06V 40/172,G07C 9/00563

2018-08-16

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) vitivio VIII oviolo olimilooliommoitio Hs (19) World Intellectual Property Organization International Bureau (10) International Publication Number WO 2019/034753 Al (43) International Publication Date 21 February 2019 (21.02.2019) WIP0 I PCT (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/40 (2006.01) CO7K 16/28 (2006.01) (21) International Application Number: PCT/EP2018/072272 HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art 21(3)) with sequence listing part of description (Rule 5.2(a)) (22) International Filing Date: 16 August 2018 (16.08.2018) English English (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/546,336 16 August 2017 (16.08.2017) US 62/582,609 07 November 2017 (07.11.2017) US (71) Applicant: TUSK THERAPEUTICS LTD [GB/GB]; Stevenage Bioscience Catalyst, Accelerator Building, Gun- nels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). (72) Inventors: GOUBIER, Anne; c/o Tusk Therapeutics Limited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). SALIMU, Josephine; c/o Tusk Therapeutics Limited, Stevenage Bio- science Catalyst, Gunnels Wood Road, Stevenage Hert- fordshire SG1 2FX (GB). GOYENECHEA, Beatriz; c/o Tusk Therapeutics Limited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). MERCHIERS, Pascal; c/o Tusk Therapeutics Lim- ited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). MOULDER, Kevin; c/o Tusk Therapeutics Limited, Stevenage Bio- science Catalyst, Gunnels Wood Road, Stevenage Hertford- shire SG1 2FX (GB). EISSLER, Nina; c/o Tusk Therapeu- tics Limited, Stevenage Bioscience Catalyst, Gunnels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). FILOSTO, Simone; c/o Tusk Therapeutics Limited, Stevenage Bio- science Catalyst, Gunnels Wood Road, Stevenage Hertford- shire SG1 2FX (GB). BARUAH, Hemanta; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). PRINZ, Bianka; c/o Adimab, LLC, 7 Lucent Drive, Lebanon, New Hampshire 03766 (US). (74) Agent: LEONARD, Thomas Charles et al.; Kilburn & Strode LLP, Lacon London, 8 Theobalds Road, London London WC1X 8NL (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (54) Title: CD38 ANTIBODY (57) : The present disclosure provides antibody sequences found in antibodies that bind to human CD38. In particular, the present disclosure provides sequences of anti-human CD38 antibodies. Antibodies and antigen-binding portions thereof including such sequences present features compatible with pharmaceutical manufacturing and development can be provided as fully human antibodies (e.g., fully human monoclonal antibodies or antigen-binding fragments) that can be useful for medical methods and compositions, in particular for treating cancer.

en

CD38 ANTIBODY

76534723_GB

77428845_GB,57667501_US,77142286_US,73527263_GB,76255639_GB,74005832_GB,73401696_GB,73433560_GB,74005848_GB

A61K 39/39558,A61K2039/507,A61P 35/00,C07K 16/2896,C07K 16/40,C07K2317/56,C07K2317/565,C07K2317/732,C07K2317/734,C07K2317/92

2017-10-27

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property C.--.` MD HIM 011101011M 01 11010101111111111011110011101101110111 OEN Organization International Bureau (10) International Publication Number 03 (43) International Publication Date ......P' WO 2018/081640 Al 03 May 2018 (03.05.2018) WIP0 I PCT (51) International Patent Classification: Sciences LLC, 269 East Grand Ave., South San Francis- GOOF 19/00 (2011.01) GOOK 9/62 (2006.01) co, California 94080 (US). KRISHNAN, Dilip; c/o Verily GOOK 9 / 4 6 (2006.01) G06T 7/00 (2017.01) Life Sciences LLC, 269 East Grand Ave., South San Fran- GOOK 9 / 5 2 (2006.01) cisco, California 94080 (US). L1VNI, Josh; c/o Verily Life Sciences LLC, 269 East Grand Ave., South San Francis- (21) International Application Number: PCT/US2017/058872 co, California 94080 (US). DESNOYER, Mark; c/o Verily Life Sciences LLC, 269 East Grand Ave., South San Fran- (22) International Filing Date: cisco, California 94080 (US). 27 October 2017 (27.10.2017) (74) Agent: MCALLISTER, Tyler et al.; Kilpatrick Townsend (25) Filing Language: English & Stockton LLP, Mailstop: IP Docketing - 22, 1100 Peachtree Street, N.E., Suite 2800, Atlanta, Georgia 30309 (26) Publication Language: English (US). (30) Priority Data: (81) Designated States (unless otherwise indicated, for every 62/414,597 28 October 2016 (28.10.2016) US kind of national protection available): AE, AG, AL, AM, (71) Applicant: VERILY LIFE SCIENCES LLC [US/US]; AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 269 East Grand Ave., South San Francisco, California CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 94080 (US). DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, (72) Inventors: ZHA, Tiantian; c/o Verily Life Sciences LLC, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, — 269 East Grand Ave., South San Francisco, California MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, 94080 (US). OVADIA, Yaniv; c/o Verily Life Sciences OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = LLC, 269 East Grand Ave., South San Francisco, Califor- nia 94080 (US). NEWBURGER, Daniel; c/o Verily Life = = (54) Title: PREDICTIVE MODELS FOR VISUALLY CLASSIFYING INSECTS = = = 102 1, 1 . 104 - 1 6 — _.I _ 108 ACCESS 114 AN WAGE DEPICTING PLURALITY OF INSECTS 112 — = = 1208 I-120N 1145 114N .._ _. • IDEN1IFY PATCH FROM MAT DEPICTS INSECT= AN IMAGE THE IMAGE AN = = = 106 = USE A PREILTAIE - i = PREDICTIVE MODE JIQ MOOEL TO EVALUATE IMAGE PATCH TO „)[ACRE INSECT(S). CLASSTY INSECT(S), AND/OR COUNT 106 iNsEcr(s)j22 11 .4 © 71' V; JJ 06 OUTPUT INSECT IN FROM THE PREDICTIVE MODEL CORRESPOIOING 10 THE EVALUATION OF THE IMAGE PATCH 124 11 GC FIG. 1 © . --- - GC (57) : Insects can be localized and classified using a predictive model. To begin, image data is obtained that corresponds to the 1 -1 insects.. Using a predictive model, samples of the image data are evaluated to determine whether the image portions include an insect 0 and, if so, into what category the insect should be classified (e.g., male/female, species A/species B, etc.). ei o [Continued on next page] WO 2018/081640 Al MIDEDIMOMMIDIRERIONEHOHINHOIHMEEN SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

PREDICTIVE MODELS FOR VISUALLY CLASSIFYING INSECTS

67553017_US

71263558_US,71308527_US,71920996_US,71938436_US,71808567_US,71883505_US

G05B 13/027,G05B 13/048,G06K 9/6267,G06K 9/627,G06N 3/0454,G06N 3/082,G06N 3/084,G06T 7/0002,G06T 7/0004,G06T2207/20081,G06T2207/20084,G06V 10/255,G06V 10/764,G06V 10/82,G06V2201/06

2017-10-17

N

FIGURE 5 Encode all source chunks at predetermined visual quail), level to determine corresponding encoded bitrates 504 Generate cumulative distribution function (CDF) of encoded bitrates 506 W O 20 18/075 465 Al Determine NI representative bitrate-quality points based on the M representative pre-encodes 512 Fit logarithmic curve to NI representative bitrate-quality points to construct a representative bitrate- quality curve 514 Set lambda to slope of tangent to representative bitrate-quality curve at representative bitrate 516 Select representative chuck and representative bitrate based on the CDF and a predetermined percentile 508 For representative chunk, generate a representative pre-encode at each of M predetermined quality levels 516 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 April 2018 (26.04.2018) WIP0 I PCT ill~~~~~~~~ 011101010VIIIOH olo mom loominiflom oimIE (10) International Publication Number WO 2018/075465 Al (51) International Patent Classification: HO4N 21/2343 (2011.01) H04N 21/845 (2011.01) (21) International Application Number: PCT/US2017/056902 (22) International Filing Date: 17 October 2017 (17.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 15/296,580 18 October 2016 (18.10.2016) US (71) Applicant: NETFLIX, INC. [US/US]; 100 Winchester Circle, Los Gatos, California 95032 (US). (72) Inventors: DE COCK, Jan; 100 Winchester Circle, Los Gatos, California 95032 (US). AARON, Anne; 100 Win- chester Circle, Los Gatos, California 95032 (US). (74) Agent: CAREY, John C. et al.; Artegis Law Group, LLP, 7710 Cherry Park Drive, Suite T104, Houston, Texas 77095 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: CONSTANT-SLOPE BITRATE ALLOCATION FOR DISTRIBUTED ENCODING (57) : In one embodiment of the present invention, a bitrate allocation engine allocates bitrates for distributed encoding of source data. Upon receiving a chunk of source data, the bitrate allocation engine generates a curve based on multiple points that each specify a different visual quality level and corresponding encoding bitrate for encoding the chunk. Subsequently, the bitrate allocation engine com- putes an optimized encoding bitrate based on the generated curve and an optimization factor that is associated with different visual quality levels and corresponding encoding bitrates for multiple chunks of the source data. The bitrate allocation engine then causes the chunk to be encoded at the optimized encoding bitrate. Advantageously, the re- sulting encoded chunk is optimized with respect to the optimization factor for multiple chunks of the source data.

en

CONSTANT-SLOPE BITRATE ALLOCATION FOR DISTRIBUTED ENCODING

56583058_US

68847351_US,71533143_US

H04N 19/184,H04N 19/21,H04N 21/234354,H04N 21/23439,H04N 21/8456

2018-02-09

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 August 2018 (16.08.2018) WIPO I PCT omit VIII °nolo VIII iflo oimIE (10) International Publication Number WO 2018/148585 Al (51) International Patent Classification: C07K 16/40 (2006.01) (21) International Application Number: PCT/US2018/017680 (22) International Filing Date: 09 February 2018 (09.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/457,722 10 February 2017 (10.02.2017) US (71) Applicant (for all designated States except AL, AT, BA, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR): GENEN- TECH, INC. [US/US]; 1 DNA Way, South San Francisco, CA 94080-4990 (US). (71) Applicant (for AL, AT, BA, BE, BG, CH, CN, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IN, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR only): F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). = (72) Inventors: CHEN, Xiaocheng; 1 DNA Way, South San Francisco, CA 94080-4990 (US). DENNIS, Mark; 1 DNA Way, South San Francisco, CA 94080-4990 (US). JACK- MAN, Janet; 1 DNA Way, South San Francisco, CA 94080-4990 (US). KOERBER, James, T.; 1 DNA Way, South San Francisco, CA 94080-4990 (US). LU, Mason; 5015 Darnell St., Houston, TX 77096 (US). MAUN, Hen- ry, R.; 1 DNA Way, South San Francisco, CA 94080-4990 (US). RAJAPAKSA, Kathila; 1 DNA Way, South San Francisco, CA 94080-4990 (US). RAMANUJAN, Saroja; 1 DNA Way, South San Francisco, CA 94080-4990 (US). STATON, Tracy; 1 DNA Way, South San Francisco, CA 94080-4990 (US). WU, Lawren; 1 DNA Way, South San Francisco, CA 94080-4990 (US). YI, Tangsheng; 1 DNA Way, South San Francisco, CA 94080-4990 (US). (74) Agent: ELBING, Karen, L.; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 1-1 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, 1 1 KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, 71' 1-1 013 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) 1-1 (54) Title: ANTI-TRYPTASE ANTIBODIES, COMPOSITIONS THEREOF, AND USES THEREOF (57) : The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as 0 well as methods of using the same.

en

ANTI-TRYPTASE ANTIBODIES, COMPOSITIONS THEREOF, AND USES THEREOF

55221849_US

67509691_US,73552939_US,74037580_US,64871504_US,74128729_US,73969440_US,73513679_US,71935521_US,73538968_US,73508553_US,55573664_US

A61K 39/3955,A61K 39/39591,A61K 45/06,A61K 47/10,A61K 47/183,A61K 47/22,A61K 47/26,A61K2039/505,A61P 1/04,A61P 3/04,A61P 7/00,A61P 11/00,A61P 11/02,A61P 11/06,A61P 11/14,A61P 17/00,A61P 17/04,A61P 17/06,A61P 19/02,A61P 29/00,A61P 37/04,A61P 37/08,A61P 43/00,C07K 16/244,C07K 16/40,C07K2317/24,C07K2317/31,C07K2317/34,C07K2317/40,C07K2317/55,C07K2317/56,C07K2317/565,C07K2317/567,C07K2317/76,C07K2317/92,C07K2317/94,C12N 15/63,C12Y 304/21059

2001-05-23

N

A system is disclosed that provides an interactive rewards-based method that uses a protocol for instructional response in order to provide a motivating, individualized educational and entertaining experience. The system utilizes an interface through a computer. The system offers the user (a.k.a. student) simulated environments that represent different realities and an opportunity to solve interesting problems and learning puzzles. When the user inputs a response this calls forth a system response using the built-in Intelligent Mentor, thereby teaching the user. The iterative response process provides the user opportunities to discovery before proceeding to a higher level of the subject material. The pedagogical system uses neural nets (engine of artificial intelligence) that drive responses that are synchronized to typographical and graphical illustrations and/or pictorial illustrations used to simulate reality and to provide dynamic interactions. Stages of progression are integrated into the pedagogical system in order to provide users with individually paced experiences determined by the level of difficulty and rate of performance per time period. Users' interaction involves real-time decision-making and fusion of the educational material. It involves programs in computer medium that create a rewards-based system to provide a motivating educational and/or entertainment environment including natural attractions that further motivate continuous involvement in the learning process. Encoded lessons are enabled in the system that provide feedback on aspects of user performance such as mission management, mathematical solutions, recognition, matching, and utilizing data to solve problems and puzzles. The user receives credits each time he/she successfully completes a section. Credits are additive and may be exchanged for material rewards by using this invention of the 'virtual mall' for the computer network. The rewards redemption system includes a server in communication with the users computer mechanism to form a network that may include the Internet. The credits may be saved or can be exchanged for material reward certificates. If redeemed, the student player is dispensed a specific verifiable reward acknowledgement. The computer system can also provide for competition games played for a rivalry of credits by a number of users. Reward information, such as reward costs in terms of specific credit redemption is automatically determined by the system. While this invention has been described in terms of several embodiments, it is contemplated that alterations, variations and equivalents thereof will become apparent to those skilled in the art of pedagogy upon a reading of the specification and study of the drawings. For example, many types of problems/solution sets and puzzles can be provided for use with the disclosed rewards based system, and the computer tool can be utilized for classroom teaching as well. Thus variations can be used. It is noted that the rewards-based system of redemption can be implemented on a single computer connected to other computers, with or without use of the Internet. However, the preferred embodiment illustrated here envisions that the invention will be used in a broad network such as the Internet. The provision of rewards can be achieved by redemption certificates or electronically. It is therefore intended that the claims include all such alterations, variations, and equivalents as fall within the spirit and scope of the present invention. This rewards-based pedagogical system offering lessons within simulated environments and providing for various reward redemptions represents advancement in pedagogical systems for computer-assisted learning and paradigms of progressive skill-development.

en

Interactive rewards-based pedagogical system using an engine of artificial intelligence

39597805_

39597806_US

G09B 19/00

2018-04-03

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT O V SID o Ho mil mil m11°1111E1° VII IE (10) International Publication Number WO 2018/178396 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2018/058479 (22) International Filing Date: 03 April 2018 (03.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/479,712 31 March 2017 (31.03.2017) US PCT/EP2018/057836 27 March 2018 (27.03.2018) EP (71) Applicant: GENMAB HOLDING B.V. [NL/NL]; Upp- salalaan 15, 3584 CT Utrecht (NL). (72) Inventors: OOSTINDIE, Simone; c/o Genmab B.V. Upp- salalaan 15, 3584 CT Utrecht (NL). BEURSKENS, Frank; c/o GENMAB B.V. Uppsalalaan 15, 3584 CT Utrecht (NL). BREIJ, Esther; c/o Gebmab B.V. Uppsalalaan 15, 3584 CT Utrecht (NL). VAN DEN BRINK, Edward; c/o Gen- mab B.V. Uppsalalaan 15, 3584 CT Utrecht (NL). HOL- LENSTEIN, Andreas; c/o Genmab B.V. Uppsalalaan 15, 3584 CT Utrecht (NL). OVERDIJK, Marije; c/o Genmab B.V. Uppsalalaan 15, 3584 CT Utrecht (NL). LINDOR- FER, Margaret; 276 Spring Meadow Lane, Keswick, Vir- ginia 22947 (US). TAYLOR, Ronald; 276 Spring Mead- ow Lane, Keswick, Virginia 22947 (US). PARREN, Paul; Werdorperwaard 17, 3984 PR Odijk (NL). VAN DER HORST, Hilma; Schoolstraat ibis, 3581 PM Utrecht (NL). E.D. CHAMULEAU, Martine; VU University Medical Center Department of Hematology De Boelelaan 1117, 1081 HV Amsterdam (NL). MUTIS, Tuna; VU University Medical Center De Boelelaan 1117, Building CCA, 4.022, 1081 HV Amsterdam (NL). SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) 1-1 t:T GC N 1-1 00 O 1-1 N C (74) Agent: GENMAB A/S; Kalvebod Brygge 43, DK-1560 Copenhagen V (DK). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (54) Title: BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF (57) : CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.

en

BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF

74314400_NL

71232504_NL,74198537_NL,57642238_NL,56521079_NL,74191430_US,73943439_US,56436408_NL,56520644_NL,74245139_NL,73740483_NL,74173349_NL,73740701_NL

A61K 49/00,A61K2039/505,A61K2039/507,A61K2039/545,A61P 35/00,C07K 16/2887,C07K 16/2896,C07K2317/21,C07K2317/24,C07K2317/31,C07K2317/34,C07K2317/526,C07K2317/565,C07K2317/72,C07K2317/732,C07K2317/734,C07K2317/92,C07K2317/94,G01N 33/68,G01N2333/70596

2017-08-29

N

InstructionSet, Activations, Weights Processing Unit 102 Storage Medium 104 Computing System MAC 108 (Linear Unit) Activation Unit 110 122 Tensor Status Elements Instruction Buffer (Tensor / DMA) 124 Tensor Traversal Unit 106 First Bank (Activations) 112-' 1 Second Bank (Weights) 114— ) (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 03 May 2018 (03.05.2018) WIP0 I PCT omit VIII °nolo III m 1111 0111 CIO iflo (10) International Publication Number WO 2018/080628 Al (51) International Patent Classification: GOON 3/04 (2006.01) GOON 3/063 (2006.01) (21) International Application Number: PCT/US2017/049165 (22) International Filing Date: 29 August 2017 (29.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 15/336,216 27 October 2016 (27.10.2016) US 15/455,685 10 March 2017 (10.03.2017) US (71) Applicant: GOOGLE LLC [US/US]; 1600 Amphitheatre Parkway, Mountain View, California 94043 (US). (72) Inventors: NARAYANASWAMI, Ravi; 1600 Amphithe- atre Parkway, Mountain View, California 94043 (US). WOO, Dong Hyuk; 1600 Amphitheatre Parkway, Moun- taro View, California 94043 (US). TEMAM, Olivier; 8 Rue de Londres, 75009 Paris (FR). KHAITAN, Harshit; 1600 Amphitheatre Parkway, Mountain View, California 94043 (US). (74) Agent: HENRY, Joel et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (54) Title: NEURAL NETWORK INSTRUCTION SET ARCHITECTURE 100 Output FIG. 1 (57) : A computer-implemented method that includes receiving, by a processing unit, an instruction that specifies data values for performing a tensor computation. In response to receiving the instruction, the method may include, performing, by the processing unit, the tensor computation by executing a loop nest comprising a plurality of loops, wherein a structure of the loop nest is defmed based on one or more of the data values of the instruction. The tensor computation can be at least a portion of a computation of a neural network layer. The data values specified by the instruction may comprise a value that specifies a type of the neural network layer, and the structure of the loop nest can be defmed at least in part by the type of the neural network layer. [Continued on next page] WO 2018/080628 Al MIDEDIMOMOIDEIREEMOOMMMONIIMEHMEEN (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3))

en

NEURAL NETWORK INSTRUCTION SET ARCHITECTURE

57394858_US

71255969_FR,56430398_US,71835542_US,56432157_US

G06F 9/30,G06F 13/28,G06N 3/02,G06N 3/04,G06N 3/0454,G06N 3/063,G06N 20/00

2017-07-11

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111411 0 11101 HOE 100011101M 01011101111101111011 OEN Organization International Bureau (10) International Publication Number (43) International Publication Date .....0\'\'\'1 WO 2018/071079 Al 19 April 2018 (19.04.2018) WIP0 1 PCT _ (51) (21) (22) (25) Filing Language: (26) (30) International Patent Classification: PCT/US2017/017841 GOOF 3/00 (2006.01) GOOF 17/30 (2006.01) 14 February 2017 (14.02.2017) US GOOF 3/048 (2013.01) GOOF 19/00 (2011.01) GOOF 9 / 4 6 (2006.01) GOOF 19/28 (2011.01) (71) Applicant: GENOMSYS SA [CH/CH]; Chemin de la Raye 13, 1024 Ecublens VD (CH). International Application Number: PCT/US2017/041585 (72) Inventor; and (71) Applicant: BALUCH, Mohamed Khoso [US/US]; 4439 International Filing Date: Woodsedge Ct, Chantilly, VA 20151 (US). 11 July 2017 (11.07.2017) (72) Inventors: ALBERTI, Claudio; Chemin des Esserts 1, English 1213 Petit-Lancy (CH). ZOIA, Giorgio; Chemin des Croix- Publication Language: English Rouges 10, 1007 Lausanne (CH). RENZI, Daniele; Route Aloys-Fauquez 105, 1018 Lausanne (CH). Priority Data: (74) Agent: BILICKI, Byron et al.; The Bilicki Law Firm, P.C., PCT/EP2016/074297 1285 North Main Street, Jamestown, NY 14701 (US). 11 October 2016 (11.10.2016) EP PCT/EP2016/074301 (81) Designated States (unless otherwise indicated, for every 11 October 2016 (11.10.2016) EP kind of national protection available): AE, AG, AL, AM, PCT/EP2016/074307 AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, 11 October 2016 (11.10.2016) EP CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, PCT/EP2016/074311 DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, 11 October 2016 (11.10.2016) EP HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, PCT/US2017/017842 KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 14 February 2017 (14.02.2017) US MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = = Title: 7! an mapped -- -- GC proposed 0 unaligned METHOD AND SYSTEMS cluster 1 -- , r / \ Signature 1 I FOR THE , l ‘ \ cluster Signature 2 INDEXING OF BIOINFORMATICS DATA \ cluster -,„ , / - ,,,, f I' I 1 ' \ \ \ \ / I/ K \ Sfrmature K • 2 The reads cluster common (signature) \c:uster M Signature M in each share a sequence Signatures can have either constant or variable length sequencing machines. The those sequence reads that cannot a method to partition and index = (54) = _ _ = = = — — = = = - = = _ 1-1 .4 Cl' It-- 0 1-1 It-- c:::: , (57) ,—I be ei C ACGT...GTG ATCT... G CC . Giai,2T...ATA AGTT...AAG : Method and apparatus for the indexing of genome sequence data produced by genome method can be applied both to raw sequence data produced by sequencing machines and to on any reference sequence according to specific matching criteria. This invention describes sequence reads to enable browsing and efficient selective access. [Continued on next page] WO 2018/071079 Al MIDEDIMOMOIDEIREIDIONOMMINECIONVOIMIE OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — as to the identity of the inventor (Rule 4.17(i)) Published: — with international search report (Art. 21(3))

en

METHOD AND SYSTEMS FOR THE INDEXING OF BIOINFORMATICS DATA

71256224_CH

71103226_CH,71896073_CH,71645555_CH,71717751_US

G06F 3/048,G06F 7/00,G06F 16/2282,G06F 16/2365,G06F 16/285,G06F 21/602,G06F 21/6218,G06F 21/6245,G16B 20/10,G16B 20/20,G16B 30/00,G16B 30/10,G16B 30/20,G16B 40/00,G16B 40/10,G16B 45/00,G16B 50/00,G16B 50/10,G16B 50/30,G16B 50/40,G16B 50/50,G16B 99/00,H03M 7/3086,H03M 7/70

2017-10-13

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 April 2018 (19.04.2018) WIP0 1 PCT omit °nolo molmo mil °nom oimIE (10) International Publication Number WO 2018/071843 Al 100 (51) International Patent Classification: GOOF 21/32 (2013.01) GOOF 21/30 (2013.01) GOOF 21/31 (2013.01) G1OL 15/22 (2006.01) (21) International Application Number: PCT/US2017/056629 (22) International Filing Date: 13 October 2017 (13.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 201610896522.3 13 October 2016 (13.10.2016) CN 15/782,729 12 October 2017 (12.10.2017) US (71) Applicant: ALIBABA GROUP HOLDING LIMITED [ /US]; Fourth Floor, One Capital Place, P.O. Box 847, George Town, Grand Cayman (KY). (72) Inventors: WU, Jun; c/o Ants Patent Team, 17F Build- ing B, Huanglong Times Plaza, No. 18 Wantang Road, Hangzhou 310099 (CN). ZENG, Xiaodong; c/o Ants Patent Team, 17F Building B, Huanglong Times Plaza, No. 18 Wantang Road, Hangzhou 310099 (CN). YIN, Huanmi; c/o Ants Patent Team, 17F Building B, Huanglong Times Plaza, No. 18 Wantang Road, Hangzhou 310099 (CN). LIN, Feng; c/o Ants Patent Team, 17F Building B, Huanglong Times Plaza, No. 18 Wantang Road, Hangzhou 310099 (CN). (74) Agent: STALFORD, Terry, J.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, MN 55440-1022 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (54) Title: SERVICE CONTROL AND USER IDENTITY AUTHENTICATION BASED ON VIRTUAL REALITY Recognize a voice command of a VR device user for performing a service that requires user identity authentisation Use a biometric sensor to collect one or 1201 more of the VR user's biometric characteristics for user identity authentication 13r3_ Perform user identity authentication based on the collected biometic characteristics Communicate with a server of the service for performing the service if the user identity authentication is successful FIG. 1 1-1 (57) : A method for service control and user identity authentication includes recognizing a voice command of a virtual reality (VR) device user for initiating a service supported by a VR application, using a biometric sensor to collect one or more biometric char- = acteristics of the VR device user, performing user identity authentication based on the collected one or more biometric characteristics, 1-1 © and communicating with a server that provides the service for performing the service if the user identity authentication is successful. C [Continued on next page] WO 2018/071843 Al MIDEDIMOMOIDEIREEMONOMOHMOIMIDOMEHMIE (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

SERVICE CONTROL AND USER IDENTITY AUTHENTICATION BASED ON VIRTUAL REALITY

11236634_

71865049_CN,67857500_CN,56455570_CN,72014544_CN

G06F 3/011,G06F 3/167,G06F 21/32,G06F 21/44,G06Q 20/40145,G10L 17/00,G10L2015/223

2018-03-23

N

WO 18/ 175 903 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIP0 I PCT ill 1111u°11101VIIIVIIIVIIIolo oloinimoiminiovoimIE (10) International Publication Number WO 2018/175903 Al RECEIVE A FILE CONTAINING VIRTUAL REALITY DATA, WHEREIN THE VIRTUAL REALITY DATA REPRESENTS A 360-DEGREE VIEW OF A VIRTUAL ENVIRONMENT 1002 (51) International Patent Classification: GOOF 3/0481 (2013.01) HO4N 21/61 (2011.01) HO4N 21/4728 (2011.01) (21) International Application Number: PCT/US2018/024057 (22) International Filing Date: 23 March 2018 (23.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/475,714 23 March 2017 (23.03.2017) US 15/927,799 21 March 2018 (21.03.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; 5775 Morehouse Drive, Attn: International IP Administra- tion, San Diego, California 92121-1714 (US). (72) Inventor: WANG, Yekui; 6264 Sunrose Crest Way, San Diego, California 92130 (US). (74) Agent: CHIANG, Campbell; 5775 Morehouse Drive, At- tn: International IP Administration, San Diego, California 92121-1714 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: ADVANCED SIGNALLING OF REGIONS OF INTEREST IN OMNIDIRECTIONAL VISUAL MEDIA (57) : In various implementations, modifications and/or addi- 1 ow tions to the ISOBMFF can indicate that a file that has been formatted according to the ISOBMFF, or a format derived from the ISOBMFF, in- cludes virtual reality content. The file can include a restricted scheme in- formation box, written into a track box in the file. The restricted scheme information box can indicate a virtual reality scheme for the contents of the track. For example, a signaling mechanism may indicate a most- viewed viewport associated with the virtual reality data. EXTRACT THE VIRTUAL REALITY DATA FROM THE FILE, WHEREIN THE VIRTUAL REALITY DATA IS STORED IN THE FILE IN ACCORDANCE WITH A FILE FORMAT, WHEREIN THE FILE FORMAT SPECIFIES PLACEMENT WITHIN THE FILE OF THE VIRTUAL REALITY DATA AND SPECIFIES PLACEMENT WITHIN THE FILE OF INFORMATION !ASSOCIATED WITH THE VIRTUAL REALITY DATA, WHEREIN THE INFORMATION ASSOCIATED WITH THE VIRTUAL REALITY DATA IS STORED WITHIN A TRACK BOX 1004 EXTRACT A SAMPLE ENTRY FROM THE TRACK BOX, WHEREIN THE SAMPLE ENTRY IS ASSOCIATED WITH ONE OR MORE SAMPLES, WHEREIN THE SAMPLE ENTRY INDICATES THAT THE TRACK IS A TIMED METADATA TRACK THAT CONTAINS INFORMATION ON A MOST- VIEWED VIEWPORT ASSOCIATED WITH THE VIRTUAL REALITY DATA 1 006 FIG. 10

en

ADVANCED SIGNALLING OF REGIONS OF INTEREST IN OMNIDIRECTIONAL VISUAL MEDIA

52280328_US

74271641_US

G06T 15/005,G06T 15/20,G06T 19/003,H04N 21/4728,H04N 21/6125,H04N 21/816

2001-09-11

Y

1. A method for producing analgesia in a mammal experiencing pain comprising systemically administering an amount of a composition comprising a sodium channel blocking compound, in a suitable pharmaceutical vehicle, effective to alleviate the pain, said compound is specifically linked with an area located on SS1 or SS2 zones of the sodium channel alpha subunit. 2. The method of claim 1, wherein the sodium channel blocking compound is one selected from the group consisting of tetrodotoxin, anhydrotetrodotoxin, tetrodaminotoxin, methoxytetrodotoxin, ethoxy-tetrodotoxin, deoxytetrodotoxin and tetrodonic acid. 3. The method of claim 1, wherein the systemic administration is performed by intramuscular injection, subcutaneous injection, intravenous injection, oral ingestion, sublingual ingestion, skin patch, implantable osmotic pump, collagen implant, aerosol inhalation, or suppository. 4. The method of claim 1, wherein the pain is caused by mechanical, chemical or ischemic stimulation, or inflammation. 5. The method of claim 1, wherein the pain is neuropathic pain. 6. The method of claim 1, wherein the pain arises from cancer. 7. The method of claim 1, wherein the sodium channel blocking compound is administered in a dose of 0.1 to 5pg per kilogram body weight. 8. The method of claim 1, wherein the composition is administered in one or more doses per day during a treatment period. 9. The method of claim 1, wherein the sodium channel blocking compound does not cause drug dependence or addiction in the mammal. 10. The method of claim 1, wherein the mammal is a female of childbearing age. 11. The method of claim 1, wherein the sodium channel blocking compound does not have any non-reversible adverse effects. 12. The method of claim 1, wherein the sodium channel blocking compound does not produce local intramuscular irritation at the region where the systemic administration is performed. 13. The method of claim 1, wherein the sodium channel blocking compound does not produce any general hypersensitivity reaction in the mammal. 14. The method of claim 1, wherein the sodium channel blocking compound does not induce haemolyzation or vascular stimulation in the mammal. 15. The method of claim 3, wherein the injectable formulation is administered every 3-12 hours during a treatment period. 16. The method of claim 15, wherein the treatment period is 1 to 10 days, preferably 3 days. 17. The method of claim 15, wherein the treatment is repeated. 18. The method of claim 3, wherein said the administration is by injection and the composition comprises an acetic acid solution of tetrodotoxin. 19. The method of claim 1, wherein the sodium channel blocking compound comprises a tetrahydropurine moiety comprising two guanidine units fused together in a stable azaketal linkage, having a molecular formula C10H17N7O4 (mol. wt. 299.30) or a derivatives thereof. 20. The method of claim 19, wherein the sodium channel blocking compound is hydroxysaxitoxin or neosaxitoxin. 21. The method according to claim 6, wherein the pain arises from a cancer selected from the group consisting of liver cancer, rectal cancer, leiomyosarcoma, bone cancer, stomach cancer, lymphatic cancer, esophageal cancer, cancers in the genital organs, prostate cancer, digestive system cancer, stomach cancer, colon cancer, breast cancer, respiratory system cancer, lung cancer, bronchial cancer, urinary system cancer, lymphoma and skin cancer. 22. A kit comprising: a pharmaceutical composition comprising a sodium channel blocking compound and a pharmaceutically acceptable carrier; and written material describing systemic administration of the pharmaceutical composition to a subject for treatment of pain.

en

A METHOD OF ANALGESIA

68113165_CN

66810870_CN,67325253_CN

A61K 31/506,A61K 31/517,A61K 31/519,A61P 23/00,A61P 23/02,A61P 25/00,A61P 25/04,A61P 29/00,A61P 35/00,A61P 43/00

2006-10-30

Y

The evaluation of alertness of an automobile driver to analyze eyelid movements, comprises associating every blinking with a duration vector of each component, calculating a cumulated duration vector of each component having summation of average duration and long duration blinking by a temporal analysis window, and deducing the comparison of the calculated values of average and long duration blinking with threshold values. The evaluation of alertness of an automobile driver to analyze eyelid movements, comprises associating every blinking with a duration vector of each component, calculating a cumulated duration vector of each component having summation of average duration and long duration blinking by a temporal analysis window, deducing the comparison of the calculated values of average and long duration blinking with threshold values, intergrating environmental information for introducing ponderation levels with a diagnostic data, which is based on the analysis of the eyelid movements, integrating the informations obtained from behavioral observations such as observation of the trajectory of the vehicle, validating the data of analysis window, if the number of blinking detected during the analysis is higher than the given threshold, and triggering the opening of the analysis window during every detection of blinking, where each opened analysis window covers a determined period of time before triggering. In the evaluation process, a preliminary stage comprises classifying the blinking duration of the drivers by implementing a fuzzy logic mathematical method, and classifying alertness of the drivers by N classes, where N is >=2. The blinking duration comprises three classes such as short duration blinking, average duration blinking and long duration blinking in which the classes are adapted to have border zone of progressive transition. The classification of alertness comprises four classes such as a waked up class defined by a number of average duration blinking lower to a given threshold, a first intermediate class corresponds to a little somnolence state defined by a number of average duration blinking higher to a given threshold and lower to an intermediate threshold, a second intermediate class corresponds to a somnolence state defined by a number of average duration blinking higher to intermediate threshold and by a number of long duration blinking lower to a given threshold, and a sleeping class defined by a number of long duration blinking higher to a given threshold. The little somnolence state is also defined by a number of long duration blinking lower to the given threshold. Analyzing the eyelid movements of the driver is determined by confidence degree of the blinkings. The confidence degree of the blinkings are determined by comparing two signals that are representative of the eyelid movements based on the criteria of predetermined comparison such as criteria relating to simultaneity, amplitude or gradients of the signals. The confidence degree (C 0>) is determined by the summation of blinking degree of each duration class multiplied by the confidence degree (Ci) of the blinking and the whole divided by the summation of blinking degree of each duration class. Combination of criteria relating to simultaneity, amplitude and gradients of two signals, which are representative of the two eyelid movements are adapted to determine the confidence degree associated with every blinking. The environmental information is a representative of conditions of control such as time of control, temperature in the vehicle, hour of the day, type of roadway (road, motorway, urban), and data concerning the driver such as age and experience.

en

Method for the evaluation of the state of vigilance of a vehicle conductor

425437_FR

1972948_FR,1972947_FR

A61B 5/18,A61B 5/7264,B60K 28/06,G08B 21/06,G16H 50/20

2018-01-05

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 1111111111111111111111111111111111111011111101111111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\'\' WO 2018/127787 Al 12 July 2018 (12.07.2018) WIP0 1 PCT (51) International Patent Classification: UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, C07K 16/28 (2006.01) A61P 35/00 (2006.01) TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, A61K 39/395 (2006.01) A61P 37/04 (2006.01) EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (21) International Application Number: MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, PCT/1B2018/000043 TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (22) International Filing Date: 05 January 2018 (05.01.2018) Published: — (25) Filing Language: English with international search report (Art. 21(3)) — before the expiration of the time limit for amending the (26) Publication Language: English claims and to be republished in the event of receipt of (30) Priority Data: amendments (Rule 48.2(h)) 62/443,281 06 January 2017 (06.01.2017) US (71) Applicant: EUTILEX CO., LTD. [KR/KR]; Suite #1401 Daeryung Technotown 17 Cha, Gasan Digital 1-ro 25, Geumcheon-gu, Seoul 08594 (KR). (72) Inventors: KWON, Byoung S.; c/o Eutilex Co., Ltd., Suite #1401 Daeryung Technotown 17 Cha, Gasan Digital f- _ ro 25, Geumcheon-gu, Seoul 08594 (KR). LEE, Seoung- Joo; c/o Eutilex Co., Ltd., Suite #1401 Daeryung Tech- - notown 17 Cha, Gasan Digital 1-ro 25, Geumcheon-gu, Seoul 08594 (KR). KIM, Young Ho; c/o Eutilex Co., Ltd., Suite #1401 Daeryung Technotown 17 Cha, Gasan Digi- tal 1-ro 25, Geumcheon-gu, Seoul 08594 (KR). OH, Ho- = =_ _ Sik; c/o Eutilex Co., Ltd., Suite #1401 Daeryung Techno- town 17 Cha, Gasan Digital 1-ro 25, Geumcheon-gu, Seoul _ 08594 (KR). LEE, Joong Won; c/o Eutilex Co., Ltd., Suite #1401 Daeryung Technotown 17 Cha, Gasan Digital 1-ro 25, Geumcheon-gu, Seoul 08594 (KR). = Agent: CHANG, Duck Soon et al.; Kim & Chang, Seyang = (74) = B/D, 39 Sajikno-8-gil, Jongno-gu, Seoul 03170 (KR). Designated States (unless otherwise indicated, for every = (81) = kind of national protection available): AE, AG, AL, AM, _ AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, = CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = = KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, = — MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, — SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = Designated States (unless otherwise indicated, for every — (84) - kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, IN GO Ir ---- (54) Title: ANTI-HUMAN 4-1 BB ANTIBODIES AND USE THEREOF IN \' (57) : Provided are anti-human 4-1BB antibodies and fragments thereof with one or more structural features that are not Il ----. found in a reference anti-human 4- 1BB antibody, where said features may improve certain characteristics of the antibody relative to GO Il a reference antibody. Various in vitro and in vivo methods and reagents related to anti-human 4-1BB antibodies described herein are © also provided. Methods include, for example, inducing T-cell proliferation, inducing T cell secretion of IFNy, as well as detection, N prevention, and/or therapeutic treatment of cancer using an anti-human 4-1BB antibody or fragment thereof. O

en

ANTI-HUMAN 4-1 BB ANTIBODIES AND USE THEREOF

71483984_KR

71944082_KR,71908088_KR,71170669_KR,72020327_KR,71854861_KR

A61K 35/17,A61K 39/395,A61K 39/3955,A61K 39/39558,A61K 45/06,A61K2039/505,A61K2039/507,A61P 35/00,A61P 37/04,C07K 16/28,C07K 16/2818,C07K 16/2878,C07K2317/24,C07K2317/34,C07K2317/51,C07K2317/515,C07K2317/565,C07K2317/567,C07K2317/75,C07K2317/76,C07K2317/92,C12N 5/0636

2018-02-21

N

80 - 60 - 0 40- o 20- o 0.00 0.01 0.1 00 -20 -40 00 -•-no ab -e-Control HulgG1 m 30 7 -A- m 10 H2 -0-target alone 100 Ab. [pg/mL] (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 September 2018 (07.09.2018) WIPO I PCT IiiimmoinionotiolomoluioluilioluovoimIE (10) International Publication Number WO 2018/158658 Al C (51) International Patent Classification: CO7K 16/28 (2006.01) (21) International Application Number: PCT/IB2018/051067 (22) International Filing Date: 21 February 2018 (21.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/466,918 03 March 2017 (03.03.2017) US (71) Applicant: RINAT NEUROSCIENCE CORP. [US/US]; 230 East Grand Avenue, South San Francisco, California 94080 (US). (72) Inventors: BUCKTROUT, Samantha Lisa; 2783 Gold- en Gate Avenue, San Francisco, California 94118 (US). CHAPARRO RIGGERS, Javier Fernando; 816 North Delaware Street, #411, San Mateo, California 94401 (US). PASCUA, Edward Derrick; 100 Grand Avenue, #1405, Oakland, California 94612 (US). SMITH, Bevin Marie Brady; 3134 Glen Canyon Road, Scotts Valley, California 95066 (US). (74) Agent: WALDRON, Roy F.; PFIZER INC., 235 East 42nd Street, MS 235/9/S20, New York, New York 10017 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: ANTI-GITR ANTIBODIES AND METHODS OF USE THEREOF Figure 4A 1 -1 (57) : The present invention provides antibodies that bind Glucocorticoid Induced Tumor necrosis factor Receptor family 0 related protein (GITR) and methods of using same. The anti-GITR antibodies can be used therapeutically alone or in combination with \' other therapeutics to treat cancer and other diseases. [Continued on next page] WO 2018/158658 Al MIDEDIM1111011111111111111111111111111111111111111011111111101111111111111111111 Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(k) with (an) indication(s) in relation to deposited biological material furnished under Rule 13bis separately from the description (Rules 13bis.4(d)(i) and 48.2(a)(viii)) with sequence listing part of description (Rule 5.2(a)) in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

en

ANTI-GITR ANTIBODIES AND METHODS OF USE THEREOF

55546251_US

74263181_US,56565770_US,73787558_US,56494930_US

A61K2039/505,A61K2039/507,A61P 35/00,C07K 16/2818,C07K 16/2827,C07K 16/2878,C07K2317/24,C07K2317/33,C07K2317/52,C07K2317/565,C07K2317/71,C07K2317/73,C07K2317/732,C07K2317/75,C07K2317/76,C07K2317/92

2017-10-24

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property - C.-- - .` Organization 03 111111111111111111111111111111111111111111111111111111111111111111111111 International Bureau (10) International Publication Number (43) International Publication Date .....•\'\' WO 2018/081163 Al 03 May 2018 (03.05.2018) WIP0 I PCT (51) International Patent Classification: 300 Washington Street, Unit 302, Newton, MA 02458 (US). G1OL 25/00 (2013.01) WEGMANN, Steven; One Gatway Center, 300 Washing- (21) International Application Number: ton Street, Unit 302, Newton, MA 02458 (US). PCT/US2017/058138 (74) Agent: BACHMANN, Steve; Bachmann Law Group, (22) International Filing Date: 19925 Stevens Creek Blvd, Ste 100, Cupertino, CA 95014 24 October 2017 (24.10.2017) (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (26) Publication Language: English AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, (30) Priority Data: CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, 62/412,165 24 October 2016 (24.10.2016) US DZ, EC, EE, EG, ES, FL GB, GD, GE, GH, GM, GT, HN, 15/792,236 24 October 2017 (24.10.2017) US HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (71) Applicant: SEMANTIC MACHINES, INC. [US/US]; MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, One Gatway Center, 300 Washington Street, Unit 302, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, Newton, MA 02458 (US). SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (72) Inventors: HALL, David Leo Wright; One Gatway Cen- ter, 300 Washington Street, Unit 302, Newton, MA 02458 (84) Designated States (unless otherwise indicated, for every — (US). KLEIN, David; One Gatway Center, 300 Washing- kind of regional protection available): ARIPO (BW, GH, ton Street, Unit 302, Newton, MA 02458 (US). ROTH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = Daniel; One Gatway Center, 300 Washington Street, Unit UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, = — 302, Newton, MA 02458 (US). GILLICK, Lawrence; One TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Gatway Center, 300 Washington Street, Unit 302, Newton, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, _ MA 02458 (US). MAAS, Andrew; One Gatway Center, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = = (54) Title: SEQUENCE - WORKS — — Text - I'm gonna need about $3.50 TO SEQUENCE TRANSFORMATIONS FOR SPEECH SYNTHESIS VIA RECURRENT NEURAL NET- (57) : A system eliminates alignment processing and performs TTS L functionality using a new neural architecture. The neural architecture in- 305 dudes an encoder and a decoder. The encoder receives an input and encodes = = Pre-Processing = r Pronuncia ti on L '310 Text Normalization it into vectors. The encoder applies a sequence of transformations to the input and generates a vector representing the entire sentence. The decoder 315 takes the encoding and outputs an audio file, which can include compressed audio frames. Context(s) Text Encoder = Encoding Pronunciation Encoder Normalized Text Encoder = = = L. 320 L. -. 325 330 = Attention Hidden State Synthesis Decoder ' 1 , 1(3 350 11 M Audio Codec 345 .-' 1 r - -IIH Stop , , 360 x-. 335 Frames Output 11 Encoding Ls 11 355 GC © Text to Speech (TTS) 300 GC 11 0 FIGURE 3 N O [Continued on next page] WO 2018/081163 Al D ill TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

SEQUENCE TO SEQUENCE TRANSFORMATIONS FOR SPEECH SYNTHESIS VIA RECURRENT NEURAL NETWORKS

71931772_US

71319034_US,72024691_US,71548584_US,71549360_US,71798378_US,71884863_US

G10L 13/02,G10L 13/047,G10L 13/08,G10L 13/10,G10L 15/1815,G10L 15/1822,G10L 15/22,G10L2015/223

2018-03-28

N

TRANSCEIVER • - • - • - • - • - • 42 WIRELESS TERMINAL TRANSCEIVER 1/4.11-1 q 4 TX I 4 W O 20 18/ 18357 8 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT ill~~~~~~~~ 011101010VIIIOH olo immlooltioluo oimIE (10) International Publication Number WO 2018/183578 Al ACCESS NODE PROCESSOR RANDOM ACCESS PROCEDURE CONTROLLER 54 50 FRAME/SIGNAL HANDLER RANDOM ACCESS RESPONSE GENERATOR c - 22A 60 40 (51) International Patent Classification: H04L 5/00 (2006.01) HO4W 74/00 (2009.01) H04Q 7/00 (2006.01) H04W 74/08 (2009.01) (21) International Application Number: PCT/US2018/024968 (22) International Filing Date: 28 March 2018 (28.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/478,530 29 March 2017 (29.03.2017) US (71) Applicant: SHARP LABORATORIES OF AMERICA, INC. [US/US]; 5750 Nw Pacific Rim Boulevard, Camas, WA 98607 (US). (72) Inventor: ISHII, Atsushi; 8611 Nw 18th Avenue, Vancou- ver, WA 98665 (US). (74) Agent: BURNAM, Jr. H., Warren; Nixon & Vanderhye P.C., 901 North Glebe Road, 11th Floor, Arlington, VA 22203-1808 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) (54) Title: RANDOM ACCESS PROCEDURE(S) FOR RADIO SYSTEM (57) : In one of its aspects the technology disclosed herein concerns a communications system comprising an access node (22) and a wireless terminal (26). The wireless terminal comprises receiving circuitry (40) and transmitting circuitry (44) as well as processor circuitry (40). The transmitting circuitry con- figured to transmit a random access preamble configured for a request of sys- tem information. The receiving circuitry configured to receive a random access response. The processor circuitry is configured to consider a reception of the 3 random access response as successful in a case that the random access response comprises a random access preamble identifier (RAPID) corresponding to the transmitted random access preamble, wherein the RAPID is in a medium access control (MAC) subheader. The processor circuitry is configured to consider a random access procedure as successfully completed in a case that a MAC ran- dom access response (MAC RAR) corresponding to the MAC subheader is not included in a MAC protocol data unit (MAC PDU). PROCESSOR 5 , 2 .1 FRAME/SIGNAL SCHEDULER/HANDLER 56 RANDOM ACCESS PROCEDURE CONTROLLER RANDOM ACCESS RESPONSE CHECKER •••• 62 4'81 USER INTERFACE 26A Fig. 1A

en

RANDOM ACCESS PROCEDURE(S) FOR RADIO SYSTEM

71110482_CN,53057618_JP

71547574_US

H04W 48/12,H04W 72/042,H04W 74/002,H04W 74/0833

2018-04-03

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT 0111111010 0111 °nolo OH H ioo IIIII IH oimIE (10) International Publication Number WO 2018/185045 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) C07K 16/40 (2006.01) (21) International Application Number: PCT/EP2018/058384 (22) International Filing Date: 03 April 2018 (03.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17164725.8 04 April 2017 (04.04.2017) EP 18158751.0 27 February 2018 (27.02.2018) EP (71) Applicant (for all designated States except US): F. HOFF- MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). (71) Applicant (for US only): HOFFMANN-LA ROCHE INC. [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jer- sey 07424 (US). (72) Inventors: BRUENKER, Peter; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). BUJOTZEK, Alexander; Fuerstenrieder Str. 82c, 80686 Muenchen (DE). DUERR, Harald; Gustav-Meyrink-Str. 7a, 82319 Starnberg (DE). GEORGES, Guy; Am Berggraben 11, 82392 Habach (DE). KLEIN, Christian; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). LECLAIR, Stephane; Schulstr. 12 1 / 4 , 82131 Gauting (DE). RAPP, Moritz; c/o Roche Glycart AG, Wagis- trasse 18, 8952 Schlieren (CH). SUM, Eva Carina; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). TRUMPFHELLER, Christine; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). UMASTA, Pablo; c/ o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). (74) Agent: KLOSTERMEYER RAUBER, Doerte; Gren- zacherstrasse 124, 4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: NOVEL BISPECIFIC ANTIGEN BINDING MOLECULES CAPABLE OF SPECIFIC BINDING TO CD40 AND TO FAP (57) : The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to CD40, and(b) at least one antigen binding domain capable of specific binding to a target cell antigen,in particular Fibroblast Activation Protein (FAP),and to methods of producing these molecules and to methods of using the same.

en

NOVEL BISPECIFIC ANTIGEN BINDING MOLECULES CAPABLE OF SPECIFIC BINDING TO CD40 AND TO FAP

55137210_CH

55173373_CH,73511938_DE,55469130_CH,73899073_CH,74102286_DE,57372022_DE,55138748_CH,73264418_CH,73715712_CH,68642378_DE

A61K 39/39558,A61K2039/505,A61K2039/5154,A61K2039/572,A61P 35/00,C07K 16/2878,C07K 16/40,C07K2317/24,C07K2317/31,C07K2317/33,C07K2317/35,C07K2317/52,C07K2317/55,C07K2317/56,C07K2317/565,C07K2317/567,C07K2317/569,C07K2317/64,C07K2317/71,C07K2317/75,C07K2317/92,C07K2317/94

2018-05-03

N

FrINTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) WIPO I PCT Hu omit VIII °nolo III VIII 110 111111 oimIE (10) International Publication Number WO 2018/204660 Al (51) International Patent Classification: H04L 5/00 (2006.01) HO4W 72/00 (2009.01) H04L 27/26 (2006.01) HO4L 5/14 (2006.01) (21) International Application Number: PCT/US2018/030908 (22) International Filing Date: 03 May 2018 (03.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/501,563 04 May 2017 (04.05.2017) US 15/969,366 02 May 2018 (02.05.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; Attn: International IP Administration, 5775 Morehouse Dri- ve, San Diego, California 92121-1714 (US). (72) Inventors: HUANG, Yi; c/o Qualcomm Incorporated, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). WANG, Renqiu; c/o Qualcomm Incorporated, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). PARK, Seyong; c/o Qualcomm Incorporated, 5775 More- house Drive, San Diego, California 92121-1714 (US). XU, Hao; c/o Qualcomm Incorporated, 5775 Morehouse Dri- ve, San Diego, California 92121-1714 (US). GAAL, Pe- ter; c/o Qualcomm Incorporated, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). CHEN, Wan- shi; c/o Qualcomm Incorporated, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). MANOLAKOS, Alexandros; c/o Qualcomm Incorporated, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (74) Agent: BINDSEIL, James J. et al.; c/o Arent Fox LLP, 1717 K Street NW, Washington, District of Columbia 20006-5344 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, = (54) Title: TRANSMITTING REFERENCE SIGNALS BASED ON WIRELESS COMMUNICATIONS TIMELINE (57) : Aspects herein describe transmitting a reference signal in wire- less communications. A configured delay value related to a delay in communi- 7 10 712 cations can be determined based on receiving a corresponding resource grant. A time division of a slot for transmitting a reference signal for the communica- tions can be determined based at least in part on the configured delay value. The reference signal can be transmitted during the time division of the slot. Ti! c 0 DI. 1 , 13CCH or Dal ILL PUSCH El Guard/GAP 0 UL Control UL DBMS MC. 7A [Continued on next page] , ,720 W O 20 18/ 20 4660 Al WO 2018/204660 Al MIDEDIMOMOIDEIRDERI0010101INIMINHOMEMOIS UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

TRANSMITTING REFERENCE SIGNALS BASED ON WIRELESS COMMUNICATIONS TIMELINE

52280328_US

56286106_US,74268558_US,69235791_US,67202208_US,56570006_US,56524717_US,71547434_US

H04L 5/0007,H04L 5/0012,H04L 5/0048,H04L 5/0051,H04L 5/0053,H04L 5/0078,H04L 5/1469,H04L 7/0337,H04L 27/2613,H04W 72/042,H04W 72/1268,H04W 72/14

2018-01-10

N

NRPDCCH BS 110 POLAR ENCODING 122 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 July 2018 (19.07.2018) WIP0 1 PCT 011101010 0111 °nolo H Imo (10) International Publication Number WO 2018/130151 Al 100 UE 102 (51) International Patent Classification: H04W 72/00 (2009.01) H04L 1/00 (2006.01) (21) International Application Number: PCT/CN2018/072038 (22) International Filing Date: 10 January 2018 (10.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/444,397 10 January 2017 (10.01.2017) US 15/865,229 08 January 2018 (08.01.2018) US (71) Applicant: MEDIATEK INC. [CN/CN]; No. 1, Dusing Road 1st, Science-Based Industrial Park, Hsin-Chu, Taiwan 300 (CN). (72) Inventors: HWANG, Chien-Hwa; No. 1, Dusing Road 1st, Science-Based Industrial Park, Hsin-Chu, Taiwan 300 (CN). YANG, Weidong; 2840 Junction Ave, San Jose, CA 95134 (US). LIAO, Pei-Kai; No. 1, Dusing Road 1st, Science-Based Industrial Park, Hsin-Chu, Taiwan 300 (CN). WU, Wei-De; No. 1, Dusing Road 1st, Science-Based Industrial Park, Hsin-Chu, Taiwan 300 (CN). (74) Agent: BEIJING SANYOU INTELLECTUAL PROP- ERTY AGENCY LTD.; 16th Fl., Block A, Corporate Square, No. 35 Jinrong Street, Beijing 100033 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (54) Title: PHYSICAL DOWNLINK CONTROL CHANNEL DESIGN FOR 5G NEW RADIO k 3 § UE 103 CE ID MASK CRC ATTACHMENT 121 UE S PEC I FC II) -10 INTER- LEAVER 123 FIG. 1 DCI BITS CE 104 (57) : A method to improve the design of new radio physical downlink control channel (NR-PDCCH) transmission and to reduce the false alarm rate of NR-PDCCH blind decoding is proposed. The downlink control information (DCI) bits are carried by NR- PDCCH to be transmitted to UEs after CRC attachment, channel encoding, interleaving, and modulation. The proposed NR-PDCCH design is separated into two parts. In a first part, a UE-ID or RNTI is used to derive a CRC mask or a scrambling sequence for CRC attachment of the DCI bits. In a second part, a UE-specific ID is used to derive an interleaver before or after channel encoding of the DCI bits. If the interleaver is placed before channel encoding, it takes the form of a bit interleaver. If the interleaver is placed after channel encoding, it takes the form of a bit interleaver or a channel interleaver. [Continued on next page] WO 2018/130151 Al MUNRO DOI 01011M1E1301111E111111111111111111111111111 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

PHYSICAL DOWNLINK CONTROL CHANNEL DESIGN FOR 5G NEW RADIO

56435382_CN

74099189_CN,74128688_CN,73551297_CN,73578314_US

H04L 1/0009,H04L 1/0041,H04L 1/0061,H04L 1/0072,H04L 1/1812,H04W 72/042,H04W 88/02

2018-04-27

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (43) International Publication Date 111111111111110111111111111111111111110 1 0 01 111 11111 1111111111 0 111110 111110 1111110 1111 (10) International Publication Number WO 2018/200918 A8 01 November 2018 (01.11.2018) WIP0 I PCT i'2 (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/28 (2006.01) (21) International Application Number: PCT/US2018/029728 (22) International Filing Date: 27 April 2018 (27.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/492,056 28 April 2017 (28.04.2017) US (71) Applicant: AMGEN INC. [US/US]; One Amgen Center Drive, Thousand Oaks, CA 91320-1799 (US). (72) Inventors: BRYCH, Stephen, Robert; 2488 Gillingham Circle, Thousand Oaks, CA 91362 (US). WONG, Lyanne, M.; 28861 Silversmith Drive, Valencia, CA 91354 (US). FALLON, Jaymille; 28915 Lodgewood Street, Newbury Park, CA 91320 (US). GOSS, Monica, Michelle; 3050 Lodgewood Street, Newbury Park, CA 91320 (US). GU, Jian, Hua; 1525 Silver Shadow Drive, Thousand Oaks, CA 91320 (US). GHATTYVENKATAKRISHNA, Pa- van, K.; 1690 Springhaven Ave., Newbury Park, CA 91320 (US). (74) Agent: HONG, Julie, J.; Marshall, Gerstein & Borun LLP, 233 S. Wacker Drive, 6300 Willis Tower, Chicago, IL 60606-6357 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, = (54) Title: FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME ,-- ,,,, ,--, \'. .-..... 'C'' W EEKS laf: X !X.r : ;.:H .2 5.2 A.::: , ..A.atei)vseVRA>goL:PS.2.. , 3iii)H F.sa. 5,2 5.2 20g1.:1.1 5.2 hi 5.2 (57) : Disclosed herein are aqueous pharmaceutical formulations comprising denosumab or another human anti-RANKL mon- oclonal antibody or portion thereof, and characteristics of pH, buffer systems, and amino acid aggregation inhibitors. Also disclosed are presentation of the formulation for use, e.g. in a single-use vial, single-use syringe, or glass container, methods of using the formulations and articles for preventing or treating diseases, and related kits. [Continued on next page] WO 2018/200918 A8 I IIIII I 11111110111111 IIIII 11111 IIIII 11011111111111 11111 11111 11111 11111 1111111110111 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) (48) Date of publication of this corrected version: 17 October 2019 (17.10.2019) (15) Information about Correction: see Notice of 17 October 2019 (17.10.2019)

en

FORMULATIONS OF HUMAN ANTI-RANKL ANTIBODIES, AND METHODS OF USING THE SAME

55579795_US

74017222_US,73537219_US,71934389_US,74323374_US,73567712_US,73567537_US

A61K 9/08,A61K 39/39591,A61K 47/183,A61K2039/505,A61K2039/54,A61K2039/545,A61P 3/14,A61P 11/00,A61P 13/08,A61P 13/12,A61P 15/14,A61P 19/08,A61P 19/10,A61P 35/00,A61P 35/04,C07K 16/2875,C07K2317/21,C07K2317/52,C07K2317/55,C07K2317/76

2018-03-29

N

Figurea 41 18 Receiving module 14i Processing module 14ii Computing Device 14 Transmitting module 14iii EEG Device 12 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT onion °noI0 OH1101OH1011VIII0II111110 0IIIIII (10) International Publication Number WO 2018/182531 Al (51) International Patent Classification: GOOF 3/01 (2006.01) (21) International Application Number: PCT/SG2018/050160 (22) International Filing Date: 29 March 2018 (29.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 10201702704W 31 March 2017 (31.03.2017) SG (71) Applicant: AGENCY FOR SCIENCE, TECHNOLO- GY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis North Tower, Singapore 138632 (SG). (72) Inventors: ANG, Kai Keng; c/o Institute for Infocomm Re- search, Agency For Science, Technology and Research, 1 Fusionopolis Way, #20-10 Connexis North Tower, Singa- pore 138632 (SG). GUAN, Cuntai; c/o Institute for Info- comm Research, Agency For Science, Technology and Re- search, 1 Fusionopolis Way, #20-10 Connexis North Tow- er, Singapore 138632 (SG). (74) Agent: DAVIES COLLISON CAVE ASIA PTE. LTD.; 10 Collyer Quay, #07-01 Ocean Financial Centre, Singa- pore 049315 (SG). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. = (54) Title: SYSTEM AND METHOD FOR DETECTING EYE ACTIVITY 10 (57) : A system for detecting eye blink activity, the system including one or more processors in communication with non- transitory data storage media having instructions stored thereon that, when executed by the one or more processors configure the one or more processors to perform the steps of receiving, with a receiving module, a signal associated with eye blink activity; filtering, at a processing module, the signal to 10 reduce noise from the signal; calculating, at the processing module, a variance of the filtered signal for estimating background noise; removing, at the processing module, background noise associated with the variance; and detecting, at the processing module, eye blink activity by performing duration detection. [Continued on next page] WO 2018/182531 Al O II (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17 (iv)) Published: with international search report (Art. 21(3)) in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

en

SYSTEM AND METHOD FOR DETECTING EYE ACTIVITY

55212881_SG

55232295_SG,73885758_SG

A61B 5/0006,A61B 5/1103,A61B 5/291,A61B 5/372,A61B 5/721,G06F 3/01,G06F 3/013,G06F 3/015,G16H 40/67

2018-03-29

N

0 11 mutant IL-2 polypeptide variable domain constant domain Fc domain 1-1 o r cc 00 O O (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT onion °nolo moimmiinimiflo oimIE (10) International Publication Number WO 2018/184964 Al (51) International Patent Classification: C07K 14/55 (2006.01) C07K 16/28 (2006.01) A61K 38/20 (2006.01) A61K 39/00 (2006.01) (21) International Application Number: PCT/EP2018/058034 (22) International Filing Date: 29 March 2018 (29.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17164533.6 03 April 2017 (03.04.2017) EP (71) Applicant (for all designated States except US): F. HOFF- MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). (71) Applicant (for US only): HOFFMANN-LA ROCHE INC. [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jer- sey 07424 (US). (72) Inventors: CODARRI DEAK, Laura; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). KLEIN, Chris- tian; c/o Roche Glycart AG, Wagistrasse 10, 8952 Sch- lieren (CH). LAUENER, Laura; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). NICOLINI, Valeria G.; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). SEEBER, Stefan; Mitterweg 2, 82404 Sindelsdorf (DE). UMASTA, Pablo; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). WALDHAUER, Inja; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). (74) Agent: KASCHAU, Nikolai; Grenzacherstrasse 124, 4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (54) Title: IMMUNOCONJUGATES OF AN ANTI-PD-1 ANTIBODY WITH A MUTANT IL-2 OR WITH IL-15 Figure 1 (57) : The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof. [Continued on next page] WO 2018/184964 Al MIDEDIMOMOIDEIREEMOMOHMOIEIHNHIMMI SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))

en

IMMUNOCONJUGATES OF AN ANTI-PD-1 ANTIBODY WITH A MUTANT IL-2 OR WITH IL-15

55137210_CH

74121054_CH,57322868_CH,55138748_CH,71176406_DE,73895509_CH,73481571_CH,55173373_CH

A61K 38/00,A61K 38/2013,A61K 39/00,A61K 39/3955,A61K 47/6813,A61K 47/6849,A61K 47/6891,A61K2039/505,A61P 35/00,C07K 14/55,C07K 16/2818,C07K 19/00,C07K2317/73,C07K2319/74

2018-11-16

N

820 FIG. 8 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 23 May 2019 (23.05.2019) WIPO I PCT 111111111111110111111111111111101111101001111111111111111111111111111011111011110111111 (10) International Publication Number WO 2019/099908 Al (51) International Patent Classification: C12Q 1/6806 (2018.01) G16B 20/00 (2019.01) G16B 35/00 (2019.01) (21) International Application Number: PCT/US2018/061629 (74) (22) International Filing Date: 16 November 2018 (16.11.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/587,634 17 November 2017 (17.11.2017) US (71) Applicant: 10X GENOMICS, INC. [US/US]; 7068 Koll Center Parkway, Suite 401, Pleasanton, California 94566 (US). (72) Inventors: BHARADWAJ, Rajiv; 7068 Koll Center Park- way, Suite 401, Pleasanton, California 94566 (US). SAX- ONOV, Serge; 7068 Koll Center Parkway, Suite 401, Pleasanton, California 94566 (US). Agent: YANDELL-ZHAO, Margaret A.; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304-1050 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (54) Title: METHODS AND SYSTEMS FOR ASSOCIATING PHYSICAL AND GENETIC PROPERTIES OF BIOLOGICAL = PARTICLES Got ON ON ON O ON O C (57) : Provided herein are methods and systems for processing a nucleic acid molecule from a biological particle (e.g., cell). A plurality of partitions (e.g., droplets) may be generated such that partitions of the plurality of partitions each include a biological particle (e.g., cell) comprising the nucleic acid molecule and a particle (e.g., bead). The partitions can be processed (e.g., imaged) to obtain one or more physical and/or optical properties of their respective biological particles. The nucleic acid molecules included in the partitions can be barcoded and sequenced (e.g., using nucleic acid barcode molecules coupled to the particles of the partitions) to generate nucleic acid sequences of the nucleic acid molecules. The nucleic acid sequences can be electronically associated with the one or more optical properties of the biological particles. [Continued on next page] WO 2019/099908 Al HINIONOIMEIHMEIMEN001 MENNEHIMOIMEMEMIE SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

en

METHODS AND SYSTEMS FOR ASSOCIATING PHYSICAL AND GENETIC PROPERTIES OF BIOLOGICAL PARTICLES

56595875_US

56599313_US,57206631_US

C12Q 1/6806,G16B 20/00,G16B 35/20

2018-04-10

N

WO 18/ 189 19 1 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) W I PO I PCT onion °nolo onoin mu Imo oimIE (10) International Publication Number WO 2018/189191 Al (51) International Patent Classification: G01S 17/42 (2006.01) G01S 7/48 (2006.01) GO6K 9/00 (2006.01) G01S 17/88 (2006.01) (21) International Application Number: PCT/EP2018/059186 (22) International Filing Date: 10 April 2018 (10.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17165849.5 10 April 2017 (10.04.2017) EP (71) Applicant: BEA SA [BE/BE]; Parc scientifique du Sart- Tilman, Allee des Noisetiers 5, 4031 Angleur (BE). (72) Inventor: RADERMECKER, Gautier; Rue Hullos 74, 4000 Liege (BE). (74) Agent: PUSCHMANN BORCHERT BARDEHLE PATENTANWALTE PARTNERSCHAFT MBB; Ba- juwarenring 21, 82041 Oberhaching (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) (54) Title: METHOD OF HUMAN BODY RECOGNITION AND HUMAN BODY RECOGNITION SENSOR (57) : The invention relates to a method of human body recog- 16 nition by analysing a detected object (P) in a monitored area and decid- ing whether or not the detected object is a human being with a laser scanner (12) comprising: the laser scanner (12) generates at least one laser curtain ( 22, 32, 34), where each laser curtain (22, 32, 34) is gen- erated by multiple pulses evaluated by time of flight (TOF) measure- ment of single pulses to generate the distance of the points of reflection with respect to the laser scanner position; combination of distances of the points of reflection with the direction of the pulse to retrieve a posi- tion in a predefined detection zone within a monitored area; projecting the points of reflection belonging to a detected object into an evaluation plane (EP) as evaluation objects (01, 02), where the evaluation plane (EP) has a Z-axis that is related to the height and a perpendicular one to the Z-axis that is related to the width in the direction of the lateral extension of the laser curtain (22, 32, 34). The invention is characterized in that the evaluation plane (EP) is evaluated based on the density dis- 14 tribution of the points of reflection along the Z-axis and the evaluation result is compared to anthropometric parameters. Fig. 1

en

METHOD OF HUMAN BODY RECOGNITION AND HUMAN BODY RECOGNITION SENSOR

74385088_BE

74116661_BE

G01S 7/4802,G01S 17/42,G01S 17/88,G01S 17/89,G06V 20/52,G06V 40/103

2018-12-26

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 06 September 2019 (06.09.2019) WIPO I PCT 11111111111110111111111111111101111101011101111111111111111111111111011111011110111111 (10) International Publication Number WO 2019/165838 Al 1900 1901 1902 1903 1904 (51) International Patent Classification: H04L 29/06 (2006.01) B60W 40/09 (2012.01) (21) International Application Number: PCT/CN2018/123759 (22) International Filing Date: 26 December 2018 (26.12.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 201810171875.6 01 March 2018 (01.03.2018) CN 201810664251.8 25 June 2018 (25.06.2018) CN (71) Applicant: BEIJING DIDI INFINITY TECHNOLOGY AND DEVELOPMENT CO., LTD. [CN/CN]; Building 34, No. 8 Dongbeiwang West Road, Haidian District, Bei- jing 100193 (CN). (72) Inventors: CHEN, Ao; Room 1601, 16F, No. 96 Hua Xing Road, Xihu District, Hangzhou, Zhejiang 310012 (CN). ZHANG, Hang; Room 1601, 16F, No. 96 Hua Xing Road, Xihu District, Hangzhou, Zhejiang 310012 (CN). WANG, Hengzhi; Room 1601, 16F, No. 96 Hua Xing Road, Xihu District, Hangzhou, Zhejiang 310012 (CN). (74) Agent: METIS IP (CHENGDU) LLC; Room 808, 8th Floor, Building B7, Block D, Tianfu Jingrong Center, No. 99 West Section of Hupan Road, Tianfu New District, Chengdu, Sichuan 610213 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: SYSTEMS AND METHODS FOR IDENTIFYING RISKY DRIVING BEHAVIOR Obtaining driving data from sensors associated with a vehicle driven by a driver 1 Determining, based on the driving data, a target time period Obtaining, based on the driving data, target data within the target time period Identifying, based on the target data, a presence of a risky driving behavior of the driver FIG. 19 (57) : The present disclosure relates to systems and methods for identifying a risky driving behavior of a driver. The systems may obtain driving data from sensors associated with a vehicle driven by a driver; determine, based on the driving data, a target time period; obtain, based on the driving data, target data within the target time period; and identify, based on the target data, a presence of a risky driving behavior of the driver. [Continued on next page] WO 2019/165838 Al HINIONOIMEIMMEMEOHNINIMIIMMOINIMOHE TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

SYSTEMS AND METHODS FOR IDENTIFYING RISKY DRIVING BEHAVIOR

56314911_CN

74195466_CN,74125948_CN,73354625_CN

B60W 40/09,B60W 50/0098,B60W2050/0052,B60W2520/105,B60W2520/14,B60W2556/10,G06F 16/22,H04L 67/125,H04L 67/535,H04W 4/027

2002-03-22

Y

The present invention relates to novel identified polynucleotides, polypeptides encoded by them and to the use of such polynucleotides and polypeptides, and to their production. More particularly, the polynucleotides and polypeptides of the present invention relate to the G-protein coupled receptor family, referred to as IGS4-family. The invention also relates to inhibiting or activating the action of such polynucleotides and polypeptides, to a vector containing said polynucleotides, a host cell containing such vector and transgenic animals where the IGS4-gene is either overexpressed, misexpressed, underexpressed or suppressed (knock-out animals). The invention further relates to a method for screening compounds capable to act as an agonist or an antagonist of said G-protein coupled receptor family IGS4 and the use of IGS4 polypeptides and polynucleotides and agonists or antagonists to the IGS4 receptor family in the treatment of PNS, psychiatric and CNS disorders, including schizophrenia, episodic paroxysmal anxiety (EPA) disorders such as obsessive compulsive disorder (OCD), post traumatic stress disorder (PTSD), phobia and panic, major depressive disorder, bipolar disorder, Parkinson's disease, general anxiety disorder, autism, delirium, multiple sclerosis, Alzheimer disease/dementia and other neurodegenerative diseases, severe mental retardation, dyskinesias, Huntington's disease, Tourett's syndrome, tics, tremor, dystonia, spasms, anorexia, bulimia, stroke, addiction/dependency/craving, sleep disorder, epilepsy, migraine; attention deficit/hyperactivity disorder (ADHD); cardiovascular diseases, including heart failure, angina pectoris, arrhythmias, myocardial infarction, cardiac hypertrophy, hypotension, hypertension e.g. essential hypertension, renal hypertension, or pulmonary hypertension, thrombosis, arteriosclerosis, cerebral vasospasm, subarachnoid hemorrhage, cerebral ischemia, cerebral infarction, peripheral vascular disease, Raynaud's disease, kidney disease-e.g. renal failure; dyslipidemias; obesity; emesis; gastrointestinal disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), gastroesophagal reflux disease (GERD), motility disorders and conditions of delayed gastric emptying, such as post operative or diabetic gastroparesis, and diabetes, ulcers-e.g. gastric ulcer; diarrhoea; other diseases including osteoporosis; inflammations; infections such as bacterial, fungal, protozoan and viral infections, particularly infections caused by HIV-1 or HIV-2; pain; cancers; chemotherapy induced injury; tumor invasion; immune disorders; urinary retention; asthma; allergies; arthritis; benign prostatic hypertrophy; endotoxin shock; sepsis; complication of diabetes mellitus; and gynaecological disorders, among others and diagnostic assays for such conditions. Preferred uses of the invention relate to disorders of the nervous system, including the central nervous system (CNS) and the peripheral nervous system (PNS), disorders of the gastrointestinal system and/or of the cardiovascular system and/or of skeletal muscle and/or of the thyroid, and/or also to lung diseases, immunological diseases and disorders of the genitourinary system. The invention also relates to the identification of the cognate ligand of the IGS4 polypeptides of the invention. High affinity binding to said IGS4 polypeptides is found for the neuropeptides known as neuromedin U.

en

Human G-protein coupled receptor

6044714_NL

6044719_NL,6044716_NL,6044717_NL,6044718_NL,6044715_NL

A01K2217/05,C07K 14/705

2018-05-09

N

DetermineTBS of TB to be mapped to sub PRB resource allocation using MCS table Map TB to resource allocation Transmit uplink data according to resource allocation Subcarrier Index RE6 (6SC) iii s ansiri ........, a l Resource Allocation Narrowband Index 3 Resource Block 2 41 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 22 November 2018 (22.11.2018) WIPO I PCT IiiimmoinionotionoloiollmolomoilomovoimIE (10) International Publication Number WO 2018/210170 Al (51) International Patent Classification: H04L 5/00 (2006.01) (21) International Application Number: PCT/CN2018/086164 (22) International Filing Date: 09 May 2018 (09.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/CN2017/084454 16 May 2017 (16.05.2017) CN (71) Applicant: QUALCOMM INCORPORATED [US/US]; Attn: International IP Administration, 5775 Morehouse Dri- ve, San Diego, CA 92121-1714 (US). (72) Inventors; and (71) Applicants (for US only): WEI, Chao [CN/CN]; 5775 Morehouse Drive, San Diego, CA 92121-1714 (US). BHATTAD, Kapil [IN/IN]; 5775 Morehouse Drive, San Diego, CA 92121-1714 (US). RICO ALVARINO, Al- berto [ES/US]; 5775 Morehouse Drive, San Diego, CA 92121-1714 (US). XU, Hao [US/CN]; 5775 Morehouse Drive, San Diego, CA 92121-1714 (US). (74) Agent: NTD PATENT & TRADEMARK AGENCY LIMITED; 10th Floor, Tower C, Beijing Global Trade Center, 36 North Third Ring Road East, Dongcheng Dis- trict, Beijing 100013 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (54) Title: TECHNIQUES AND APPARATUSES FOR SUB-PHYSICAL RESOURCE BLOCK RESOURCE ALLOCATION FOR MACHINE TYPE COMMUNICATION 400 405 Grant N O 00 O O FIG. 4 (57) : A method, a user equipment, an apparatus, and a computer program product for wireless communication are provided. The apparatus may receive a grant identifying an uplink resource allocation of less than one physical resource block (PRB), wherein the grant identifies a particular PRB in which the uplink resource allocation is included and at least a group of subcarriers allocated for the apparatus; and transmit uplink data using the uplink resource allocation. Numerous other aspects are described. [Continued on next page] WO 2018/210170 Al MIDEDIMOMOIDEIREIDI 0 01 IIII 010 IIMMEHOMEEN (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

TECHNIQUES AND APPARATUSES FOR SUB-PHYSICAL RESOURCE BLOCK RESOURCE ALLOCATION FOR MACHINE TYPE COMMUNICATION

52280328_US

68937361_US,74294967_IN,71201088_CN,73286869_CN

H04L 5/0012,H04L 5/0044,H04L 5/0094,H04W 4/70,H04W 72/0453,H04W 72/1289,H04W 72/14

2018-05-02

N

subframellsubframe n+1 310 subframe n+2 315 subframe n+3 320 subframe n+4 325 300 FIG. 3 335-b k sTTIsH 340 C) 330 335-a N 71' 71' O r•i 00 O 1-1 r•i C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) WIPO I PCT ~ill IIIIIIIIImillion ono o Holonmomiloommo oimIE (10) International Publication Number WO 2018/204467 Al (51) International Patent Classification: H04L 5/00 (2006.01) (21) International Application Number: PCT/US2018/030602 (22) International Filing Date: 02 May 2018 (02.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/500,472 02 May 2017 (02.05.2017) US 15/968,154 01 May 2018 (01.05.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; Attn: International IP Administration, 5775 Morehouse Dri- ve, San Diego, California 92121-1714 (US). (72) Inventors: HOSSEINI, Seyedkianoush; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). CHEN, Wanshi; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). RICO ALVARINO, Alberto; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). GAAL, Peter; 5775 Morehouse Drive, San Diego, Califor- nia 92121-1714 (US). (74) Agent: LARSEN, Per H.; Holland & Hart LLP, P.O. Box 11583, Salt Lake City, Utah 84147 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) (54) Title: CHANNEL STATE INFORMATION REPORTING FOR SYSTEMS WITH MULTIPLE TRANSMISSION TIME IN- TERVALS (57) : A user equipment (UE) may establish a configuration for communication utilizing a first transmission time interval (TTI) length and a second TTI length that is shorter than the first TTI length. The first TTI length may be associated with a first traffic type (e.g., a first latency or reliability characteristic) and the second TTI length may be associated with a second traffic type (e.g., a second latency or reliability characteristic). The UE may identify a trigger for a channel state information (CSI) report associated with the second TTI length and identify a reference resource for the CSI report (e.g., having the second TTI length). The UE may generate the CSI report based on the reference resource, and may transmit the CSI report during a reporting TTI and in response on the identified trigger.

en

CHANNEL STATE INFORMATION REPORTING FOR SYSTEMS WITH MULTIPLE TRANSMISSION TIME INTERVALS

52280328_US

56524717_US,56286106_US,68937361_US,68311679_US

H04L 1/0026,H04L 5/0048,H04L 5/0057,H04W 24/10,H04W 72/042,H04W 72/0446

2018-03-07

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 September 2018 (13.09.2018) WIP0 I PCT ill~~~~~~~~ 0111111010VIIIOH oI0 VIIIVIIIOH0111010u Oil m° oimIE (10) International Publication Number WO 2018/162517 Al (51) International Patent Classification: C07K 16/00 (2006.01) C12N 15/67(2006.01) C07K 16/46 (2006.01) C12N 15/85 (2006.01) (21) International Application Number: PCT/EP2018/055532 (22) International Filing Date: 07 March 2018 (07.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17160415.0 10 March 2017 (10.03.2017) EP (71) Applicant (for all designated States except JO, US): F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacher- strasse 124, 4070 Basel (CH). (71) Applicant (for US only): HOFFMANN-LA ROCHE INC. [US/US]; Great Notch, 150 Clove Road, 8th Floor, Little Falls, New Jersey 07424 (US). (72) Inventors: SEEBER, Stefan; c/o Roche Diagnos- tics GmbH, Nonnenwald 2, 82377 Penzberg (DE). GOEPFERT, Ulrich; c/o Roche Diagnostics GmbH, Non- nenwald 2, 82377 Penzberg (DE). OSTERLEHNER, An- drea; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). KETTENBERGER, Hubert; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). PAUL, Wolfgang; c/o Roche Diagnostics GmbH, Nonnen- wald 2, 82377 Penzberg (DE). (74) Agent: SKOLAUT, Alexander et al.; Roche Diagnostics GmbH, Patent Department (LPP 6164), P.O.Box 11 52, 82372 Penzberg (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (54) Title: METHOD FOR PRODUCING MULTISPECIFIC ANTIBODIES Figure 1D Re l. a bu ndance —> 100 90 80 70 60 50 40 30 20 10 0 N 00 O C 2800 3000 3020 3040 3060 3080 3100 3120 mh-> (57) : Herein are provided a method for producing a multispecific antibody comprising the steps of providing a mammalian cell expressing the antibody, transfecting said mammalian cell with an expression vector comprising an expression cassette encoding a polypeptide of the antibody that has a domain crossover, cultivating the transfected cell and recovering the antibody from the cell or the cultivation medium and thereby producing the multispecific antibody. [Continued on next page] WO 2018/162517 Al MIDEDIMOMOIDEIREEMOMOHIMOMMERMIS SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3))

en

METHOD FOR PRODUCING MULTISPECIFIC ANTIBODIES

55137210_CH

73789522_DE,71176406_DE,74140251_DE,73568073_DE,74179471_DE

C07K 16/00,C07K 16/18,C07K 16/2818,C07K 16/2878,C07K 16/2881,C07K 16/40,C07K 16/468,C07K2317/10,C07K2317/31,C07K2317/35

2018-04-24

N

ESSENTIALACTIVATING DOMAIN:CDX W O 18/ 200 496 Al 5'LTR scFv CDS?, KIR CAR VECTOR CONSTRUCT TARGET BINDING DOMAIN: ANTIBODY DERIVED )scFv) HINGE RA.NSMEMBRANE DOMAIN COSTIMULATORY DOMAIN:CD28 CAR-ENGINEERED T CELL FIG. 1A (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT ~ill IIIIIIIIIImillIVIIIIIIIHo o olo um Immo oimIE (10) International Publication Number WO 2018/200496 Al (51) International Patent Classification: A61P 35/02 (2006.01) C07K 16/28 (2006.01) (21) International Application Number: PCT/US2018/029107 (22) International Filing Date: 24 April 2018 (24.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/489,258 24 April 2017 (24.04.2017) US (71) Applicant: KITE PHARMA, INC. [US/US]; 2225 Col- orado Avenue, Santa Monica, CA 90404 (US). (72) Inventors: WILTZIUS, Jed, J.W.; c/o Kite Pharma, Inc., 2225 Colorado Avenue, Santa Monica, CA 90404 (US). SIEVERS, Stuart, A.; c/o Kite Pharma, Inc., 2225 Col- orado Avenue, Santa Monica, CA 90404 (US). (74) Agent: BARBIC, Andrej et al.; Proskauer Rose LLP, One International Place, Boston, MA 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) (54) Title: HUMANIZED ANTIGEN-BINDING DOMAINS AGAINST CD19 AND METHODS OF USE (57) : The invention provides a humanized anti-CD 19 antibody or antigen binding fragment thereof comprising a light chain variable (VL) region and a heavy chain variable (VH) region in which the humanized VL and VL regions are derived from the mouse anti-CD 19 clone FMC63 antibody; the humanized VL and/or humanized VH region comprise one or more amino acid substitutions in the framework region. The humanized anti-CD 19 antibody or antigen binding fragment may be part of a single chain variable fragment (scFv), a chimeric antigen receptor (CAR) or a T cell receptor (TCR). Other aspects of the invention relate to cells compris- ing the CAR or the TCR and their use in a T cell therapy.

en

HUMANIZED ANTIGEN-BINDING DOMAINS AGAINST CD19 AND METHODS OF USE

57557233_US

65135778_US,74269976_US

A61K 35/17,A61K2039/505,A61K2039/572,A61P 35/00,A61P 35/02,C07K 14/7051,C07K 16/2803,C07K2317/24,C07K2317/31,C07K2317/55,C07K2317/56,C07K2317/565,C07K2317/622,C07K2317/73,C07K2317/92,C07K2317/94,C07K2319/02,C07K2319/03,C07K2319/30,C07K2319/33

2018-02-08

N

1 co 00 O O (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 August 2018 (16.08.2018) WIP0 1 PCT omit VIII °nolo 010 mil mil minim oimIE (10) International Publication Number WO 2018/148396 Al (51) International Patent Classification: G05D 1/02 (2006.01) A61G 5/00 (2006.01) (21) International Application Number: PCT/US2018/017403 (22) International Filing Date: 08 February 2018 (08.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/456,254 08 February 2017 (08.02.2017) US 15/891,202 07 February 2018 (07.02.2018) US (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application: US 15/891,202 (CON) Filed on 07 February 2018 (07.02.2018) (71) Applicant: BRAIN CORPORATION [US/US]; 9401 Waples Street, Suite 100, San Diego, California 92121 (US). (72) Inventor: IZHIKEVICH, Eugene; 10844 Corte de Marin, San Diego, California 92130 (US). (74) Agent: GUTIERREZ, Peter, J., III et al.; Gazdzinski & Associates, PC, 16644 West Bernardo Drive, Suite 201, San Diego, California 92127 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (54) Title: SYSTEMS AND METHODS FOR ROBOTIC MOBILE PLATFORMS FIG. 2C (57) : Systems and methods for robotic mobile platforms are disclosed. In one exemplary implementation, a system for enabling autonomous navigation of a mobile platform is disclosed. The system may include a memory having computer readable instructions stored thereon and at least one processor configured to execute the computer readable instructions. The execution of the computer readable instructions causes the system to: receive a first set of coordinates corresponding to a first location of a user; determine a different second location for the mobile platform; navigate the mobile platform between the second location and the first location; and receive a different second set of coordinates. Methods, apparatus and computer-readable mediums are also disclosed. [Continued on next page] WO 2018/148396 Al MIDEDIMOMOIDEIREEMOMMIUMBEROMEHOIMI SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) Published: — with international search report (Art. 21(3))

en

SYSTEMS AND METHODS FOR ROBOTIC MOBILE PLATFORMS

73456593_US

73538963_US

A61G 5/04,A61G2203/14,A61G2203/18,A61G2203/22,A61G2203/30,B60W 60/001,G01C 21/005,G01C 21/20,G05D 1/0088,G05D 1/0234,G05D 1/0274,G05D 1/0276,G05D 1/028,G05D2201/0206,G06Q 20/127,G06Q 20/145,G06Q 20/3224,G07F 17/0057

2018-04-10

N

WO 18/ 19 1224 Al AL L FIG. 20C (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) WIP0 I PCT IiiimmoimiolollmonolomomuomomolommovoimIE (10) International Publication Number WO 2018/191224 Al (51) International Patent Classification: H04N 19/597 (2014.01) H04N 19/61 (2014.01) H04N 19/105 (2014.01) H04N 19/593 (2014.01) HO4N 19/176 (2014.01) H04N 19/167 (2014.01) (21) International Application Number: PCT/US2018/026828 (22) International Filing Date: 10 April 2018 (10.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/484,218 11 April 2017 (11.04.2017) US 62/525,880 28 June 2017 (28.06.2017) US (71) Applicant: VID SCALE, INC. [US/US]; 200 Bellevue Parkway, Suite 300, Wilmington, DE 19809 (US). (72) Inventors: HANHART, Philippe; 7916 Avenida Navidad, Apartment 150, San Diego, CA 92122 (US). HE, Yuwen; 13542 Silver Vine Path, San Diego, CA 92130 (US). YE, Yan; 5001 Pearlman Way, San Diego, CA 92130 (US). (74) Agent: ROCCIA, Vincent, J. et al.; Condo Roccia Koptiw LLP, 1800 JFK Blvd., Suite 1700, Philadelphia, PA 19103 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) (54) Title: 360-DEGREE VIDEO CODING USING FACE CONTINUITIES (57) : A coding device (e.g., that may be or may include encoder and/ or decoder) may receive a frame-packed picture of 380-degree video. The cod- ing device may identify a face in the frame-packed picture that the current block belongs to. The coding device may determine that a current block is located at a boundary of the face that the current block belongs to. The coding device may identify multiple spherical neighboring blocks of the current block. The coding device may identify a cross-face boundary neighboring block. The cod- ing device may identify a block in the frame-packed picture that corresponds to the cross-face boundary neighboring block. The coding device may determine whether to use the identified block to code the current block based on avail- ability of the identified block. The coding device may code the current block based on the determination to use the identified block.

en

360-DEGREE VIDEO CODING USING FACE CONTINUITIES

74266140_US

74319629_US,74127766_US,73974945_US

H04N 19/105,H04N 19/117,H04N 19/167,H04N 19/174,H04N 19/176,H04N 19/52,H04N 19/593,H04N 19/597,H04N 19/61

2018-03-27

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) W I PO I PCT omit VIII °nolo mu VIII oinio oimIE (10) International Publication Number WO 2018/191011 Al (51) International Patent Classification: HO4L 27/26 (2006.01) (21) International Application Number: PCT/US2018/024647 (22) International Filing Date: 27 March 2018 (27.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/485,822 14 April 2017 (14.04.2017) US 15/936,200 26 March 2018 (26.03.2018) US (71) Applicant: QUALCOMM INCORPORATED [US/US]; ATTN: International IP Administration, 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (72) Inventors: LY, Hung; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). ABEDINI, Navid; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). LUO, Tao; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). JI, Tingfang; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). LEE, Heechoon; 5775 Morehouse Drive, San Diego, California 92121-1714 (US). (74) Agent: YEUNG, Derek; Loza & Loza, LLP, 305 North Se- cond Avenue #127, Upland, California 91786 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (54) Title: SYNCHRONIZATION SIGNAL BLOCK DESIGNS FOR WIRELESS COMMUNICATION Frequency -o Cr Ct Con Con Con 700 4) ro 17: 1 W O 20 18/ 19 10 11 Al Time FIG. 7 (57) : Aspects of the present disclosure provide various synchronization signal (SS) block designs that can facilitate channel estimation and demodulation in 5G New Radio (NR) networks. An exemplary SS block includes a set of time-frequency resources that are allocated to carry a Primary Synchronization Signal (PSS), a Secondary Synchronization Signal (SSS) and a Physical Broadcast Channel (PBCH) that are time and/or frequency multiplexed within the SS block. In some examples, unused time-frequency resources of the SS block may be used or allocated for supplemental channels that can improve and/or extend wireless link coverage. [Continued on next page] WO 2018/191011 Al MIDEDIMOMOIDEIREEMOMOHHOEIREEMEN (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

SYNCHRONIZATION SIGNAL BLOCK DESIGNS FOR WIRELESS COMMUNICATION

52280328_US

65672214_US,68847639_US,56543372_US,56552177_US,71935361_US

H04J 11/0073,H04J 11/0076,H04L 5/0023,H04L 5/0051,H04L 5/0053,H04L 5/0064,H04L 25/0204,H04L 27/2613,H04L 27/2692

2018-03-14

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIP0 I PCT onion °nolo VIII omioliono oimIE (10) International Publication Number WO 2018/175163 Al (51) International Patent Classification: GOOF 21/62 (2013.01) (21) International Application Number: PCT/US2018/022284 (22) International Filing Date: 14 March 2018 (14.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 15/466,988 23 March 2017 (23.03.2017) US (71) Applicant: MICROSOFT TECHNOLOGY LI- CENSING, LLC [US/US]; One Microsoft Way, Redmond, Washington 98052-6399 (US). (72) Inventor: ALLEN, Phillip David; Microsoft Technology Licensing, LLC, One Microsoft Way, Redmond, Washing- ton 98052-6399 (US). (74) Agent: MINHAS, Sandip S. et al.; Microsoft Technology Licensing, LLC, One Microsoft Way, Redmond, Washing- ton 98052-6399 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (54) Title: CONFIGURABLE ANNOTATIONS FOR PRIVACY-SENSITIVE USER CONTENT 800 FIGURE 8 (57) : Systems, methods, and software for data privacy annotation frameworks for user applications are provided herein. An exemplary method includes identifying at least a first threshold quantity, an elasticity factor for modifying the first threshold quantity to a second threshold quantity, and an indication of a threshold resiliency property indicating when the second threshold quantity overrides the first threshold quantity. The method includes monitoring a content edit process of user content to identify a quantity of the user content that contains sensitive data corresponding to one or more predetermined data schemes, and during the content edit process, enabling and disabling presentation of annotation indicators for the content elements based at least in part on a current quantity with regard to the first threshold quantity, the elasticity factor for the first threshold quantity when enabled, and the indication of the threshold resiliency property. [Continued on next page] WO 2018/175163 Al MIDEDIM01101 DIONER13010M111111111111110111111111111111111111 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

CONFIGURABLE ANNOTATIONS FOR PRIVACY-SENSITIVE USER CONTENT

55457742_US

73453094_US

G06F 21/6245

2020-05-07

Y

A system for geolocation awareness for voice activated digital assistants comprising: a plurality of digital assistants in communication with a network; a cloud computing system in communication with the plurality of digital assistants via the network; a power transmission line monitor in communication with the network, the power transmission line monitor configured to monitor temperature, electric current in the power transmission line, and three-axis shock above a threshold level; a remote server in communication with the power transmission line monitor via the network and in communication with the cloud computing system via the network, the remote server configured to determine if the monitored temperature indicates an emergency event, and configured to determine if the monitored electric current indicates an emergency event, and configured to determine if the monitored three-axis shock indicates an emergency event, the remote server further configured to transmit to the cloud computing system the type and location of an indicated emergency event; and where the cloud computing system is configured to instruct the digital assistants within a predetermined distance from the emergency event to audibly alert about the emergency event for a predetermined time period. A digital assistant comprising a non-transitory computer-readable medium, where the medium includes a set of instructions stored thereon that when accessed by a processor enable the processor to perform a method of geolocation awareness for the digital assistant, the method comprising: configuring the digital assistant to be in communication with a network; configuring the digital assistant to be in communication with a cloud computing system via the network; configuring the digital assistant to be in communication with a remote server via the cloud computing system; configuring the digital assistant to be in communication with a power transmission line monitor via the remote server; receiving information from the cloud computing system that an emergency event is detected by the power transmission line monitor; issuing an emergency audible alert by the digital assistant if the digital assistant is within a predetermined distance of the emergency event. A power transmission line monitor comprising a non-transitory computer-readable medium, where the medium includes a set of instructions stored thereon that when accessed by a processor enable the processor to perform a method of geolocation awareness for a digital assistant, the method comprising: configuring the power transmission line monitor to be in communication with a network; configuring the power transmission line monitor to be in communication with a remote server via the network; configuring the power transmission line monitor to be in communication with a cloud computing system via the remote server; configuring the power transmission line monitor to be in communication with a digital assistant located in a residence or a business via the cloud computing system; monitoring temperature, electric current in a power transmission line, and three-axis shock above a threshold level, transmitting the temperature, electric current, and three-axis shock information to the remote server.

en

System for geolocation awareness for voice activated digital assistants

7095985_US,7095984_US

7095984_US,7095985_US

G08B 3/10,G08B 7/06,G08B 19/00,G08B 21/182,G08B 25/10,G08B 27/005,H04W 4/02,H04W 4/021,H04W 4/90

2018-03-29

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT D IV °nolo iflo oimIE (10) International Publication Number WO 2018/184966 Al (51) International Patent Classification: C07K 16/30 (2006.01) A61K 39/00 (2006.01) A61K 47/68 (2017.01) (21) International Application Number: PCT/EP2018/058043 (22) International Filing Date: 29 March 2018 (29.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17164466.9 03 April 2017 (03.04.2017) EP (71) Applicant (for all designated States except US): F. HOFF- MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). (71) Applicant (for US only): HOFFMANN-LA ROCHE INC. [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jer- sey 07424 (US). (72) Inventors: HOFER, Thomas; c/o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). KOENIG, Maximil- iane; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). MOESSNER, Ekkehard; c/o Roche Gly- cart AG, Wagistrasse 18, 8952 Schlieren (CH). NIE- WOEHNER, Jens; c/o Roche Diagnostics GmbH, Non- nenwald 2, 82377 Penzberg (DE). WEINZIERL, Tina; c/ o Roche Glycart AG, Wagistrasse 18, 8952 Schlieren (CH). LARIVIERE, Laurent; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) 1-1 71 00 - 1-1 00 1-1 O (74) Agent: CUENI, Leah; Grenzacherstrasse 124, 4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: ANTIBODIES BINDING TO STEAP-1 (57) : The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding mole- cules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

en

ANTIBODIES BINDING TO STEAP-1

55137210_CH

73566162_DE,74140728_DE,74120849_CH,73996790_CH,55549953_CH,55498784_DE

A61K2039/505,A61P 35/00,C07K 16/2809,C07K 16/30,C07K 16/3069,C07K2317/31,C07K2317/55,C07K2317/565,C07K2317/71

2018-02-27

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 September 2018 (07.09.2018) WIPO I PCT omit VIII °nolo omioollm 1o11 oo1 IIII mom oimIE (10) International Publication Number WO 2018/160536 Al W O 20 18/1605 36 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/395 (2006.01) A61K 39/00 (2006.01) A61K 39/21 (2006.01) (21) International Application Number: PCT/US2018/019868 (22) International Filing Date: 27 February 2018 (27.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/464,738 28 February 2017 (28.02.2017) US 62/468,527 08 March 2017 (08.03.2017) US (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). (72) Inventors: LOFFREDO, John T.; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). LEWIS, Katherine E.; 19719 53rd Avenue NE, Lake Forest Park, Washing- ton 98155 (US). GRAZIANO, Robert F.; c/o Bristol-My- ers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). KORMAN, Alan J.; c/ o Bristol-Myers Squibb Company, 700 Bay Road, Redwood City, California 94063 (US). (74) Agent: BELLOMY, Gregory R. et al.; Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: USE OF ANTI-CTLA-4 ANTIBODIES WITH ENHANCED ADCC TO ENHANCE IMMUNE RESPONSE TO A VAC- CINE (57) : The present invention provides methods of enhancing immune response to a vaccine using variant forms of anti-CTLA-4 antibodies having enhanced ADCC activity. Variant anti-CTLA-4 antibodies for use in the present invention include nonfucosylated ipilimumab.

en

USE OF ANTI-CTLA-4 ANTIBODIES WITH ENHANCED ADCC TO ENHANCE IMMUNE RESPONSE TO A VACCINE

55492741_US

68156622_US,74179212_US,55302322_US,73487501_US

A61K 39/12,A61K 39/21,A61K 39/3955,A61K2039/505,A61K2300/00,C07K 16/2818,C07K2317/21,C07K2317/41,C07K2317/524,C07K2317/71,C07K2317/73,C07K2317/732,C07K2317/76

2010-11-08

Y

FIELD: medicine, pharmaceutics.SUBSTANCE: invention refers to a compound of formulawherein Rrepresents hydrogen or Calkyl; Rrepresents groupsandor may be specified in a group consisting of, wherein Rrepresents hydrogen, halogen or aryl optionally substituted by halogen; X represents a bond, -(CH)-, -CHRCH-, -CHR(CH)-, -O-CHRCH- or -(Ccyclopropyl)-CH-CH-, and R represents Calkyl or Calkyl substituted by halogen; Rrepresents a) Calkyl; b) hydrogen; c) NH-phenyl optionally substituted by one or more substitutes specified in halogen or Calkyl substituted by halogen; d) NH-6-merous heteroaryl containing 1 or 2 heteroatoms N optionally substituted by one or more substitutes specified in halogen or C-alkyl substituted by halogen; e) (CR'R')-C-cycloalkyl optionally substituted by halogen, Calkyl, Calkyl substituted by halogen, halogen-substituted phenyl or heteroaryl, which represents pyridine; f) 6-merous heterocycloalkyl containing 1 or 2 heteroatoms specified in N and O, optionally substituted by halogen or Calkyl substituted by halogen; g) (CR'R')-5-6-merous monocyclic or 9-10-mrous bicyclic heteroaryl containing 1-3 heteroatoms specified in N, S and O, optionally substituted by halogen, Calkoxy, Calkyl, substituted by halogen, Calkoxy substituted by halogen, Calkyl, Ccycloalkyl, NHC(O)-Calkyl, cyano, S(O)-Calkyl, NRRor 5-6-merous heteroaryl containing 1 or 2 heteroatoms, N or 6-merous heterocyclyl containing 1 or 2 heteroatoms specified in N, O and S, wherein S is optionally specified by two oxygen molecules, which is optionally substituted by halogen; h) (CR'R')-phenyl optionally substituted by halogen, Calkyl substituted by halogen, C-alkoxy substituted by halogen, Calkyl, Calkinyl, Calkoxy, CH-Calkoxy or cyano; i) -O(CH)-phenyl optionally substituted by halogen, Calkoxy or Calkyl substituted by halogen; R' and R' independently represent hydrogen, Calkoxy or Calkyl; or together with atom C may form C-cycloalkyl group; Rrepresents phenyl or 10-merous heteroaryl containing 1 heteroatom N, wherein the above aromatic rings are optionally substituted by one or more substitutes specified in halogen or Calkoxy; Rrepresents Calkyl, phenyl or 6-merous heteroaryl containing 1 heteroatom N, wherein the above aromatic rings are optionally substituted by one or more substituted specified in halogen, cyano or Calkoxy; Rrepresents hydrogen, Calkyl or phenyl substituted by halogen; R/Rindependently represent hydrogen, Calkyl or (CH)-O-Calkyl; m equals to 0, 1 or 2; n equals to 1, 2 or 3; o equals to 0 or 1; p equals to 0, 1 or 2; or their pharmaceutically acceptable acid addition salt. The invention also refers to compounds which represent 4-[2-((S)-2-amino-4,5-dihydrooxazol-4-yl)-ethyl]-N-(4-chlor-phenyl)-benzamide or (S)-4-(2-(2-amino-4,5-dihydrooxazol-4-yl)-ethyl)-N-(5-ethynylpyridin-2-yl)benzamide. The compositions according to the invention are applicable to produce a pharmaceutical composition having a high affinity to trace amine associated receptors.EFFECT: oxazoline derivatives applicable in treating depression, bipolar disorder, attention deficit/hyperactivity syndrome (ADHD), psychotic disorders, schizophrenia, Parkinson's disease, migraine and addictive substance abuse.23 cl, 1 tbl, 233 ex

en

OXAZOLINE DERIVATIVES FOR TREATING CNS DISORDERS

68045222_CH

63553801_DE,64208045_CH,68568736_CH

A61K 31/421,A61P 1/14,A61P 3/00,A61P 3/04,A61P 3/06,A61P 3/10,A61P 9/00,A61P 9/12,A61P 25/00,A61P 25/06,A61P 25/08,A61P 25/16,A61P 25/18,A61P 25/20,A61P 25/22,A61P 25/24,A61P 25/28,A61P 25/30,C07D 263/28,C07D 401/12,C07D 401/14,C07D 403/10,C07D 403/12,C07D 409/12,C07D 413/10,C07D 413/12,C07D 413/14,C07D 417/12,C07D 471/04

2018-02-07

N

WO 18/ 148 296 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 16 August 2018 (16.08.2018) WIP0 1 PCT omit VIII °nolo VIII IH 11010111001 IIII 1111101 ow (10) International Publication Number WO 2018/148296 Al (51) International Patent Classification: A61B 5/00 (2006.01) (21) International Application Number: PCT/US2018/017247 (22) International Filing Date: 07 February 2018 (07.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 15/431,531 13 February 2017 (13.02.2017) US (71) Applicant: HEALTH CARE ORIGINALS, INC. [US/US]; 150 Lucius Gordon Drive, Suite 100F, West Hen- rietta, New York 14586 (US). (72) Inventors: DWARIKA, Jared; 190D Westview Com- mons Blvd., Rochester, New York 14624 (US). SAMJITSINGH, Sharon; 190D Westview Commons Blvd., Rochester, New York 14624 (US). (74) Agent: LIN, Vic; Innovation Capital Law Group, LLP, 19800 MacArthur Blvd., Suite 270, Irvine, California 92612 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: WEARABLE PHYSIOLOGICAL MONITORING SYSTEMS AND METHODS (57) : A physiological monitoring system can use physiological wearable monitors to collect and/or detect various parameters, such as cough, wheeze, heart rate, skin tempera- 10 tune, activity, respiration rate, skin impedance, electro-cardiogram data, blood pressure, gal- vanic skin response, and the like. One or more of these parameters, or other such parameters, may be used in methods in the fields of lung cancer, physiotherapy, monitoring disabled or challenged individuals, monitoring end of life conditions, monitoring breathing gas usage, monitoring patients and individual wellness, data acquisition, athletic sports monitoring, ath- letic sports entertainment, virtual reality feedback, telemedicine, hospital aid, illness detec- tion and its severity, and public service, as examples. Such methods can use data from one or more wearable devices with the appropriate data processing to present the user or healthcare provider with the appropriate analysis. FIG. 1A

en

WEARABLE PHYSIOLOGICAL MONITORING SYSTEMS AND METHODS

71327023_US

74007322_US,74321414_US

A61B 5/01,A61B 5/021,A61B 5/024,A61B 5/08,A61B 5/0816,A61B 5/14542,A61B 5/165,A61B 5/318,A61B 5/486,A61B 5/6801,A61B 5/6833,A61B 5/742,A61B2503/10,A63F 13/212,A63F2300/8082

2014-03-03

N

The invention entails a method of Etiological prioritization based on an original symbolic model of the causative construction of singular logical relations which are built from an initiation of sensed masses in patterns, the naming of sensed patterns into words, the description of the relations of masses using specific English language primitives, the relations between masses and words, and the relations between primitive words. This process is built upon a theory and model of discretized human capabilities and learned experiential meanings. Human capabilities and learned experiential meanings are identified as singular primitives and amount to words identified and matched to singular parts that make up human capabilities and the inventive model of the experiences of the sensing and understanding of the spatiotemporal physical world. Continued etiological development of the inventive model entails new primitive meanings being built via the combination of the inventive model of the primitives of human capabilities with the inventive model of the primitives not representing human capabilities. The method of etiological prioritization is used to create the inventive model of the definitions of many hundreds of English language words and is applied to the explication of specialized domains of knowledge. In accordance with the invention, the method may comprise identifying a plurality of primitive words in a first group, where the primitive words in the first group have a singular meaning. The plurality of primitive words in the first group having a singular meaning are stored at a first set of storage locations in a computing device. A plurality of primitive words in a second group are identified. The plurality of primitive words in the second group have associated meanings which may be defined by the primitive words in the first group and/or other primitive words in the second group. The plurality of primitive words in the second group are stored at a second set of storage locations in a computing device. For each of the primitive words in the second group, its respective associated meanings are stored as definitional linking information, linking a respective primitive word to respective defining primitive words in the first group and/or other primitive words in the second group, whereby upon the identification of any word, a definition comprising linked primitive words may be retrieved. For each of a plurality of definable words, wherein the definable words are selected from the first and second groups, one selects words from the first and second groups as relative words having substantially the same meaning as its respective definable word, and/or associates words in the first and second groups into respective relative phrases having substantially the same meaning as its respective definable word, each of the definable words, together with its respective relative words and relative phrases forming a relative set. For each of the definable words, relative set linking information linking each of the definable words to its respective relative words and relative phrases is stored, whereby upon the identification of any word, the other members of a relative set may be retrieved.

en

ARTIFICIAL INTELLIGENCE METHOD AND APPARATUS

47262799_US

47262799_US

G06F 7/24,G06F 16/24578,G06F 16/3334,G06F 16/338,G06F 16/35,G06F 16/367,G06F 16/93,G06F 16/951,G06N 5/022,G06N 20/00

2018-01-15

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 July 2018 (26.07.2018) WIP0 I PCT oimitia °nolo Immo mmoo mnio oimIE (10) International Publication Number WO 2018/133754 Al (51) International Patent Classification: H04W 16/10 (2009.01) H04W 72/04 (2009.01) (21) International Application Number: PCT/CN2018/072573 (22) International Filing Date: 15 January 2018 (15.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/448,676 20 January 2017 (20.01.2017) US (71) Applicant: GUANGDONG OPPO MOBILE TELECOMMUNICATIONS CORP., LTD. [CN/CN]; No. 18 Haibin Road, Wusha, Chang'an, Dongguan, Guang- dong 523860 (CN). (72) Inventors: SHEN, Jia; No. 18 Haibin Road, Wusha, Chang'an, Dongguan, Guangdong 523860 (CN). XU, Hua; 5 Appaloosa Dr, Ottawa, Ontario K2M1N6 (CA). (74) Agent: CHINA PAT INTELLECTUAL PROPERTY OFFICE; 2nd Floor, Zhongguancun Intellectual Property Building, Block B, No. 21 Haidian South Road, Haidian District, Beijing 100080 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (54) Title: SEPARATE CONFIGURATION OF NUMEROLOGY-ASSOCIATED RESOURCES Separately configure a first message and a second message for / 301 PDCCH and another physical channel 302 Transmit the first message and the second message / 303 Transmit the PDCCH / 304 Transmit the another physical channel FIG. 3 (57) : Disclosed is a method and apparatus for separately configuring sets of frequency resources for a PDCCH and another physical channel. According to the method, the first and second messages are configured separately to respectively indicate the sets of frequency resources with associated numerologies for the PDCCH and other physical channels. Therefore, different sets of frequency resources and/or different associated numerologies may be respectively configured for the PDCCH and other physical channels, thereby effectively utilizing bandwidth resources and providing flexibility of resource configuration. [Continued on next page] WO 2018/133754 Al MIDEDIMOHNIIMEIDIOMOINIMMINHINVOIS MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

SEPARATE CONFIGURATION OF NUMEROLOGY-ASSOCIATED RESOURCES

56273917_CN

71765203_CA,73280209_CN

H04L 1/1642,H04L 5/0007,H04L 5/0044,H04L 5/0053,H04L 5/0094,H04L 27/2607,H04W 16/10,H04W 72/04,H04W 72/042,H04W 72/0453,H04W 72/1273,H04W 76/27

2018-04-13

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 18 October 2018 (18.10.2018) W I PO I PCT oimiolo VIII °nolo VIII 01 ois (10) International Publication Number WO 2018/190732 A2 (51) International Patent Classification: G01N 29/024 (2006.01) (21) International Application Number: PCT/NZ2018/050052 (22) International Filing Date: 13 April 2018 (13.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/485,614 14 April 2017 (14.04.2017) US 62/516,579 07 June 2017 (07.06.2017) US (71) Applicant: FISHER & PAYKEL HEALTHCARE LIMITED [NZ/NZ]; 15 Maurice Paykel Place, East Tama- ki, Auckland, 2013 (NZ). (72) Inventors: BURGESS, Russel William; 15 Maurice Paykel Place, East Tamaki, Auckland, 2013 (NZ). BARK- ER, Dean Antony; 15 Maurice Paykel Place, East Tamaki, Auckland, 2013 (NZ). (74) Agent: BALDWINS INTELLECTUAL PROPERTY; PO BOX 852, Wellington, 6011 (NZ). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: FLOW PATH SENSING FOR FLOW THERAPY APPARATUS /0 /7 N O 00 O C FIG. I (57) : A respiratory flow therapy apparatus including a sensor module can measure a flow rate of gases or gases concentra- tion provided to a patient. The sensor module can be located after a blower and/or mixer. The sensor module can include at least an ultrasonic transmitter, a receiver, a temperature sensor, a pressure sensor, a humidity sensor and/or a flow rate sensor. The receivers can be immersed in the gases flow path. The receivers can cancel delays in the transmitters and improve accuracy of measurements of characteristics of the gases flow. The receivers can allow for detection of a fault condition in a blower motor of the apparatus. [Continued on next page] WO 2018/190732 IIIIIIIIIIIIIIIII IIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIIII TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

en

FLOW PATH SENSING FOR FLOW THERAPY APPARATUS

55211753_NZ

57358033_NZ,69690153_NZ

A61M 16/0003,A61M 16/0051,A61M 16/0066,A61M 16/0069,A61M 16/024,A61M 16/0672,A61M 16/1005,A61M 16/1065,A61M 16/1085,A61M 16/1095,A61M 16/125,A61M 16/16,A61M 16/161,A61M 16/202,A61M 16/203,A61M2016/0018,A61M2016/0027,A61M2016/0039,A61M2202/0225,A61M2205/125,A61M2205/13,A61M2205/18,A61M2205/3334,A61M2205/3368,A61M2205/3372,A61M2205/3375,A61M2205/3561,A61M2205/3592,A61M2205/502,A61M2205/52,A61M2205/70,A61M2205/8206,A61M2230/205,A61M2230/40,A61M2230/432,A61M2240/00,G01F 1/668,G01F 15/024,G01F 25/15,G01N 29/024,G01N 29/32,G01N 29/4472,G01N2291/011,G01N2291/0215,G01N2291/02809,G01N2291/02836,G01N2291/048,G01N2291/105

2017-10-13

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 April 2018 (19.04.2018) omit VIII °nolo olo IID OH 1101 (10) International Publication Number WO 2018/071822 A3 WIPO I PCT (2006.01) (2006.01) (2006.01) (51) International Patent Classification: A61K 39/12 (2006.01) C07K 14/18 A61K 39/395 (2006.01) A61P 31/12 C07K 16/10 (2006.01) A61K 39/00 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). • N QC N 1-1 O 00 O 1-1 N O (21) International Application Number: PCT/US2017/056596 (22) International Filing Date: 13 October 2017 (13.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/408,020 13 October 2016 (13.10.2016) US (71) Applicants: MASSACHUSETTS INSTITUTE OF TECHNOLOGY [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02139 (US). NATIONAL UNIVERSITY OF SINGAPORE [SG/SG]; 21 Lower Kent Ridge Road, Singapore 119077 (SG). (72) Inventors: SASISEKHARAN, Ram; 53 Colony Road, Lexington, MA 02421 (US). THARAKARAMAN, Kan- nan; 295 Salem St #64, Woburn, MA 01801 (US). CHAN, Kuan, Rong; Duke-nus Medical School, 8 College Road, Singapoe 169857 (SG). WATANABE, Satoru; Duke-nus Medical School, 8 College Road, Singapore 169857 (SG). VASUDEVAN, Subhash, G.; Duke-nus Medical School, 8 College Road, Singapore 169857 (SG). 001, Eng, Eong; Duke-nus Medical School, 8 College Road, Singapore 169857 (SG). (74) Agent: MANDRAGOURAS, Amy, E. et al.; Nelson Mullins Riley & Scarborough LLP, One Post Office Square, Boston, MA 02109-2127 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (88) Date of publication of the international search report: 24 May 2018 (24.05.2018) (54) Title: ANTIBODIES THAT BIND ZIKA VIRUS ENVELOPE PROTEIN AND USES THEREOF (57) : Isolated monoclonal antibodies which bind to Zika virus envelope protein and related antibody-based compositions and molecules are disclosed. Also disclosed are therapeutic and diagnostic methods for using the antibodies.

en

ANTIBODIES THAT BIND ZIKA VIRUS ENVELOPE PROTEIN AND USES THEREOF

52661157_SG,56296133_US

71921843_SG,56600676_US,53305610_SG,53209506_SG,71167363_SG,56593515_US

A61K 39/12,A61K 39/395,A61K 39/42,A61K2039/505,A61P 31/12,A61P 31/14,C07K 14/1825,C07K 16/10,C07K 16/1081,C07K2317/21,C07K2317/33,C07K2317/565,C07K2317/76,C07K2317/92,C12N 15/63,C12N2770/24111,C12N2770/24122,Y02A 50/30

2018-04-05

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT omit VIII °nolo HE ollimoino oimIE (10) International Publication Number WO 2018/185232 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2018/058752 (22) International Filing Date: 05 April 2018 (05.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/481,973 05 April 2017 (05.04.2017) US (71) Applicant: SYMPHOGEN A/S [DK/DK]; Pederstrupvej 93, 2750 Ballerup (DK). (72) Inventors: LINDSTED, Trine; Hyldevwnget 13, 3520 Farum (DK). GRANDAL, Michael Monrad; Solbrinken 26a, 2750 Ballerup (DK). MELANDER, Eva Maria Carlsen; Ostra Hyllievagen 111, 216 23 Malmo (SE). FROHLICH, Camilla; Nojsomhedsvej 13, 2. th, 2100 Kobenhavn 0 (DK). PEDERSEN, Mikkel Wandahl; Forelvej 17, 3450 Alleroed (DK). KRAGH, Michael; Lwssoesgade 1A, 5. Tv., 2200 Copenhagen N (DK). LANTTO, Johan; Bryggaregaten 4, 227 36 Lund (SE). GAD, Monika; Gravenstensvej 8, 3450 Allerod (DK). HO- RAK, Ivan David; Rundholtsvej 26, 2300 Copenhagen S (DK). (74) Agent: POHLMAN, Sandra; TheatinerstraBe 16, 80333 Mfinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) ot CO (54) Title: COMBINATION THERAPIES TARGETING PD-1, TIM-3, AND LAG-3 1-1 0 (57) : This disclosure relates to combination therapies targeting two or all of PD-1, TIM-3, and LAG-3 using antibodies \' specific for these targets in patients who are in need of enhanced immunity. Also included in the disclosure are compositions useful in 0 the therapies. The therapies are useful in treating diseases such as cancers.

en

COMBINATION THERAPIES TARGETING PD-1, TIM-3, AND LAG-3

67239168_DK

68206308_DK,74400377_SE,73413026_DK,74182709_DK,73542578_SE,63724039_DK,63947487_DK,63724087_DK,69650425_DK

A61K 45/06,A61K2039/505,A61K2039/507,A61P 35/00,C07K 16/2803,C07K 16/2818,C07K2317/31,C07K2317/565,C07K2317/76,C07K2317/92

2018-03-09

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 13 September 2018 (13.09.2018) WIP0 I PCT onion °noI0 OilIIIII010010 1111111 Oil ow (10) International Publication Number WO 2018/162749 Al (51) International Patent Classification: C07K 16/10 (2006.01) C07K 16/28 (2006.01) (21) International Application Number: PCT/EP2018/055977 (22) International Filing Date: 09 March 2018 (09.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PA 2017 00164 09 March 2017 (09.03.2017) DK PA 2017 00408 11 July 2017 (11.07.2017) DK (71) Applicant: GENMAB A/S [DK/DK]; Kalvebod Brygge 43, 1560 Copenhagen V (DK). (72) Inventors: ALTINTAS, Isil; c/o Genmab B.V., Upp- salalaan 15, 3584 CT Utrecht (NL). SATIJN, David; c/ o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). VAN DEN BRINK, Edward; c/o Genmab B.V., Upp- salalaan 15, 3584 CT Utrecht (NL). VERZIJL, Dennis; c/ o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). RADEMAKER, Rik; c/o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). PARREN, Paul; Werdorperwaard 17, 3984 PR Odijk (NL). DE GOEIJ, Bart; c/o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) W O 20 18/ 16 27 49 Al (74) Agent: GENMAB A/S; Kalvebod Brygge 43, 1560 Copen- hagen V (DK). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: ANTIBODIES AGAINST PD-L1 (57) : The present invention relates to novel antibodies and their use in medicine. In particular, the invention relates to bispecific antibodies capable of binding human PD-L1 and capable of binding human CD3. Novel classes of antibodies capable of binding human PD-L1 are also provided. The invention furthermore relates to uses of the antibodies of the invention and to methods, nucleic acid constructs and host cells for producing antibodies of the invention.

en

ANTIBODIES AGAINST PD-L1

56341074_DK

73431867_NL,56438089_NL,56436408_NL,56510511_NL,56248531_NL,56521079_NL,74244347_NL

A61K 39/3955,A61K 45/06,A61P 35/00,C07K 16/1045,C07K 16/2809,C07K 16/2827,C07K 16/4258,C07K2317/14,C07K2317/21,C07K2317/24,C07K2317/31,C07K2317/33,C07K2317/34,C07K2317/35,C07K2317/524,C07K2317/526,C07K2317/53,C07K2317/55,C07K2317/565,C07K2317/567,C07K2317/71,C07K2317/732,C07K2317/76,C07K2317/92

2019-06-28

N

The present invention provides gambling games that are fast to play, easy to learn, and have a high likelihood of a winning Player for each play. Additionally, the games may be operated so as to have a large and growing bonus for each play. Additionally, certain embodiments of the gambling games offer a sequence of decision points to accept an accrued payout or risk the payout in further play to obtain an even larger payout, in some embodiments, exceeding a billion dollars. After a first successful wager in such a game, a Player is offered the opportunity to accept accrued winnings, i.e., accept 'The Deal,' or decline to accept the accrued winnings i.e. decide 'No Deal,' and risk the accrued winnings in an additional play of the game. The gaming method comprises: a) defining collections of objects to be used in playing a game according to the method; b) assigning a first collection of the objects to a dealer party, and a second collection of the objects to a first wagering party, the second collection of the objects comprising at least the same objects as the first collection of objects; c) accepting a first wager of funds of a defined value from the first wagering party, the wager contingent upon the outcome of random selections of objects from the first and second collections of objects; d) making a random selection of a subset of objects from the first collection of objects and a random selection of a subset of objects from the second collection of objects; e) comparing the subset of objects from the first collection of objects with the subset of objects from the second collection of objects; f) if the subset of objects from the first collection of objects does not correspond to one of a predefined set of matching relationships with the subset of objects from the second collection of objects, transferring the defined value of the first wager of funds to the dealer party; g) if the subset of objects from the first collection of objects has a matching relationship to the subset of objects from the second collection of objects that corresponds to one of the predefined set of matching relationships, transferring a payout of X times the defined value of the funds of the first wager from the dealer party to the first wagering party, wherein X is a function of the probability of occurrence of the corresponding one of the predefined set of matching relationships. WO 2016/205708 PCT/US2016/038175 PROVIDE PLAYER'S DEFINE COLLECTION OF COLLECTION I PROVIDEDEALER'S OBJECTS OF OBJECTS COLLECTION OF PLAYER OBJECTS WAGER | 406 RANDOM SELECTION 408 OF SUBSET OF PLAYER'S COLLECTION -------- 410 ------- ----- END RANDOM RANDOM GAME- ANY 412 SELECTION SELECTION 414- HOUSE MATCH? OF SUBSET |OF SUBSET KEEPS OF PLAYER'S |OF DEALER'S COLLECTION COLLECTION MATCH 4440----- NO EXCEEDS QUALITY 432 END THRESHOLD? ANY NO GAME HOUSEPAYS MATCH? HOUSE PLAYERFOR KEEPS FIRST TIER WIN Y 438 4 YES WAGER HOUSE OFFERS TO END YES MAXIMUM CONTINUE PLAY GAME JACKPOT? NO PLAYER HOUSE OFFERS TO CONTINUES PLAY? CONTINUE PLAY PLAYER WAGERS CONTINUES PLAY? ACCRUED WINNINGS 422 I PLAYER ACCRUED YES WINNINGS 446 PLAYER WAGERS ACCRUED WINNINGS

en

Games of chance

55522784_US

57186152_,57258130_,57075141_

G07F 17/3209,G07F 17/3211,G07F 17/3213,G07F 17/3216,G07F 17/3258,G07F 17/326,G07F 17/3262,G07F 17/3293

2018-04-23

N

COMPUTINGSYSTEM CO MNIUNI CATIO N SUBSYSTEM GPS SUBSYSTEM ] 1LG INPUT SUBSYSTEM DISPLAY SUBSYSTEM 106 LOGIC MACI IN F 102 STORAGE MACITINE 104 O N O 00 O O (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 15 November 2018 (15.11.2018) WIPO I PCT omit VIII °nolo oloionmollm °HIND oimIE (10) International Publication Number WO 2018/207015 Al (51) International Patent Classification: G07B 15/02 (2011.01) G06Q 20/04 (2012.01) G06Q 30/02 (2012.01) GO6Q 20/32 (2012.01) (21) International Application Number: PCT/IB2018/000505 (22) International Filing Date: 23 April 2018 (23.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/405,185 10 May 2017 (10.05.2017) US 15/949,760 10 April 2018 (10.04.2018) US (72) Inventor; and (71) Applicant: MANGO, Moua Branckay, Cesar, Serge [FR/FR]; Residence Anthurium, Villa #4, 69-70 Rue De L'escale, Oyster Pond, Saint Martin 97150 (FR). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: UNIVERSAL FARE PAYMENT AND COLLECTION SYSTEM (57) : A universal fare payment and collection system configured to allow users to purchase tickets and/or passes for a plurality of public transport authorities using a single account or device. The system is configured to detect a first ticketing technology of a first nearby transportation system, configure the traveler's electronic device for authorizing at least one of a ticket and a pass via the first ticketing technology, detect a second ticketing technology of a second nearby transportation system, the second ticketing technology being different from the first ticketing technology, and configure the traveler's electronic device for authorizing at least one of a ticket and a pass via the second ticketing technology. [Continued on next page] WO 2018/207015 Al MIDEDIMOHNIIME1010010101101101g0MMUMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with amended claims (Art. 19(1))

en

UNIVERSAL FARE PAYMENT AND COLLECTION SYSTEM

73312406_FR

73312406_FR

G06Q 20/045,G06Q 20/3224,G06Q 20/326,G06Q 20/3278,G07B 15/02,G07F 17/42

2018-02-22

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 August 2018 (30.08.2018) WIPO I PCT IiiimmoimmonotiolomonllnolomolioluovoimIE (10) International Publication Number WO 2018/153340 Al (51) International Patent Classification: A61K 39/00 (2006.01) Cl 2N 15/13 (2006.01) C07K 16/28 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/CN2018/076940 (22) International Filing Date: 22 February 2018 (22.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/CN2017/074365 22 February 2017 (22.02.2017) CN PCT/CN2017/088570 16 June 2017 (16.06.2017) CN (71) Applicant: I-MAB; Grand Pavilion, Hibiscus Way, 802 West Bay Road, PO Box 31119, Cayman KY1-1205 (KY). (72) Inventors: FANG, Lei; Suite 802, West Tower, OmniVi- sion, 88 Shangke Road, Shanghai 201206 (CN). WANG, Zhengyi; Suite 802, West Tower, OmniVision, 88 Shangke Road, Shanghai 201206 (CN). GUO, Bingshi; Suite 802, West Tower, OrrmiVision, 88 Shangke Road, Shanghai 201206 (CN). ZANG, Jingwu; Suite 802, West Tower, OmniVision, 88 Shangke Road, Shanghai 201206 (CN). JIANG, Wenqing; Suite 802, West Tower, OmniVi- sion, 88 Shangke Road, Shanghai 201206 (CN). WANG, Yongqiang; Suite 802, West Tower, OrrmiVision, 88 Shangke Road, Shanghai 201206 (CN). (74) Agent: SHANGHAI BESHINING LAW OFFICE; 21st Floor Sfeco Mansion 681 Xiaomuqiao Road, Shanghai 200032 (CN). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) 1-1 0 (57) : Provided are antibodies that bind Lymphocyte Activation Gene-3 (LAG-3). Also provided are methods of stimulating \' an immune response, inhibiting growth of tumor cells, and treating an autoimmune, inflammatory, or viral disease. (54) Title: ANTI-LAG-3 ANTIBODIES AND USES THEREOF

en

ANTI-LAG-3 ANTIBODIES AND USES THEREOF

57083201_

71545054_CN,56614065_CN,73305655_CN,71548502_CN,72014534_CN,71181906_CN

A61K 35/17,A61K2039/505,A61K2039/507,A61P 25/00,A61P 29/00,A61P 35/00,A61P 37/02,A61P 37/04,C07K 16/2803,C07K 16/2818,C07K 16/2827,C07K2317/21,C07K2317/24,C07K2317/31,C07K2317/33,C07K2317/53,C07K2317/55,C07K2317/56,C07K2317/565,C07K2317/75,C07K2317/76,C07K2317/92,G01N 33/6893,G01N2333/70503

2018-03-14

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIP0 I PCT 0111111010 0111 °nolo Oil ioo VIII Immo oimIE (10) International Publication Number WO 2018/167481 Al (51) International Patent Classification: CO7K 16/42 (2006.01) GO1N 33/566 (2006.01) GO1N 33/537 (2006.01) (21) International Application Number: PCT/GB2018/050645 (22) International Filing Date: 14 March 2018 (14.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1704115.3 15 March 2017 (15.03.2017) GB (71) Applicant: OXFORD GENETICS LIMITED [GB/GB]; First Floor, Medawar 1, Robert Robinson Avenue, The Ox- ford Science Park, Oxford Oxfordshire OX4 4GA (GB). (72) Inventors: CAWOOD, Ryan; C/o Oxford Genetics Limit- ed, First Floor, Medawar 1, Robert Robinson Avenue, The Oxford Science Park, Oxford Oxfordshire OX4 4GA (GB). PAYNE, Thomas; C/o Oxford Genetics Limited, First Floor, Medawar 1, Robert Robinson Avenue, The Oxford Science Park, Oxford Oxfordshire OX4 4GA (GB). PARK- ER-MANUEL, Richard; C/o Oxford Genetics Limited, First Floor, Medawar 1, Robert Robinson Avenue, The Ox- ford Science Park, Oxford Oxfordshire OX4 4GA (GB). TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (74) Agent: DEHNS; St Bride's House, 10 Salisbury Square, London Greater London EC4Y 8JD (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 1-1 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 00 1-1 71' (54) Title: METHOD OF SELECTING FOR ANTIBODIES 1-1 (57) : The present invention relates to a method for identifying specific binding partners (e.g. antibodies or antibody mimetics) which bind to a desired target polypeptide. In particular, the method involves expressing a library of antibodies or antibody mimetics in a population of mammalian cells, wherein each cell in the population of cells displays the target polypeptide on the outer surface of N the cell, and identifying or isolating cells within the population of cells to which antibodies or antibody mimetics are bound.

en

METHOD OF SELECTING FOR ANTIBODIES

64516189_GB

67421381_GB,66882218_GB,73948105_GB

C07K 14/705,C07K 16/30,C07K 16/42,C07K2319/03,C12N 15/1037,C40B 30/04,C40B 40/02,C40B 40/10,G01N 33/5032,G01N 33/531,G01N 33/537,G01N 33/566,G01N 33/6845,G01N 33/6854,G01N2500/04,G01N2500/10

2018-04-03

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 11 October 2018 (11.10.2018) WIPO I PCT omit VIII °nolo OH H ioo im mil ono oimIE (10) International Publication Number WO 2018/185043 Al (51) International Patent Classification: CO7K 16/28 (2006.01) (21) International Application Number: PCT/EP2018/058382 (22) International Filing Date: 03 April 2018 (03.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17165125.0 05 April 2017 (05.04.2017) EP (71) Applicant (for all designated States except US): F. HOFF- MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH). (71) Applicant (for US only): HOFFMANN-LA ROCHE INC. [US/US]; Overlook at Great Notch, 150 Clove Road, 8th Floor, Suite 8 - Legal Department, Little Falls, New Jer- sey 07424 (US). (72) Inventors: CODARRI DEAK, Laura; c/o Roche Gly- cart AG, Wagistrasse 10, 8952 Schlieren (CH). FISCH- ER, Jens; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). IMHOF-JUNG, Sabine; c/o Roche Diagnostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). KLEIN, Christian; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). SEEBER, Stefan; c/o Roche Diag- nostics GmbH, Nonnenwald 2, 82377 Penzberg (DE). WE- BER, Patrick Alexander Aaron; c/o Roche Glycart AG, Wagistrasse 10, 8952 Schlieren (CH). (74) Agent: KLOSTERMEYER RAUBER, Doerte; Gren- zacherstrasse 124, 4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) GO (54) Title: BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3 0 (57) : The invention relates to bispecific antibodies comprising a first antigen binding domain that specifically binds to PD1 \' and a second antigen binding domain that specifically binds to LAG3. The invention further relates to methods of producing these 0 molecules and to methods of using the same.

en

BISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO PD1 AND LAG3

55137210_CH

74051981_DE,73299812_CH,71176406_DE,73895509_CH,55138748_CH,73275094_CH,57509648_DE

A61K 35/17,A61K 39/001102,A61K 39/3955,A61K 45/06,A61K2039/505,A61K2039/507,A61K2300/00,A61P 31/12,A61P 35/00,C07K 16/2803,C07K 16/2809,C07K 16/2818,C07K 16/3007,C07K2317/24,C07K2317/31,C07K2317/33,C07K2317/41,C07K2317/52,C07K2317/522,C07K2317/526,C07K2317/55,C07K2317/64,C07K2317/66,C07K2317/71,C07K2317/74,C07K2317/75,C07K2317/76,C07K2317/77,C07K2317/92,C07K2317/94,C07K2319/00,C07K2319/30,C07K2319/74,C07K2319/75

2018-01-04

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 September 2018 (07.09.2018) WIPO I PCT oimiolo VIII °nolo VIII ioo no Elul° oimIE (10) International Publication Number WO 2018/160055 Al (51) International Patent Classification: A61K 31/192 (2006.01) A61P 25/28 (2006.01) A61K 31/196 (2006.01) A61P 43/00 (2006.01) A61P 25/18 (2006.01) (21) International Application Number: PCT/MY2018/000001 (22) International Filing Date: 04 January 2018 (04.01.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/466,749 03 March 2017 (03.03.2017) US (71) Applicants: EXCELSIOR PHARMATECH LABS [CN/CN]; 14F-7, No. 3, Park St., Nangang Dist., Taipei, Taiwan 11503 (CN). YING-TUNG, Lee [MY/MY]; 8, Jalan Bukit Permai 1/3, Taman Bukit Permai, Bandar Sun- gai Long, Selangor, 43000 (MY). (72) Inventor; and (71) Applicant: HSIEN-YUAN, Lane [CN/CN]; 12F-5, No.360, Jianxing Rd., North Dist., Taichung, 404 (TW). (72) Inventor: PIN-CHEN, Yang; No. 100, Tzyou 1st Road, Kaohsiung, 807 (TW). (74) Agent: JUSTIN, Anandan Santiago; Nanyang IP Sdn Bhd, 30-3, Jalan Bangsar Utama 1, Bangsar, Kuala Lumpur, 59000 (MY). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: of inventorship (Rule 4.17(iv)) as to non prejudicial disclosures or exceptions to lack of novelty (Rule 4.17(v)) Published: with international search report (Art. 21(3)) O O (54) Title: METHOD FOR PREVENTING OR TREATING AUTISM SPECTRUM DISORDERS BY BENZOIC ACID SALT 00 (57) : The present disclosure provides a method for preventing or treating an autism spectrum disorder in a subject in need O thereof. The method includes administering to the subject a composition containing a therapeutically effective amount of a benzoic acid salt and a pharmaceutically acceptable excipient thereof. Also provided is a composition for use in preventing or treating an autism C spectrum disorder in a subject in need thereof.

en

METHOD FOR PREVENTING OR TREATING AUTISM SPECTRUM DISORDERS BY BENZOIC ACID SALT

74159071_MY,73557282_CN,73280597_CN

74169790_TW,73557282_CN

A61K 31/192,A61K 31/196,A61P 25/18,A61P 25/28,A61P 43/00

2003-10-30

N

The invention provides a method of conferring donor CDR binding affinity onto an antibody acceptor variable region framework. The method consists of: (a) constructing a population of altered antibody variable region encoding nucleic acids, said population comprising encoding nucleic acids for an acceptor variable region framework containing a plurality of different amino acids at one or more acceptor framework region amino acid positions and donor CDRs containing a plurality of different amino acids at one or more donor CDR amino acid positions; (b) expressing said population of altered variable region encoding nucleic acids, and (c) identifying one or more altered variable regions having binding affinity substantially the same or greater than the donor CDR variable region. The acceptor variable region framework can be a heavy or light chain variable region framework and the populations of heavy and light chain altered variable regions can be expressed alone to identify heavy or light chains having binding affinity substantially the same or greater than the donor CDR variable region. The populations of heavy and light chains additionally can be coexpressed to identify heteromeric altered variable region binding fragments. The invention also provides a method of simultaneously grafting and optimizing the binding affinity of a variable region binding fragment. The method consists of: (a) constructing a population of altered heavy chain variable region encoding nucleic acids comprising an acceptor variable region framework containing donor CDRs and a plurality of different amino acids at one or more framework region and CDR amino acid positions; (b) constructing a population of altered light chain variable region encoding nucleic acids comprising an acceptor variable region framework containing donor CDRs and a plurality of different amino acids at one or more framework regions and CDR amino acid positions; (c) coexpressing said populations of heavy and light chain variable region encoding nucleic acids to produce diverse combinations of heteromeric variable region binding fragments, and (d) identifying one or more heteromeric variable region binding fragments having affinity substantially the same or greater than the donor CDR heteromeric variable region binding fragment. A method of optimizing the binding affinity of an antibody variable region is also provided. The method consists of: (a) constructing a population of antibody variable region encoding nucleic acids, said population comprising two or more CDRs containing a plurality of different amino acids at one or more CDR amino acid positions; (b) expressing said population of variable region encoding nucleic acids, and (c) identifying one or more variable regions having binding affinity substantially the same or greater than the donor CDR variable region. The variable region populations can be heavy or light chains and can be expressed as individual populations or they can be coexpressed to produce heteromeric variable region binding fragments.

en

Heteromeric variable regions with unvaried human framework regions

18513956_,18513955_,19712166_

18513959_US,18513960_US,15341529_US

C07K 16/00,C07K 16/2878,C07K 16/36,C07K 16/464,C07K 16/465,C07K2317/24,C07K2317/55,C07K2317/56,C07K2317/92

2018-03-23

N

NRC 49.1160100.4i . l aitib 02 -it- Mil 102 10.3 104 104 10 10-7 o 0 4 0.0 10 NR (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIP0 I PCT o mum °nolo UI n ono oimIE (10) International Publication Number WO 2018/175833 Al (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/18 (2006.01) A61K 39/00 (2006.01) C07K 16/28 (2006.01) A61K 45/06 (2006.01) C07K 14/00 (2006.01) (21) International Application Number: PCT/US2018/023927 (22) International Filing Date: 23 March 2018 (23.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/475,573 23 March 2017 (23.03.2017) US (71) Applicant: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104 (US). (72) Inventors: SONG, Wenchao; 213 Cornell Drive, Bryn Mawr, PA 19010 (US). MIWA, Takashi; 191 Presiden- tial Blvd., Unit 323, Bala Cynwyd, PA 19004 (US). SA- TO, Sayaka; 2130 Locust Street, Apt. #A1, Philadelphia, PA 19103 (US). GULLIPALLI, Damodar; 4007 Wood- land Avenue, Apt. B, Philadelphia, PA 19106 (US). (74) Agent: HAAS, Dennis, L. et al.; Riverside Law, LLP, Glenhardie Corporate Center, 1285 Drummers Lane, Suite 202, Wayne, PA 19087 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: ANTI-05A ANTIBODIES AND USES THEREOF 7Al2 Control anti-05 mAb 00 Figure 1 N 1-1 1-1 (57) : This invention relates to inhibition of the complement signaling using anti-05a antibody. Specifically, the invention © relates to methods of treating a complement-mediated disease or complement-mediated disorder in an individual by contacting the C individual with an anti-05a antibody. [Continued on next page] WO 2018/175833 Al MIDE111111011111 1111E111E31111111111111111111111111111111101111111111 Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))

en

ANTI-C5A ANTIBODIES AND USES THEREOF

56465002_US

73807667_US,74262490_US,74127656_US,73547843_US

A61K 39/395,A61K2039/505,C07K 16/18,C07K 16/28,C07K2317/24,C07K2317/54,C07K2317/565,C07K2317/622,C07K2317/76,C12N 15/85,C12N2015/8518

2003-07-28

Y

A biped walking humanoid robot is disclosed having an arrangement whereby shocks acting on various parts of the robot when it falls can be relieved and its state of fall can then be detected. The robot has a body ( 11 ) capable of bending forward, a pair of legs ( 12 L, 12 R) attached to a lower part of the body at a pair of opposite sides thereof, respectively, a pair of arms ( 13 L, 13 R) attached to an upper part of the body at a pair of opposite sides, respectively, and a head ( 14 ) attached to an upper end of the body, each of the legs having a upper leg ( 15 L, 15 R) attached to the body so as to be pivotally movable relative thereto triaxially, a lower leg ( 16 L, 16 R) attached to a lower end of the upper leg so as to be pivotally movable relative thereto monoaxially and a foot ( 17 L, 17 R) attached to a lower end of the lower leg so as to be pivotally movable relative thereto biaxially, each of the arms having an upper arm ( 25 L, 25 R) attached to the body so as to be pivotally movable relative thereto biaxially, a lower arm ( 26 L, 26 R) attached to the upper arm so as to be pivotally movable relative thereto monoaxially and a hand ( 27 L, 27 R) attached to the lower hand so as to be pivotally movable relative thereto biaxially, the robot also having drive means ( 23 L, 23 R, 24 L, 24 R; 21 L, 21 R; 19 L, 19 R, 20 L, 20 R, 18 L, 18 R; . . . ) associated with the feet, the lower legs and the upper legs of the legs, the hands, the lower arms and the upper arms of the arms and a body bending-forward region for pivotally moving them, respectively, a control stage ( 51 ) for controlling driving actions of the drive means, and a contact detector ( 40 ) mounted at each of an outer elbow surface area formed between the upper and lower arms, and an outer wrist surface area between the lower arm and the hand of each of the arms, and a lower toe surface area of the foot, a lower heal surface area of the foot, an outer knee surface area between the upper and lower legs of each of the legs, and a hip surface area and a back surface area of the body, the contact detector at each of these surface areas comprising a casing portion ( 41 ) made of a material forming an outer covering surface area of the robot, a pressure sensor ( 42 ) for sensing a pressure acting on the casing portion and a shock absorbing material ( 43 ) for absorbing a shock acting on the casing portion. Thus, when the biped walking humanoid robot is having a fall, the state or type of this fall can be determined by the control stage in response to a contact signal detected by the pressure sensor in the contact detector at a relevant part of the abovementioned robot parts which is brought into contact with the floor or ground. Then, on the basis of the type of the fall determined, the control stage is allowed to act on the drive means to move the arm and leg parts suitably so as to cause the robot to take a corrective falling action to have a safety fall and then to move to taking a rising action to get up on its feet.

en

Two-leg walking humanoid robot

5341880_JP

8207132_JP,8207131_JP,6696658_JP

B25J 5/00,B25J 13/081,B25J 19/0091,B62D 57/032

2018-05-01

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) WIPO I PCT (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/00 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/EP2018/061084 (22) International Filing Date: 01 May 2018 (01.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1706915.4 02 May 2017 (02.05.2017) GB 1717958.1 31 October 2017 (31.10.2017) GB 1805873.5 09 April 2018 (09.04.2018) GB (71) Applicant: ALLIGATOR BIOSCIENCE AB [SE/SE]; Medicon Village, SE-233 81 Lund (SE). (72) Inventors: ELLMARK, Peter; Alligator Bioscience AB, Medicon Village, SE-233 81 Lund (SE). FUREBRING, Christina; Alligator Bioscience AB, Medicon Village, SE-233 81 Lund (SE). NORLEN, Per; Alligator Bio- science AB, Medicon Village, SE-233 81 Lund (SE). VEI- TONMAKI, Niina; Alligator Bioscience AB, Medicon Village, SE-233 81 Lund (SE). (74) Agent: SMITH, Stephen Edward; Potter Clarkson LLP, The Belgrave Centre, Talbot Street, Nottingham NG1 5GG (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (54) Title: BISPECIFIC ANTIBODY AGAINST OX40 AND CTLA-4 - (57) : The present invention provides bispecific polypeptides, such as bispecific antibodies, comprising a first binding domain = capable of specifically binding to OX40, and a second binding domain capable of specifically binding to CTLA-4. The invention further — provides compositions of said bispecific polypeptides, as well as methods and uses of the same. ill 1111u°111110111sOHo o Holonomioomnium (10) International Publication Number WO 2018/202649 Al W O 20 18/ 20 26 49 Al [Continued on next page] WO 2018/202649 Al 0 111 Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

en

BISPECIFIC ANTIBODY AGAINST OX40 AND CTLA-4

73491999_SE

74176998_SE,74400426_SE,74251085_SE,73493260_SE

A61K 47/6803,A61K 47/6849,A61K2039/505,A61K2039/507,A61P 35/00,C07K 16/2818,C07K 16/2878,C07K2317/31,C07K2317/33,C07K2317/73,C07K2317/732,C07K2317/74,C07K2317/75,C07K2317/92,C07K2317/94

1999-07-29

Y

1. A method of treating a patient for a Sleep Disorder, which is not caused by Fibromyalgia, by administering to the patient a therapeutically sufficient amount of R-(+)-alpha-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 wherein the Sleep Disorder is Insomnia. 3. The method of claim 1 wherein the Sleep Disorder is Obstructive Sleep Apnea. 4. The method of claim 1 wherein the Sleep Disorder is Primary Insomnia. 5. The method of claim 1 wherein the Sleep Disorder is Insomnia related to another Mental Disorder. 6. The method of claim 1 wherein the Sleep Disorder is Substance-Induced Insomnia. 7. A method of treating a patient for a Sleep Disorder, and another Condition treatable with of R-(+)-alpha-2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or a pharmaceutically acceptable salt thereof, by administering to the patient a therapeutically sufficient amount of R-(+)-alpha-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol or a pharmaceutically acceptable salt thereof with proviso that said other condition is not Fibromyalgia. 8. The method of claim 7 wherein the Sleep Disorder is Insomnia. 9. The method of claim 7 wherein the Sleep Disorder is Obstructive Sleep Apnea. 10. The method of claim 7 wherein the Sleep Disorder is Primary Insomnia. 11. The method of claim 7 wherein the Sleep Disorder is Insomnia related to another Mental Disorder. 12. The method of claim 7 wherein the Sleep Disorder is Substance-Induced Insomnia. 13. The method of claim 7 wherein the Condition is schizophrenia. 14. The method of claim 7 wherein the Condition is obsessive-compulsive disorder. 15. The method of claim 7 wherein the Condition is coronary vasospasm. 16. The method of claim 7 wherein the Condition is thrombotic illness. 17. The method of claim 7 wherein the Condition is stenocardia. 18. The method of claim 7 wherein the Condition is anorexia nervosa. 19. The method of claim 7 wherein the Condition is Raynaud's phenomenon. 20. The method of claim 7 wherein the Condition is extrapyramidial symptoms. 21. The method of claim 7 wherein the Condition is anxiety. 22. The method of claim 7 wherein the Condition is arrhythmias. 23. The method of claim 7 wherein the Condition is depressive disorders. 24. The method of claim 7 wherein the Condition is bipolar depression. 25. The method of claim 7 wherein the Condition is schizophrenia and the Sleeping Disorder is Insomnia. 26. The method of claim 7 wherein the Condition is schizophrenia and the Sleeping Disorder is Obstructive Sleep Apnea. 27. The method of claim 7 wherein the Condition is schizophrenia and the Sleeping Disorder is Primary Insomnia. 28. The method of claim 7 wherein the Condition is schizophrenia and the Sleeping Disorder is Insomnia related to another Mental Disorder. 29. The method of claim 7 wherein the Condition is schizophrenia and the Sleeping Disorder is Substance Induced Insomnia.

en

METHOD OF TREATING A PATIENT FOR A SLEEP DISORDER

68715674_US

64817021_US,67776144_US,64728500_US

A61K 31/445,A61K 31/4465,A61P 11/00,A61P 21/00,A61P 25/00,A61P 25/18,A61P 25/20

2018-03-14

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIP0 I PCT omit VIII °nolo O II oimIE (10) International Publication Number WO 2018/167151 Al (51) International Patent Classification: CO7K 14/705 (2006.01) A61K 38/17 (2006.01) CO7K 14/725 (2006.01) (21) International Application Number: PCT/EP2018/056399 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: PCT/EP2017/056086 14 March 2018 (14.03.2018) English English Published: — with international search report (Art. 21(3)) 15 March 2017 (15.03.2017) EP (71) Applicants: BIONTECH CELL & GENE THERAPIES GMBH [DE/DE]; An der Goldgrube 12, 55131 Mainz (DE). TRON — TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JO- HANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH [DE/DE]; Freiligrathstrasse 12, 55131 Mainz (DE). UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ [DE/DE]; Langenbeckstrasse 1, 55131 Mainz (DE). (72) Inventors: VOSS, Ralf Holger; Lotharstrasse 32, 55218 Ingelheim (DE). SAHIN, Ugur; c/o BioNTech AG, An der Goldgrube 12, 55131 Mainz (DE). SIMON, Petra; c/o BioNTech AG, An der Goldgrube 12, 55131 Mainz (DE). BIRTEL, Matthias; Boppstrasse 1, 55118 Mainz (DE). CASPAR, Janina; Genheimerstrasse 16, 55425 Wal- dalgesheim (DE). (74) Agent: SCHNAPPAUF, Georg; ZSP Patentanwalte PartG mbB, Hansastr. 32, 80686 Miinchen (DE). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, (54) Title: ANTIGEN RECEPTORS AND USES THEREOF (57) : The present invention generally embraces the treatment of diseases by targeting cells expressing an antigen on the cell surface. In particular the invention relates to recombinant antigen receptors and uses thereof. T cells engineered to express such antigen receptors are useful in the treatment of diseases characterized by expression of one or more antigens bound by the antigen receptors.

en

ANTIGEN RECEPTORS AND USES THEREOF

74294316_DE,74138323_DE

73362322_DE,73893570_DE,56373447_DE,73325729_DE,74388557_DE

A61K 38/00,A61P 35/00,C07K 14/70503,C07K 14/7051,C07K 14/70521,C07K 16/28,C07K2319/00,C07K2319/02,C07K2319/03,C07K2319/70,C12N 5/0636,C12N 15/90

2018-07-30

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date ~ill IIIIIIIIII1101010IIIIIIIIII o ollio1 0101110110111110 011 (10) International Publication Number WO 2019/027896 Al 07 February 2019 (07.02.2019) WIP0 I PCT (51) International Patent Classification: TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, GOOK 9/00 (2006.01) KM, ML, MR, NE, SN, TD, TG). (21) International Application Number: PCT/US2018/044370 (22) International Filing Date: 30 July 2018 (30.07.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 201710637558.4 31 July 2017 (31.07.2017) CN (71) Applicant: ALIBABA GROUP HOLDING LIMITED [ /US]; Fourth Floor, One Capital Place, P.O. Box 847, George Town (KY). (72) Inventors: ZHAI, Fen; c/o Ants Patent Team, 17F Build- ing B, Huanglong Times Plaza, No. 18 Wantang Road, Hangzhou, 310099 (CN). GU, Chunlei; c/o Ants Patent Team, 17F Building B, Huanglong Times Plaza, No. 18 Wantang Road, Hangzhou, 310099 (CN). LU, Lei; c/o Ants Patent Team, 17F Building B, Huanglong Times Plaza, No. 18 Wantang Road, Hangzhou, 310099 (CN). LIU, Yanghui; c/o Ants Patent Team, 17F Building B, Huan- glong Times Plaza, No. 18 Wantang Road, Hangzhou, 310099 (CN). Published: — with international search report (Art. 21(3)) (74) Agent: STALFORD, Terry, J. et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, MN 55440-1022 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 1-1 MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, 01 00 N (54) Title: BIOMETRIC FEATURE DATABASE ESTABLISHING METHOD AND APPARATUS (57) : A usage frequency attribute of each biometric feature in a biometric feature database is obtained. An indication is 01 generated of matching success frequency of the biometric feature based on the usage frequency attribute. The biometric features are 0 arranged in descending order of matching success frequency based on the usage frequency attribute. Recognition of a user is performed N based on one of the biometric features having a higher frequency.

en

BIOMETRIC FEATURE DATABASE ESTABLISHING METHOD AND APPARATUS

11236634_

74067154_CN,73775750_CN,71898065_CN,57597087_CN

G06F 7/08,G06F 16/51,G06F 16/5838,G06F 16/5854,G06K 9/6256,G06Q 20/40145,G06V 10/40,G06V 40/168,G06V 40/172,G06V 40/50,H04L 63/0861

2018-04-26

N

1 N N O O N FIG. 1 AJAporksio4pektiewil Arousal EEG Airflow Effort {Rib Cage) Effort (Abdomen) Effort (Pes) Sa0 2 10 sec (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT omit VIII °nolo Holollomoinno oimIE (10) International Publication Number WO 2018/200775 Al (51) International Patent Classification: A61K 31/137 (2006.01) A61K 31/551 (2006.01) A61K 31/42 (2006.01) A61K 31/7008 (2006.01) A61K 31/506 (2006.01) A61K 45/06 (2006.01) (21) International Application Number: PCT/US2018/029518 (22) International Filing Date: 26 April 2018 (26.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/491,504 28 April 2017 (28.04.2017) US 62/558,814 14 September 2017 (14.09.2017) US (71) Applicant: THE BRIGHAM AND WOMEN'S HOSPI- TAL, INC. [US/US]; 75 Francis Street, Boston, Massachu- setts 02115 (US). (72) Inventors: WELLMAN, D. Andrew; 57 Clubhouse Lane, Wayland, Massachusetts 01778 (US). TARANTO-MON- TEMURRO, Luigi; 55 Sherman Road, Chestnut Hill, Massachusetts 02467 (US). (74) Agent: DEYOUNG, Janice Kugler et al.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA 1-1 (57) : Methods and compositions for the treatment of conditions associated with pharyngeal airway muscle collapse while the subject is in a non-fully conscious state, e.g., sleep apnea and snoring, comprising administration of a norepinephrine reuptake inhibitor C (NRI) and a muscarinic receptor antagonist. [Continued on next page] WO 2018/200775 Al MIDEDIMOMMIDIREIDIHNONIFIEMOMOVOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

en

METHODS AND COMPOSITIONS FOR TREATING SLEEP APNEA

55583432_US

73552754_US,74324791_US

A61K 9/0053,A61K 31/135,A61K 31/137,A61K 31/138,A61K 31/216,A61K 31/222,A61K 31/335,A61K 31/381,A61K 31/46,A61K 31/5375,A61K 31/55,A61K 31/553,A61K 45/06,A61K2300/00,A61P 1/00,A61P 25/00

2018-01-19

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 26 July 2018 (26.07.2018) WIP0 I PCT IiiimmomiolollmonolomoilimuioloilionovoimIE (10) International Publication Number WO 2018/136823 Al (51) International Patent Classification: A01K 67/027 (2006.01) CO7K 16/00 (2006.01) (21) International Application Number: PCT/US2018/014568 (22) International Filing Date: (25) Filing Language: (26) Publication Language: (30) Priority Data: 62/448,317 (71) Applicant: OPEN MONOCLONAL TECHNOLOGY, INC. [US/US]; 3911 Sorrento Valley Boulevard, Suite 110, San Diego, CA 92121 (US). (72) Inventors: BUELOW, Roland; 2747 Ross Road, Palo Al- to, CA 94303 (US). BRUGGEMANN, Marianne; 2 Sta- tion Road, Fexton, Cambridge CB22 6SA (GB). MA, Biao; Top Floor Flat, 99 Hills Road, Cambridge CB2 1PG (GB). OSBORN, Michael, J.; Jasmine Cottage, Sturmer, Haver- hill, Suffolk CB9 7XF (GB). - ( 74 ) Agent: LORENZ, Todd, A. et al.; Arnold & Porter Kaye Scholer Llp, Three Embarcadero Center, 10th Floor, San Francisco, CA 94111 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a)) 19 January 2018 (19.01.2018) English English 19 January 2017 (19.01.2017) US - (54) Title: HUMAN ANTIBODIES FROM TRANSGENIC RODENTS WITH MULTIPLE HEAVY CHAIN IMMUNOGLOBULIN LOCI FIC14 (OmniRat 1) Hu BAC6-3 182 kb AsiSI-Ascl _ 10.0 kb Hu BAC3 173 kb Notl D1-1 D7-27 —Tt - (7 - 2;E; - ,1.3 kb Hu-Rat Annabel 193 kb Notl W O 20 18/1368 23 Al op Ov1 6y2b HC1 4 (Osborn et at, JO HC30 HC14/1-1C30 occasionally found in pale color t t tt tt .t tt t t t t tttt t t t tt ft t tf t t t t tttt t FIG. IA (57) : The invention relates to transgenic animals useful for optimal production of functional immunoglobulins with human idiotypes.

en

HUMAN ANTIBODIES FROM TRANSGENIC RODENTS WITH MULTIPLE HEAVY CHAIN IMMUNOGLOBULIN LOCI

73977378_US

73527353_GB,73809981_GB,73566675_US,74186442_GB

A01K 67/0275,A01K 67/0278,A01K2217/052,A01K2217/075,A01K2217/15,A01K2227/105,A01K2267/01,A61P 37/02,C07K 16/00,C07K2317/24,C07K2317/76,C12N 15/8509

1973-11-15

Y

An optical information retrieval apparatus which utilizes the correlation detection function of a hologram to check coincidence matching between an interrogation signal and information recorded in a hologram memory is provided with an acousto-optic deflector serving as an input means for the interrogation signal. Both the interrogation signal and the hologram memory information are represented in the form of an M-out-of-N code, and identification of coincidence matching therebetween is effected on code-by-code basis. The interrogation signal to be digitally coded is applied through the acousto-optic deflector to an optical system for identification of coincidence matching. The acousto-optic deflector is driven by M different electric inputs having M different frequencies selected from N different frequencies so that a laser light beam incident onto the deflector is spatially modulated to simultaneously produce M deflected beams in M different directions determined by the M different driving frequencies, each of the deflected beams representing a '1' bit of an M-out-of-N code. The M deflected beams have differences in frequency corresponding to the differences between the individual driving frequencies, respectively, because upon deflection each of the deflected beams is deviated in frequency from the frequency of the incident laser beam by the amount of the corresponding driving frequency among the M driving frequencies. The M deflected beams representing an interrogation code are focussed onto the hologram to check coincidence matching between the interrogation code and the digitally coded hologram memory information. The result of coincidence matching occurs in diffracted light outputs from the hologram and is detected by photo diodes. The deflected light beams which were diffracted by the hologram are incident onto the photo diodes, and, consequently, due to an optical heterodyne phenomena, one or more beat outputs having one or more beat frequencies corresponding to the differences in frequency of the incident light beams can be obtained at the outputs of the photo diodes. If there exists coincidence matching between the interrogating and the interrogated codes, M different light beams having M different frequencies, respectively, impinge onto the photo diodes, while light beams having different frequencies in number equal to or less than (M-1) irradiate onto the photo diodes when no coincidence exists between the interrogating and the interrogated codes. Accordingly, for coincidence or non-coincidence the frequency components of the beat outputs differ, which means that the presence or absence of coincidence can be detected by analyzing the frequency of the beat oUtputs. When a 2-out-of-N code is used as an example of an M-out-of-N code, a beat output appears only upon existence of coincidence, rendering the simplest identification of coincidence matching.

en

Optical information retrieval apparatus

15877098_

38934412_

G11C 13/042,G11C 15/00

2018-05-04

N

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) WIPO I PCT olimion ono oIIIDIDIIIIIIH1101HIIII111111 DIIIIII (10) International Publication Number WO 2018/204895 Al (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/28 (2006.01) C07K 16/18 (2006.01) (21) International Application Number: PCT/US2018/031263 (22) International Filing Date: 04 May 2018 (04.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/501,981 05 May 2017 (05.05.2017) US (71) Applicant: VACCINEX, INC. [US/US]; 1895 Mount Hope Avenue, Rochester, New York 14620 (US). (72) Inventors: SMITH, Ernest S.; 67 Longton Place, W. Hen- rietta, New York 14586 (US). CORNELISON, Angelica; 14 Rainbrooke Drive, Pittsford, New York 14534 (US). SCRIVENS, Maria G.M.; 71 Courtly Circle, Rochester, New York 14615 (US). PARIS, Mark; 24 Bosworth Field, Mendon, New York 14506 (US). ZAUDERER, Maurice; 44 Woodland Road, Pittsford, New York 14534 (US). (74) Agent: HAANES, Elizabeth J. et al.; Fisherbroyles LLP, 945 East Paces Ferry Road NE, Suite 2000, Atlanta, Georgia 30328 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: HUMAN ANTI-SEMAPHORIN 4D ANTIBODY FIGURE 1 mAb binding to huCD100-his mAb binding to cynaCD100-his mAb binding to marmCD100-his mAb binding to mouseCD100 GC 71' 1 -1 (57) : Compositions and method are provided for treating diseases associated with semaphorin-4D (SEMA4D) pathology, 0 including autoimmune diseases, inflammatory diseases, cancers, neuroinflammatory disorders and neurodegenerative diseases. o [Continued on next page] WO 2018/204895 Al MIDEDIMOMMIDIREIDIHNOMINCIMEMOVOIS TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3))

en

HUMAN ANTI-SEMAPHORIN 4D ANTIBODY

56554037_US

73547885_US,56322121_US,73787941_US,65853591_US,56433456_US

A61K2039/505,A61P 25/00,A61P 25/28,A61P 29/00,A61P 35/00,A61P 37/00,C07K 16/2803,C07K2317/33,C07K2317/73,C07K2317/76,C07K2317/92

2019-08-01

Y

A device for training a cognitive model to provide a new answer to a new question associated with an issue, the device including one or more processors that receive issue resolution information based upon which the cognitive model will be trained, the issue resolution information including an item of issue resolution information that describes an issue and a resolution corresponding to the issue, analyze domain hierarchy information, associated with a plurality of domain hierarchies, and the item of issue resolution information, automatically determine, based on analyzing the domain hierarchy information and the item of issue resolution information, that the item of issue resolution is to be assigned to a particular domain hierarchy, the particular domain hierarchy being one of the plurality of domain hierarchies and associated with a domain that includes a category to which the issue corresponds, automatically assign the item of issue resolution information to the particular domain hierarchy based on automatically determining that the item of issue resolution is to be assigned to the particular domain hierarchy, the assigned item of issue resolution information provided to a first user via a first user device for reviewing and/or modifying the particular domain hierarchy, analyze, using a paraphrasing technique, the assigned item of issue resolution information including the reviewed and/or modified particular domain hierarchy, automatically generate, based upon analyzing the assigned item of issue resolution information, a set of questions and an answer for inclusion in the item of issue resolution information, the assigned item of issue resolution information provided to a second user via a second user device for modifying and/or removing one or more of the set of questions and the answer, the second user selected based upon the second user identified as having expertise associated with the particular domain hierarchy, the second user different from the first user, approve the set of questions and the answer corresponding to the item of issue resolution information, the approving of the set of questions and the answer based on input provided by a third user via a third user device, the third user different from the first user and the second user, generate, based on approving the set of questions and the answer, a set of question/answer (QA) pairs for the set of questions and the answer, each QA pair, of the set of QA pairs, associated with a question, of the set of questions, and the answer, create a data corpus including the set of QA pairs, provide the data corpus to cause the cognitive model to be trained based upon a portion of the data corpus, and receive the new question and generate, based upon the trained cognitive model, the new answer. Cu E _n a) 0 ' 0)- d Ia CD Cu> Cu C n~ CO n Q)(D(D q i!L ?L 0)>a

en

PROCESSING DATA FOR USE IN A COGNITIVE INSIGHTS PLATFORM

54000148_IE

56048950_,56223137_,54023784_,56167916_,56294781_,53064664_

G06N 3/006,G06N 5/043,G06N 5/045,G06N 20/00

2017-10-26

N

BC / 310 -\' v 320 FIG. 3 340 _ 350- z- 360a D 360b 360c 360d 1-1 00 1-1 71. 1-1 00 1-1 O (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 03 May 2018 (03.05.2018) WIP0 I PCT omitia °nolo ommim olo mil °nom° oimIE (10) International Publication Number WO 2018/081418 Al (51) International Patent Classification: G09G 5/00 (2006.01) (21) International Application Number: PCT/US2017/058520 (22) International Filing Date: 26 October 2017 (26.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 201610951000.9 26 October 2016 (26.10.2016) CN 15/792,628 24 October 2017 (24.10.2017) US (71) Applicant: ALIBABA GROUP HOLDING LIMITED [ /US]; Fourth Floor, One Capital Place, P.O. Box 847, George Town (KY). (72) Inventor: YIN, Huanmi; c/o Ants Patent Team, 17f Build- ing B, Huanglong Times Plaza, No. 18 Wantang Road, Hanzhou, 310099 (CN). (74) Agent: STALFORD, Terry, J.; Fish & Richardson P.C., P.O. Box 1022, Minneapolis, MN 55440-1022 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: PERFORMING VIRTUAL REALITY INPUT TRAJECTORY OF OPERATION FOCUS 330-, 300 (57) : A virtual reality (VR) device presents a virtual element in a VR scenario of a VR application. An effective interaction region (EIR) of the virtual element is determined that the virtual element can effectively interact with. A trajectory of an operational focus of the VR application is determined based on a movement sensed by the VR device. The virtual element is selected if an interaction between the trajectory of the operational focus and the EIR satisfies one or more conditions for triggering a selection event of the virtual button.

en

PERFORMING VIRTUAL REALITY INPUT

11236634_

71865049_CN

G06F 3/011,G06F 3/012,G06F 3/017,G06F 3/0236,G06F 3/04815,G06F 3/0482,G06F 3/04842,G06F 3/04886,G06F2203/012,G06T 19/003

2017-12-20

N

A computer-implemented method including accessing an order history that, for each of one or more past orders, indicates (i) one or more order details associated with the order, and (ii) a fulfillment outcome associated with the order, wherein the order fulfillment outcome is selected from among multiple pre-defined order fulfillment outcomes including one or more intended order fulfillment outcomes and one or more unintended order fulfillment outcomes, for each of one or more particular unintended order fulfillment outcomes, selecting one or more particular past orders that are associated with the particular unintended order fulfillment outcome, for each of the one or more particular unintended order fulfillment outcomes, generating, using the one or more order details associated with the one or more particular past orders that are associated with the particular unintended order fulfillment outcome as training data, a predictive model that is trained to estimate, based on one or more given order details associated with a given order, a likelihood that the given order will be associated with the particular unintended order fulfillment outcome, receiving one or more order details associated with a subsequently received order, for each of the predictive models, providing the one or more order details as input to the predictive model, in response to providing the one or more order details as input to the predictive model, receiving, from each of the predictive models, a likelihood that the one or more order details will be associated with the particular unintended order fulfillment outcome, determining, for each indication of the likelihood, whether the likelihood satisfies a threshold, for likelihoods that satisfy the threshold, determining a remedial action that, when implemented, adjusts the likelihood to not satisfy the threshold, wherein determining the remedial action includes selecting actions from a group of predetermined actions stored in an actions database, applying the selected actions to the one or more given order details associated with the subsequently received order to create revised order details, and providing the revised order details as input to the predictive model to determine whether the remedial action determined based on the revised order details, when implemented, will adjust the likelihood to not satisfy the threshold, providing, for output, data indicating the remedial action, and preventing an order associated with the one or more order details associated with the subsequently received order from processing until execution of the remedial action. -0> L4o 0 0) N0 cN a N 0 C,4 -7 >~Cl >~> _ >-0 (N ) 0 a) >a)CD N- nEF '( -I- LE5 0N CN mcn a) U0 > N- C U = CD 77 cu 2 CD 0 a~ a E a)C) LOL CDCDC .=a)- -0:a (D-. 0 = 73U ne I > 0~ nn Cl) coI U CU Nnn I U 00/))

en

PREDICTIVE MODELING FOR UNINTENDED OUTCOMES

5918584_IE

55009126_,52857887_,54844244_,54932629_,55387891_

G06N 7/005,G06N 20/00,G06Q 30/0633

2017-10-12

N

WO 18/07 167 6 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 April 2018 (19.04.2018) WIP0 1 PCT omit VIII °nolo mom VIII ioo mom° oimIE (10) International Publication Number WO 2018/071676 Al (51) International Patent Classification: A01N 1/02 (2006.01) A61K 39/395 (2006.01) A61B 5/055 (2006.01) (21) International Application Number: PCT/US2017/056349 (22) International Filing Date: 12 October 2017 (12.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/407,390 12 October 2016 (12.10.2016) US (71) Applicant: BIOVERATIV USA INC. [US/US]; 951 Gate- way Blvd., South San Francisco, CA 94080 (US). (72) Inventors: PANICKER, Sandip; 951 Gateway Boulevard, South San Francisco, CA 94080 (US). PARRY, Graham; 951 Gateway Boulevard, South San Francisco, CA 94080 (US). STAGLIANO, Nancy, E.; 951 Gateway Boulevard, South San Francisco, CA 94080 (US). (74) Agent: KIM, Ji-Eun et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW, Washington, DC 20005 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOF (57) : The present disclosure provides antibodies that specifically bind complement pathway component Cls. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the anti-Cls antibodies; and host cells comprising the nu- cleic acids. The present disclosure provides compositions comprising the anti-Cls antibodies. The present disclosure provides methods of use of the anti-Cls antibodies.

en

ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOF

68298444_US

56583569_US,56583552_US,71321258_US

A61K 38/00,A61K 45/06,A61K2039/505,A61P 43/00,C07K 16/18,C07K2317/24,C07K2317/52,C07K2317/76,C07K2317/92,C07K2317/94

2018-02-20

N

International Patent Classification: A63B 24/00 (2006.01) A63B 22/02 (2006.01) A63B 71/06 (2006.01) A63B 21/06 (2006.01) A63B 21/00 (2006.01) GO7F 9/00 (2006.01) A63B 21/055 (2006.01) W O 20 18/ 156 48 2 Al 300 200a 350 40013-- \ 400c-N400c1\400e7 \ E V_ 410 2006 200c 200e 2001 RG. 1 10 0 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 August 2018 (30.08.2018) WIP0 I PCT ill 1111u°111110111sOHolo monnommoilimio oimIE (10) International Publication Number WO 2018/156482 Al (21) International Application Number: PCT/US2018/018700 (22) International Filing Date: 20 February 2018 (20.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 15/440,880 23 February 2017 (23.02.2017) US 15/440,795 23 February 2017 (23.02.2017) US (71) Applicant: ELWHA LLC [US/US]; 3150 139th Ave SE, Bellevue, Washington 98005-4046 (US). (72) Inventors: HYDE, Roderick A.; 9915 161st Ave NE, Red- mond, Washington 98052 (US). SHARADIN, Katherine E.; 15810 NE 136th Place, Redmond, Washington 98052 (US). SWEENEY, Elizabeth A.; 702 N. 143rd Street, Seat- tle, Washington 98133 (US). (74) Agent: MALASKA, Stephen L. et al.; 3150139th Ave SE, Bellevue, Washington 98005-4046 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) (54) Title: PERSONAL THERAPY AND EXERCISE MONITORING AND OVERSIGHT DEVICES, SYSTEMS, AND RELATED METHODS (57) : Embodiments disclosed herein are directed to personal therapy and exercise systems as well as to methods related thereto. For example, a personal therapy system can be a modular system that can include multiple therapy gear modules.

en

PERSONAL THERAPY AND EXERCISE MONITORING AND OVERSIGHT DEVICES, SYSTEMS, AND RELATED METHODS

71763103_US

71726694_US,71937676_US,74324538_US

A61H 1/00,A61H 3/00,A61H 7/001,A61H2201/165,A61H2201/5061,A61H2201/5064,A61H2201/5069,A61H2201/5071,A61H2201/5076,A61H2201/5079,A61H2201/5082,A61H2201/5084,A61H2201/5089,A61H2201/5092,A61H2230/08,A61H2230/085,A61H2230/20,A61H2230/201,A61H2230/207,A61H2230/62,A61H2230/625,A63B 21/026,A63B 21/0552,A63B 21/06,A63B 21/0724,A63B 22/0076,A63B 22/02,A63B 22/0605,A63B 22/0664,A63B 24/0062,A63B 24/0075,A63B2071/063,A63B2071/065,A63B2071/0655,A63B2220/30,A63B2220/40,A63B2220/50,A63B2220/56,A63B2220/805,A63B2220/833,A63B2225/50,A63B2225/54,A63B2230/045,A63B2230/085,A63B2230/425,A63B2230/438,G09B 5/02,G09B 5/04,G09B 19/003,G09B 19/0038

2018-02-27

N

CCSF1R . 0 Li? ANTIGEN PRESENTING CELL NO ARC PRESENT CSF1 IL-34 CSFia_e IL-34 4 SUPPRESSION ACTIVATION CSF1R-Fc-CD4OL 7k. \':\' 4ACTIVATION VIA CD40 COMPETITIVE INHIBITION OF CSF1R (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 August 2018 (30.08.2018) WIP0 I PCT IiiimmomiolollmonolomolloomomioommovoimIE (10) International Publication Number WO 2018/157164 Al 1-1 71- 1-1 N 1-1 00 (51) International Patent Classification: A61K 38/00 (2006.01) C07K 19/00 (2006.01) C07K 14/705 (2006.01) C12N 15/11 (2006.01) (21) International Application Number: PCT/US2018/020039 (22) International Filing Date: 27 February 2018 (27.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/463,997 27 February 2017 (27.02.2017) US (71) Applicant: SHATTUCK LABS, INC. [US/US]; 3317 Bowman Ave., Austin, TX 78703 (US). (72) Inventors: SCHREIBER, Taylor; 3317 Bowman Ave., Austin, TX 78703 (US). FROMM, George; 3317 Bowman Ave., Austin, TX 78703 (US). DE SILVA, Suresh; 3317 Bowman Ave., Austin, TX 78703 (US). (74) Agent: ALTIERI, Stephen, L. et al.; Morgan, Lewis & Bockius LLP, 1111 Pennsylvania Avenue, NW, Washing- ton, DC 20004 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: CSF1R-BASED CHIMERIC PROTEINS FIG. - IA el (57) : The present invention relates, in part, to, chimeric proteins which include the extracellular domain of colony stimulating 0 factor 1 receptor (CSF1R) and their use in the treatment of diseases, such as immunotherapies for cancer and/or an inflammatory disease.

en

CSF1R-BASED CHIMERIC PROTEINS

73807326_US

56576045_US,56600752_US,57393962_US

A61K 38/00,A61P 29/00,A61P 35/00,A61P 37/02,A61P 37/04,A61P 37/06,C07K 5/0606,C07K 5/06095,C07K 5/06165,C07K 5/081,C07K 14/53,C07K 14/70575,C07K 14/70578,C07K 14/7153,C07K2317/53,C07K2319/00,C07K2319/30,C07K2319/31,C07K2319/33

2002-02-25

N

This invention can permanently in the future develop minds and personalities of creatures which were considered in the past to decay and become extinct owing to ageing and death, by transferring minds and personalities of creatures to new clone bodies, with preserving self-identity. This invention is particularly valid in the case that an invalid has little chance of recovery due to serious multiple organ failures, in the case that general prostration or severe senility of the whole body makes urgent organ exchanges ineffective, in the case that it will not be long before an individual moves to new clone bodies on some other grounds, etc. My invention is the repetitive processes of transferring central nervous systems and other systems of individuals and old clone bodies to new clone bodies. Besides the process of transferring central nervous systems themselves to new clone bodies, as FIG. 1 shows, by inputting memories retained in original individuals and clone bodies to central nervous systems of new clone bodies beforehand, creatures can obtain existence bases of themselves in succession, because memory itself can be regarded as the independent personality. Combining freely a great many of organs such as central nervous systems, peripheral nervous systems, and other systems, can enlarge memory capacities. Moreover, by establishing new active pathways, the originality worth of oneself can be formed. Remaking gray matters into chips such as semiconductors, various integrated circuits, etc., makes nervous systems light and convenient. The information interchange between lots of brains beyond a tiny skull and the construction of new nervous systems can evolve central nervous systems as a whole. Creatures can maintain self-identity even if constituent elements of succeeding creatures are different from those of preceding creatures, because ceatures always exchange their constituent elements by respiration and metabolism. Furthermore, the consciousness of oneself can maintain continuity in the case that the infant self is lasting to the adult self, in the case that a particular self can put on weight and can lose weight, and in the case that the organs of oneself were injured in diseases, accidents, etc., and the self gets one's health back again. Namely, ceatures can transfer themselves in succession to new clone bodies continuously and spaciously, even if succeeding creatures have different shapes, sizes, functions, constituent elements, etc. Therefore, with keeping self-continuity, I can create the existence of multi-arms and multi-legs, by making the most of lots of other systems in addition to nervous systems simultaneously. And, by obtaining various new organs, I can extend individual faculties of creatures diversely and remarkably.

en

Mind personality transfer method

30417776_

19532301_JP

A61B 5/167,A61B 5/4064,A61B 5/415,A61B 5/418

2001-04-06

N

A compound of formula (I) is described. The compounds can be used in the manufacture of a medicament for treating or preventing mood disorders, dysthymic disorders, depressive neurosis and neurotic depression, melancholic depression, anorexia, weight loss, insomnia, early morning waking and psychomotor retardation, atypical depression (or reactive depression), including increased appetite, hypersomnia, psychomotor agitation or irritability, seasonal affective disorder and pediatric depression ; or bipolar disorders or manic depression; anxiety disorders, specific phobias, stress disorders; borderline personality disorder; schizophrenia, psychotic disorders, psychotic disorders, autistic disorder, delerium, dementia, and other cognitive or neurodegenerative disorders, such as Parkinson's disease, Huntington's disease, Alzheimer's disease, memory disorder and vascular dementia, Pick's disease, Creutzfeldt-Jakob disease; movement disorders such as akinesias, dyskinesias; extra-pyramidal movement disorders such as medication-induced movement disorders; substance related disorders arising from the use of alcohol, amphetamines, caffeine, cannabis, cocaine, hallucinogens, inhalants and aerosol propellants, nicotine, opioids, phenylglycidine derivatives, sedatives, hypnotics, and anxiolytics; epilepsy; Down's syndrome; pain and migraine; multiple sclerosis and amylolateral sclerosis, peripheral neuropathy, respiratory diseases such as chronic obstructive airways disease, bronchopneumonia, chronic bronchitis, cystic fibrosis, inflammatory diseases; HIV infections; allergies; ophthalmic diseases; cutaneous diseases; neoplasms, including breast tumours, gastric carcinomas, gastriclymphomas, neuroganglioblastomas and small cell carcinomas gastrointestinal disorders, adverse immunological reactions such as rejection of transplanted tissues; disorders of bladder function; fibrosing and collagen diseases; blood flow disorders caused by vasodilation and vasospastic diseases such as angina and Reynaud's disease; angiogenesis; cardiovascular disorders; eating disorders, such as anorexia nervosa and bulimia nervosa ; attention deficit hyperactivity disorder; chronic fatigue syndrome; sexual dysfunctions including premature ejaculation and male erectile dysfunction; premenstrual syndrome and premenstrual dysphoric disorder; fibromyalgia; and rheumatic diseases such as fibrositis. Also described are compounds of formula (II). In the compounds of formula (I) and (II) Q is C=S or C=O; Y is N and Z is CH or Y is CH and Z is N; W is a 1 or 2 carbon linking group. In formula (I) B is absent methylene or ethylene, G is NH(CH2)q, S(CH2)q or O(CH2)q wherein q is 0 or 1, with the proviso that when q is 0, G is NH, S or O and p is 0, 1 or 2.

en

Benzoamide piperidine containing compounds and related compounds

12651345_

33984544_,13206406_,33984543_,33984541_,33984542_,33984545_,15028271_,33978976_

A61P 1/00,A61P 1/04,A61P 1/14,A61P 1/16,A61P 3/04,A61P 9/00,A61P 9/10,A61P 11/00,A61P 11/02,A61P 11/06,A61P 13/02,A61P 13/10,A61P 17/04,A61P 17/06,A61P 17/16,A61P 19/02,A61P 21/04,A61P 25/00,A61P 25/04,A61P 25/08,A61P 25/14,A61P 25/16,A61P 25/18,A61P 25/20,A61P 25/22,A61P 25/24,A61P 25/28,A61P 25/30,A61P 25/32,A61P 25/36,A61P 27/02,A61P 29/00,A61P 31/04,A61P 31/18,A61P 35/00,A61P 37/06,A61P 37/08,A61P 43/00,C07D 401/12,C07D 401/14,C07D 405/14,C07D 413/14,C07D 471/10,C07D 491/10

2019-07-10

N

RESOLVINGANAPHORIC REFERENCES IN CONVERSATIONAL SYSTEMS USING HIERARCHICALLY STACKED NEURAL NETWORKS Conversational systems are required to be capable of handling more sophisticated interactions than providing factual answers only. Such interactions are handled by resolving abstract anaphoric references in conversational systems which includes antecedent fact references and posterior fact references. The present disclosure resolves abstract anaphoric references in conversational systems using hierarchically stacked neural networks. In the present disclosure, a deep hierarchical maxpool network based model is used to obtain a representation of each utterance received from users and a representation of one or more generated sequences of utterances. The obtained representations are further used to identify contextual dependencies with in the one or more generated sequences which helps in resolving abstract anaphoric references in conversational systems. Further, a response for an incoming sequence of utterances is retrieved based on classification of incoming sequence of utterances into one or more pre-created responses. The proposed model takes lesser time to retrain. [To be published with FIG. 2] rol 200 Receiving, in a multi-turn retrieval chat-bot, a plurality of consecutive utterances comprising of at least a sub- set of 202 utterances indicative of anaphoric reference to specific entities or facts comprised in past utterances, in a multi-turn retrieval chat-bot Generating, (i) one or more sequences of the plurality of consecutive utterances and (ii) obtaining one or more pre- 204 created corresponding responses from the database for each of the one or more generated sequences Training, a Deep Hierarchical Maxpool Network (DHMN) based model, using the one or more generated sequences, and the plurality of consecutive utterances, to (a) obtain a representation for each of (i) the one or more generated 206 sequences, and (ii) the plurality of consecutive utterances, (b) identify contextual dependencies within the one or more generated sequences using each representation to resolve anaphoric references Updating, using a Character to Word Encoder (CWE) network comprised in the DHMN based model, the representation of 208 the plurality of consecutive utterances based on a presence or an absence of discrepancies in one or more utterances comprised in an incoming sequence of utterances Classifying, using the trained DHMN based model and the identified contextual dependencies, the incoming sequence 210 of utterances, based on at least one of (i) the updated o representation, and (ii) the representation of the one or more generated sequences, into at least one of the one or more pre created corresponding answers

en

Resolving Abstract Anaphoric References in Conversational Systems Using Hierarchically Stacked Neural Networks

6182385_IN

48992766_,70310688_,53816745_,15030891_

G06F 40/295,G06F 40/30,G06K 9/6293,G06N 3/0445,G06N 3/0454,G06N 3/08,G06N 3/084,G10L 15/24,G10L 15/32,H04L 51/02